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Measurement of the bioavailability of a drug in the skin after topical application is an 
important objective when attempting to assess whether the target-site concentrations 
are satisfactory to treat the disease. However, determining the amount of drug that 
reaches the different skin layers is still a challenge. Self-evidently, this challenge 
requires knowledge of both the drug input rate into the skin ‘compartment’ and its 
subsequent clearance therefrom.  
The Chapter 2 of this thesis focused on characterising experimentally (using in vitro 
permeation tests) the input functions of two transdermal drugs, buprenorphine and 
nicotine, from commercially available patches. In addition, the input-rate of diclofenac 
from a medicated plaster was determined using the same approach as demonstrated 
for the transdermal drugs. A good agreement between the experimentally determined 
input-rates of the two transdermal drugs and their labelled performance in vivo was 
found, lending support to the potential utility of the in vitro approach proposed to 
define topical drug input-rates more broadly. 
The Chapter 3 described an investigation of the behaviour of diclofenac in the stratum 
corneum. The uptake of diclofenac into the stratum corneum and its clearance 
therefrom following application of a medicated plaster was investigated in vivo in 
human. The results presented in this chapter have utility with respect to the application 
of stratum corneum tape-stripping to derive useful skin pharmacokinetic parameters 
related to drug partitioning into and diffusion across the stratum corneum. 
The results described in chapter 3 suggested that diclofenac uptake into the stratum 
corneum may be modified by the presence of excipient(s). Therefore, the work 
described in Chapter 4 focused on exploring the uptake of two excipients/co-solvents, 
propylene glycol and butylene glycol, into the stratum corneum in vivo in human, 
following application of the diclofenac medicated plaster. The results obtained from 
the uptake of propylene and butylene glycol suggests that these volatile solvents were 
rapidly taken into the stratum corneum. In parallel, evaporation of the solvents was 
identified. 
The work described in Chapter 5 investigated the hypothesis that information about 
clearance from the skin can be derived from available systemic pharmacokinetic data 
for drugs administered via transdermal delivery systems. A statistical mathematical 
model describing drug clearance from the skin in terms of drug molecular descriptors 
was developed. The model showed a good predictive ability. It has been further 
demonstrated that the empirical model closely predicts the results obtained in in vitro 
skin experiments. 
Overall, this thesis has provided useful information on the application of different 
strategies to predict topical skin delivery upon which further development and 
optimisation might be based. 
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Chapter 1:  Introduction  
 
The skin performs a variety of barrier functions, for example, impeding the 
loss of water as well as the ingress of materials contacting its surface. The latter, of 
course, plays a crucial role in determining the effectiveness of a topical1 drug 
treatment. A variety of topical drug formulations have been developed to treat 
dermatological, locally-acting or systemic diseases. The efficiency of the majority of 
these products approved for therapeutic use is, however, rather poor, and typically, 
only a few per cent of the applied drug dose actually becomes available at the site of 
action. 
It follows that the optimization of any dermatological therapy requires an 
understanding of the skin’s physical barrier and of the physicochemical mechanisms 
involved in cutaneous drug uptake and transport. However, as dermal tissue is 
(virtually) experimentally inaccessible (at least, in vivo in humans), local drug 
concentration profiles have proven difficult to obtain. The development of models to 
correctly predict drug bioavailability in the skin after topical administration is, 
therefore, essential. 
The goal of this thesis is to develop a physiologically-based pharmacokinetic 
model for dermal drug products, using in vitro/ex vivo and in vivo skin experiments 
and to demonstrate that the model’s kinetic and distribution parameters can be 






                                                          
1 The term ‘topical’ can be used to refer to non-oral extravascular routes of administration, such as nasal 
and ocular. However, throughout this work, the term topical will be used to refer to administration of a 
drug to the skin and this includes those used in dermatology, drugs to treat local subcutaneous pain and 




1.1 The structure of the skin 
As the largest organ of the human body, skin is accessible for both topical and 
systemic drug delivery (Zaffaroni, 1991; Gauglitz and Schauber, 2013; Kumar et al., 
2015). The skin is composed of two main layers: the epidermis and the dermis (Figure 
1).  
The epidermis is the outermost layer of the skin, approximately 150 μm thick and 
can be divided into two layers: stratum corneum and viable epidermis. It is an 
avascular layer and relies on the dermis for nutrition. It has a multilamellar structure 
that represents the different stages of cell differentiation. Moving upwards from the 
bottom layer, the cells change in an ordered fashion from metabolically active and 
dividing cells to dense, flattened, functionally dead, keratinized cells, known as 
corneocytes (Moser et al., 2001b). The epidermal turnover time, i.e., the time needed 
for a given cell to pass from the basal layer to the outer surface of the skin, represents 
about 52–75 days in the normal epidermis (Piérard, Hermanns-Lê and Piérard-
Franchimont, 2017).  
The stratum corneum has frequently been described as a ‘bricks and mortar’ 
structure (Michaels, Chandrasekaran and Shaw, 1975; Elias et al., 1981) (Figure 2). 
The ‘bricks’ represent the tightly packed corneocytes, and they are embedded in a 
‘mortar’ of lipid bilayers. Corneocytes are flat, polygonal cells, primarily composed 
of keratin surrounded by an envelope of cross-linked proteins and lipids. These cells 
are typically 0.2–1.5 μm thick, have diameters of approximately 30–50 μm and are 
held together by specialized protein structures called corneodesmosomes, which 
confer structural stability to the stratum corneum. The composition of the intercellular 
lipids varies according to the individual and the anatomical site, but it mostly 
constitutes ceramides, fatty acids and cholesterol (Hadgraft, 2000; Guy, 2013). The 
lipid matrix provides the primary barrier function of the stratum corneum, impeding 
the ingress of materials contacting the skin into the body and minimising water loss, 
which means that - in most cases - it is relatively impermeable to the penetration of 
xenobiotics (Kumar et al., 2015). 
The stratum corneum is, on average, 15–20 cells thick – around 10 μm in thickness 
when dry, however the corneocytes may hydrate extensively, resulting in significant 
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changes to the packing, structure, thickness and permeability of the stratum corneum. 
In addition, the corneocytes change in their morphological and biochemical functions 
as they progress from the inner to outer part of the stratum corneum (Michel et al., 
1988; Norlén and Al-Amoudi, 2004; Norlén, 2006; Rawlings, 2010).  
As cells move towards the outer layers of the stratum corneum, 
corneodesmosomes holding the cells together begin to break down causing loss of the 
corneocytes from the skin’s surface, known as desquamation. The entire stratum 
corneum is turned over in around 2-3 weeks (Michel et al., 1988).  
Beneath the epidermis is the dermis, the innermost layer, which is a thick, aqueous, 
gel-like tissue. The dermis consists mainly of elastin and collagen fibres and contains 
many blood capillaries, nerves and lymphatic vessels. The capillaries of the cutaneous 
microcirculation extend to the top of the dermis, and follow the undulations of the 
boundary between the dermis and the epidermis. These capillaries deliver nutrients to 
the skin as well as providing a clearance mechanism by which penetrating xenobiotics 
are eliminated into the systemic circulation.   
Also, the skin has a number of appendages – the hair follicles, sebaceous and sweat 
glands (Haake, Scott and Holbrook, 2001; Menon, 2015). Hair follicles can be found 
on all areas of the skin at differing densities except on the palms of the hands, soles of 
the feet and lips. Sebaceous glands are most abundant on the forehead and secrete 
sebum, which serves to regulate surface pH and keep the skin moist. Sweat glands 
help regulate body temperature and are found across most of the skin surface (Benson, 
2012).  
1.2 Permeation pathways through the stratum corneum  
Despite the efficient barrier function of the skin, it is evident that some compounds 
can pass through the stratum corneum, reach the viable skin and, ultimately, the 
systemic circulation. Potentially, there are three possible pathways for a compound’s 
transport across the stratum corneum and, then, penetration into the deeper layers of 
skin: the intercellular (around the corneocytes, shown as (a) in Figure 1), the 
transcellular (through the corneocytes, shown as (b) in Figure 1) and through skin 
appendages (sweat glands and hair follicles, shown as (c) in Figure 1) (Hadgraft, 
2000). The contributions of these three routes to the percutaneous absorption of a 
topically applied compound, from the surface of the skin either into the skin or into 
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systemic circulation, depend on the nature of the permeating molecules and the density 
of appendages, such as hair follicles and sweat ducts, at the site of application 
(Schaeffer and Redelmuer, 1996).  
The intercellular pathway is thought to be the major pathway for the permeation 
of small (< 500 Da, Bos and Meinardi (2000)) and uncharged molecules (Elias, 1983; 
Simonetti et al., 1995; Ng and Lau, 2015). Intercellular lipids, providing the only 
continuous phase within the SC, form lamellar structures between corneocytes. The 
permeation of compounds via this route is believed to occur by diffusion along and/or 
across lipid lamellae (Schaeffer and Redelmuer, 1996). Potts and Francoeur (1991) 
demonstrate that the water pathlength across the stratum corneum is 50 times greater 
than its thickness, i.e., the molecule travels up to 500 µm to cross the ~15 µm thick 
stratum corneum. Therefore, it was suggested the molecules take a ‘tortuous’ route 
around the corneocytes. 
The transcellular route requires the repeated penetration of the permeating 
compound into and out of the corneocytes and the intercellular lipids. In this route of 
permeation, the compound must therefore diffuse through both lipophilic regions 
(lipids) and hydrophilic regions (hydrated keratin within corneocytes) of the SC. 
Under normal conditions, penetration through the skin appendages is not 
considered important because they occupy a low fraction of skin area (for example, 
only ~ 0.2% of area on the chest and upper arm (Otberg et al., 2004)). However, this 
pathway plays a large role in iontophoresis and is thought to be quite important for 
compounds of low stratum corneum diffusivity, such as hydrophilic and large 
molecular weight compounds (Williams and Barry, 2012).  
Despite evidence suggesting that the major route is through the intercellular 
spaces, the transport across the stratum corneum barrier might occur by any 
combination of the three aforementioned pathways (Bunge, Guy and Hadgraft, 1999; 
Moser et al., 2001b; Hadgraft, 2004).  
Once a molecule has traversed the stratum corneum it must then partition into the 
viable epidermis the environment of which is much more aqueous in nature. 
Compounds that are particularly lipophilic may therefore partition into the stratum 
corneum relatively easily but partitioning into the lower epidermis becomes difficult 
(Guy, 2013). Poor partition into the viable epidermis may create a ‘reservoir’ whereby 
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a lipophilic compound accumulates in the stratum corneum from which it is then 
slowly released into the viable tissue and circulation (Roberts, Cross and Anissimov, 
2004). Depending on the rate of removal of this compound from the reservoir, the 
compound could also potentially be lost via desquamation of the stratum corneum. Of 
course, due to the relatively slow rate of epidermal turnover, this is only likely to be 
significant for compounds with extremely slow absorption (Reddy, Guy and Bunge, 
2000). 
Figure 1. The structure of human skin. (a), (b) and (c) show potential routes for skin 
permeation; a = intercellular, b = transcellular, c = appendageal (i.e., via a hair follicle 




Figure 2. The schematic structure of stratum corneum. The corneocytes (in grey) and 
the intercellular lipids (continuous domain in dots) represent the bricks and mortar, 
respectively. Two routes potentially contributing to the percutaneous absorption of 
topically applied compounds, the transcellular and intercellular routes are shown. 
Corneodesmosomes are presented as black diamonds between the individual 
corneocytes.  
 
1.3 Percutaneous absorption 
The drug’s journey from the formulation applied on the skin to the local capillary 
network and, eventually, the systemic circulation is a multiple-step process which 
involves repeated processes of partitioning and diffusion (Kalia and Guy, 2001) 
(Figure 3). Many factors can influence these two processes (partition and diffusion) 
and, consequently, rate and extent of the absorption of a drug into and through the 
skin.  
Before entering the skin, the presence of certain components of the formulation 
can play an important role in controlling rate (Garg, Rath and Goyal, 2015). Once in 
the skin, the properties and the conditions of the skin can significantly affect the rate 
at which the permeant will cross the skin layers (Hwa, Bauer and Cohen, 2011). Lastly, 
it has been demonstrated that the physicochemical properties of a permeant greatly 
influence the processes involved in dermal and transdermal permeation (Guy, 2016). 




Figure 3.  Key processes that determine the extent of compound permeation through 
the skin. 
 
1.3.1 Drug-related factors affecting percutaneous absorption 
Over half a century ago, Blank, Scheuplein and colleagues started to 
investigate the role of the physicochemical properties of a chemical in the 
percutaneous absorption process (Scheuplein, 1965, 1967; Robert J Scheuplein and 
Blank, 1971). Since then, enormous effort has been dedicated to identifying the key 
physicochemical parameters determining the rate and extent of penetration of a 
chemical across the skin.  
For oral delivery, in order to assess whether a particular drug is likely to exhibit 
poor permeability or other pharmacokinetic properties, a commonly adopted strategy 
is to use Lipinski’s Rules of Five (Lipinski et al., 1997). This rule qualitatively outlines 
the physiochemical space defined by the majority of well-absorbed drugs, which 
include (1) molecular weight (MW) < 500, (2) number of hydrogen bond donors ≤ 5, 
(3) number of hydrogen bond acceptors ≤ 10, and (4) octanol−water partition 
coefficient (log P) < 5. Interestingly, research has suggested that this rule also works 
reasonably well for the transdermal route: as a general rule, big molecules (>500 Da) 
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and very lipophilic compounds (log P > 5) have low transdermal flux rates; very polar 
compounds, capable of donating or accepting lots of hydrogen-bonds, do not partition 
very well into the lipophilic stratum corneum, and therefore penetrate very slowly as 
well (Bos and Meinardi, 2000; Wiedersberg and Guy, 2014; Guy, 2016).   
Molecular weight (MW) of the permeant 
An inverse relationship between permeant diffusivity (D) within a lipid 
membrane, such as the stratum corneum, and its molecular weight/volume is 
anticipated by the theories of Cohen and Turnbull (1959) and Lieb and Stein (1986). 
Both theories suggest that the dependence of D on molecular volume is exponential 
(Equation 1). 
𝐷 =  𝐷0𝑒
−𝛽 .  𝑀𝑉                                               (Equation 1) 
where D0 is the diffusivity of a hypothetical molecule having zero molecular volume 
(MV) and β is a constant. This means that drug diffusivity across the stratum corneum 
decreases as MW increases since MV and MW are interdependent. 
Magnusson et al. (2004) demonstrated that the maximum flux (Jmax) across 
human epidermal skin of 278 compounds in aqueous solution decreased with 
increasing MW. A linear relationship between log Jmax and MW was observed (Figure 
4).  It should be noted that just a few molecules go beyond 500 Da, and this reﬂects 
the fact that the literature contains very little quantitative information on the passive 
percutaneous absorption of chemicals of higher molecular weight. The observation is 
rather a reﬂection of two phenomena: (i) The skin transport of molecules having MW 
> 500 Da is almost certainly going to be low (and possibly difﬁcult to detect without 
recourse to very sensitive analytical chemistry), and (ii) very few compounds in this 
MW range have been properly and quantitatively evaluated for their ability to cross 




Figure 4. Logarithm of the maximum flux (Jmax) of chemicals across human epidermis 
as a function of molecular weight (MW). (Magnusson et al., 2004). Permission to 
reproduce this image has been granted by the publisher. 
 
Hydrophilicity/ lipophilicity of the permeant 
A work published by Michaels, Chandrasekaran and Shaw (1975) shows that 
transdermal flux of 10 drugs increased linearly with their mineral oil – water partition 
coefficients (Km,w) when 10
-4 < Km,w < 10
0 . From Km,w of approximately 10
0 to 104, 
no further change to transdermal flux was observed.  
In a later work, Yano et al. (1986) investigated the skin permeabilities of a 
series of eight salicylates (log P range: 1.13 – 3.96) and ten non-steroidal anti-
inflammatory (log P range: 0.77 – 4.88) drugs in human subjects. A parabolic 
relationship between the logarithms of drug absorption through intact skin and log P 
of the test compounds was obtained in both compound series. 
More recently, the effect of lipophilicity (log P) of 10 phenolic compounds 
(log P range: 1.95 – 3.38) with similar MW (~ 150 Da) on skin permeation was 
investigated by Zhang et al. (2009). They showed that Jmax shows a bilinear (Equation 
2) or parabolic (Equation 3) relationship with lipophilicity (Figure 5). They suggested 
that the observed relationship reflected the variation in solubility in the stratum 





log Jmax =  −2.1 + 1.7 logP − 21.6(log10
−4 × 10logP + 1)         (r2 = 0.86 ; n = 10)        
        (Equation 2)          
 
log Jmax =  −7.2 + 6.5 logP − 1.2(log P)
2           (r2 = 0.74 ; n = 10)                     
        (Equation 3) 
 
 
Figure 5. Relationship between transdermal maximum flux (Jmax) and log P for 
penetration of phenolic compounds through excised human epidermal membrane 
(mean ± SD). Bilinear (solid line) and parabolic (dashed line) model fits. (Zhang et 
al., 2009). Permission to reproduce this image has been granted by the publisher. 
In general, it could be observed that the better skin penetrants tend to have log 
P values in the range of 1-3, that is, overall somewhat lipophilic but retaining a decent 
solubility in aqueous media. 
Hydrogen bonding  
Another important determinant of the permeability of any given molecule is its 
hydrogen bonding capacity (Potts and Guy, 1995). To cross a biological membrane, a 
molecule must first break any hydrogen bonds that it forms with water. The more 
potential hydrogen bonds a molecule can make, the more energy this bond-breaking 
costs, and so high hydrogen-bonding potential is an unfavourable property that is often 
related to low permeability and absorption (van de Waterbeemd and Gifford, 2003). 
Attempts to measure the hydrogen bonding capacity of a molecule have been made 
by the difference between octanol/water and alkane/water partitioning, but this 
technique is limited by the fact that some molecules are poorly soluble in the alkane 
 15 
 
phase. Most recently, a variety of computational approaches have addressed the 
problem of estimating hydrogen bonding capacity, ranging from simple heteroatom 
(O and N) counts, the consideration of molecules in terms of the number of hydrogen 
bond acceptors and donors, and more sophisticated measures that take into account 
such parameters as free-energy factors (Raevsky et al., 2000) and topological polar 
surface area (TPSA) (Stenberg et al., 2001).  
Potts and Guy (1995) observed that an increase in the hydrogen bonding activity 
(both acceptor and donor) decreases partitioning into the organic phase, presumably 
due to the free energy cost associated with disruption of the hydrogen bonds in the 
aqueous phase.  
With regard to TPSA, previous studies have found an inverse correlation between 
TPSA and the passage of molecules through the brain-blood barrier (Clark, 1999; 
Kelder et al., 1999) and a sigmoidal relationship was found with respect to the 
intestinal membrane (Palm et al., 1997; Winiwarter et al., 1998; Stenberg et al., 1999). 
No study was found, however, that specifically investigated the relationship between 
TPSA and drug skin permeation. 
 
1.3.2 Formulation-related factors affecting percutaneous absorption 
The efficacy of a topically applied medicine is often limited by the poor 
penetration of the drug into the skin, more specifically by the permeation across the 
stratum corneum. Methods for improving cutaneous delivery rely either on the use of 
chemical penetration enhancers or more complex physical enhancement strategies, 
such as, the use of microneedle arrays (McAllister, Allen and Prausnitz, 2000; Mikszta 
et al., 2002) or electrical current (e.g., iontophoresis (Delgado-Charro and Guy, 2001; 
Fan, Sirkar and Michniak, 2008)). The addition of chemicals into the formulation, 
however, is the most common approach applied to enhance a drug’s permeation 
through the skin (Moser et al., 2001a). 
Three different strategies have been used to maximise the permeation of the 
drug through the stratum corneum: (i) increase drug diffusivity in the stratum 
corneum; (ii) increase the drug solubility in the stratum corneum, i.e., increase drug 
partitioning into the membrane, and; (iii) increase the degree of saturation of the drug 
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in the formulation. The latter strategy is based on interaction between the drug and the 
vehicle, while the first two approaches imply an effect of the vehicle on the barrier 
function of the stratum corneum (e.g., via movement of chemical penetration enhancer 
into the stratum corneum and subsequent disordering of the intercellular stratum 
corneum lipids, or the extraction of such lipids by solvating component of the 
formulation) (Moser et al., 2001b).    
The diffusion coefficient of the drug in the stratum corneum can be increased 
by disordering the stratum corneum lipids. Fatty acids are a class of compounds 
frequently used to increase skin permeation and they are generally believed to increase 
diffusivity across the stratum corneum. Other examples include: oleic acid (Alberti et 
al., 2001), azone (Bouwstra et al., 1989; Schückler and Lee, 1992; Harrison et al., 
1996) and dimethyl sulfoxide (DMSO) (Kligman, 1965; Klamerus and Lee, 1992). 
Penetration enhancement of a drug into the stratum corneum can also occur by 
increasing the drug’s solubility in this layer. Agents which are typically thought to act 
in this way include, for example, propylene glycol (Herkenne et al., 2008) and ethanol 
(Hatanaka et al., 1993). 
Optimization of the degree of drug saturation is important for simple 
formulations as well as those containing chemical penetration enhancers. The degree 
of saturation can be increased by raising the drug concentration in the vehicle or by 
decreasing the solubility of the drug in the vehicle. Both approaches lead to an 
enhanced thermodynamic activity of the drug in the formulation and therefore to an 
increased skin permeation (Moser et al., 2001b). A transient increase of the degree of 
saturation to greater than one (a saturated solution implies a thermodynamic activity 
of unit) can be achieved via supersaturation. Supersaturated formulations, however, 
are inherently thermodynamically unstable (Pellett et al., 1997), and it is only a matter 
of time before crystallization of the drug occurs within the formulation (Brouwers, 
Brewster and Augustijns, 2009). If the solubility of the compound in the formulation 
is low, then further delivery is compromised because only drug in the molecular form 
can diffuse (Frederiksen, Guy and Petersson, 2016).  
Although many compounds have been shown to have enhancement properties, 
most of the studies have been conducted using binary mixtures, that is, a single drug 
is delivered in a single vehicle (Karadzovska et al., 2013). ‘Real world’ formulations, 
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however, often contain a large number of compounds which may interact with each 
other (and with the stratum corneum) synergistically (Karande and Mitragotri, 2009). 
Therefore, elucidation of the mechanism of action(s) regarding skin penetration 
enhancement is not straightforward and remains poorly understood (Karadzovska et 
al., 2013).  
 
1.4 Measuring rate and extent of chemical compounds absorption across the skin 
1.4.1 In vitro and ex vivo methods 
In vitro cutaneous permeation studies are generally performed using diffusion 
cells, for example the Franz diffusion cell (Figure 6). Briefly, these diffusion cells 
consist of two chambers, the donor, where the tested product is applied, and the 
receptor, separated by a synthetic membrane or a piece of skin. The receptor 
compartment is filled with a solution that favours sink conditions, that is, the 
dissolution of the compound into the receptor solution is not rate-limiting (solubility 
in the receptor solution should be at least 10-fold higher than the highest observed 
sample concentration (OECD, 2004)). The receptor solution is stirred with a magnetic 
stir-bar and is normally maintained at 37°C (by the water jacket – through which the 
temperature-controlled water is recirculated) with the aim of achieving a skin surface 
temperature of ~32 °C, representative of the temperature of the skin surface in vivo at 
rest. Permeation of a compound through the membrane is monitored by periodic 
sampling of the receptor solution from the sampling port. Samples are then analysed 





Figure 6. A Franz-type diffusion cell (retrieved from: http://permegear.com/franz-
cells/).  
The characterisation of percutaneous absorption is, commonly, observed 
through the use of ex vivo biological membranes. These tests can be performed through 
excised skin (human or animal). Generally, skin used in dermal absorption studies is 
not full-thickness. The use of full-thickness skin often results in lower levels of the 
test compound in the receptor solution (Wilkinson et al., 2006) and increased lag 
times. This is because full-thickness skin, consisting of stratum corneum, ‘viable’ 
epidermis, dermis and subdermal tissues (2000 – 3000 μm thick). If full-thickness skin 
is used, it should be kept in mind that in vivo the permeating molecule would not 
necessarily have to cross the dermal layer to achieve the desired pharmacological 
effect or to be absorbed into the systemic circulation. 
Probably the most commonly used is split-thickness or dermatomed skin. A 
dermatome is an instrument that can cut the skin to a nominal depth that would usually 
include the epidermis and part of the dermis.  
Another common method for preparing the skin is by heat separation (Kligman 
and Christophers, 1963), the process of submerging the skin in water at 60 ºC. This 
causes the epidermis to separate from the dermis without significantly impairing the 
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barrier function. The upper layers can then be used for diffusion studies. Stratum 
corneum can also be isolated by trypsin digestion (Onken and Moyer, 1963).  
After the skin has been prepared, it is common to freeze it for later use, it is 
generally accepted that barrier function is not affected by this process (Rosado and 
Rodrigues, 2003). If the skin is to be used for regulatory studies then tests are 
performed to determine the integrity of the barrier. Methods to measure barrier 
integrity include transepidermal water loss (Fluhr, Feingold and Elias, 2006), 
capacitance (Palenske and Morhenn, 1999) or diffusion of tritiated water (Robert 
Scheuplein and Ross, 1970).  
Obviously, the best and most relevant membrane to assess permeation of a 
compound through the skin is human skin, which can be obtained from cosmetic 
surgery or cadavers. However, the use of human skin can be expensive, logistically 
difficult and susceptible to ethical considerations. The pieces of skin are also often 
small and irregularly shaped, which can make handling and preparation difficult. 
For these reasons, numerous animal skin models have been suggested as a 
surrogate to human skin, including, rat (Panchagnula et al., 2001; Pillai and 
Panchagnula, 2003), hairless mouse (Rhee et al., 2008; Lanke et al., 2009), guinea pig 
(Barbero and Frasch, 2009), pig (Barbero and Frasch, 2009), snake (Megrab, Williams 
and Barry, 1995) and non-human primate (Wester, Noonan and Maibach, 1980) skins. 
It is important to bear in mind that the absorption of chemicals varies between species, 
due to differences in follicular density, number of layers of corneocytes, and water and 
lipid content (Scheuplein, 1978; Panchagnula, Stemmer and Ritschel, 1997). Porcine 
skin is thought to be a good model for human skin as it has a similar lipid composition 
(Gray and White, 1978) and follicle density (Sekkat and Guy, 2001; Jacobi et al., 
2007) and, most importantly, studies have demonstrated similar barrier properties to 
human skin (Sekkat and Guy, 2001; Cnubben et al., 2002; Vallet et al., 2007). 
In addition to animal models, cultured human cell lines represent another 
alternative for skin permeation studies. Generally speaking, there are two main type 
of cultured skin tissues:  living skin equivalents comprising a dermis, epidermis and 
(partially) differentiated stratum corneum, but without skin appendages; and human 
reconstructed epidermis which consists simply of keratinocytes grown on a substrate 
(Russell and Guy, 2009).  
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The morphology and biochemistry of human reconstructed epidermis has been 
compared with ex vivo human tissues. Both have a differentiated stratum corneum, but 
several histological and biochemical differences are apparent, for example the stratum 
corneum of the reconstructed epidermis is typically thicker (Monteiro‐Riviere et al., 
1997; Netzlaff et al., 2005). In general, chemical penetration across human 
reconstructed epidermis is quite reproducible, but significantly higher than through 
human, pig or rat skin. Several possible reasons for the measured higher drug flux 
across these membranes have been suggested, including differences in lipid 
composition and stratum corneum packing that result in a less efficient barrier 
(Schmook, Meingassner and Billich, 2001; Schafer-Korting et al., 2006). 
Living skin equivalents, despite their greater similarity with human skin, have 
shown to similarly overestimate chemical penetration. For example, in a study by 
Schmook, Meingassner and Billich (2001), the permeation characteristics of human, 
porcine and rat skins with a living skin equivalents model were compared using four 
dermatological (salicylic acid, hydrocortisone, clotrimazole and terbinafine) drugs 
with different hydrophilicities (log P = 1.2, 2.0, 3.1 and 3.8, respectively). The 
permeation of more hydrophobic compounds (clotrimazole and terbinafine) through 
the skin equivalents resulted in an 800–900 fold higher flux than through human skin. 
On the other hand, transdermal flux of a less hydrophobic compound, salicylic acid, 
was in the same order of magnitude as fluxes obtained with human skin.  
  Overall, therefore, while valuable, for example, for skin irritation assessment, 
skin cell culture models are not yet able to provide quantitative predictions of 
percutaneous penetration. 
 
1.4.2 In vivo methods 
        In vitro/ex vivo measurement of skin penetration is very useful for 
assessing the disposition of a drug in skin and its kinetic parameters; however, such 
studies cannot always provide all the necessary information to predict the local 
bioavailability of a drug. Therefore, the ultimate evaluation of topical drug delivery 
into and through the skin is likely to be performed in human in vivo. 
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Measuring the rate and extent of drug absorption into the systemic circulation 
after transdermal administration is relatively easily achieved. In vivo pharmacokinetic 
studies can be performed, with blood and/or urine samples collected at intervals. While 
these studies are useful for assessing the bioavailability of transdermal drugs (i.e., 
drugs whose site of action is reached via the systemic circulation), they may not be 
suitable for all topical dermatological drugs (i.e., drugs whose site of action is in the 
skin). There are exceptions, however, especially when there is significant drug 
absorption (i.e., drug plasma concentrations are high enough to be detected by 
analytical chemistry methods) and depending on the site of action. For example, the 
United States Food & Drug Administration (FDA) recommends that bioequivalence 
of lidocaine2 topical patches can be demonstrated by pharmacokinetic studies (FDA, 
2016). In contrast, for the antifungals, whose site of action is the upper layers of the 
skin (normally located in the stratum corneum), assessment of bioavailability from 
blood levels is consequently not appropriate. 
In addition to the pharmacokinetic studies, there are, at least, three notable 
methods to assess the bioavailability of a compound in the skin: tape-stripping, 
microdialysis (including open-flow microperfusion), punch biopsy and suction blister 
approaches. 
Tape-stripping 
Tape-stripping is a method for collection of stratum corneum. It is performed 
by placing an adhesive tape-strip onto the skin surface and subsequently removal. This 
action is then repeated on the same skin site, typically between 10 and 30 times. It can 
be used, in combination with analytical techniques, to measure the distribution of a 
molecule within the stratum corneum both in vivo and in vitro (Lademann et al., 2009), 
and to estimate the total thickness of the stratum corneum (Russell, Wiedersberg and 
Delgado-Charro, 2008).  
Tape-stripping is relatively painless and non-invasive, given that only dead 
cells (corneocytes) embedded in their lipid matrix are removed. Due to the rapid repair 
response from the epidermis, the barrier function of the stratum corneum is soon 
restored (Menon, Feingold and Elias, 1992; Denda et al., 1996).  
                                                          
2 Lidocaine is local anaesthetic agent where the site of action are nerve endings in the skin. 
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Weighing the tapes before and after the tape-stripping process allows 
estimation of the mass (m) of stratum corneum that has been removed. As the area (A) 
of stratum corneum stripped and the density (ρ) of the stratum corneum (normally 
assumed as 1 g cm-3 (Anderson and Cassidy, 1973)) are both known, it is possible to 
convert the stratum corneum weight into a depth (thickness) or distance (x), into the 
barrier (Equation 4).   
x =
m
A .  ρ
                                                            (Equation 4) 
The tapes are then extracted and quantified for the compound of interest. Using 
a combination of the estimated mass of stratum corneum and the concentrations of the 
molecule within the stratum corneum, a depth profile can be plotted. Figure 7 
illustrates the steps normally followed for a tape-stripping experiment. Note that to 
estimate the mass of stratum corneum removed, the tapes are weighted before and after 
stripping. 
 
Figure 7. Method of tape-stripping  
In general, the method development of a tape-stripping experiment consists of 
a series of preliminary tests performed to choose an optimal condition for a specific 
drug/formulation. Firstly, it is necessary to define the area of formulation application. 
It depends upon the ability of the drug to penetrate the stratum corneum: for a poorly 
penetrating drug, it may be necessary to increase the application area (and then the 
stripped area) to have enough drug in the tape strips for reliable quantification. The 
number of replicates and application time points desired are also important factors to 
be considered when developing the study protocol. After the desired application time, 
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the formulation is removed from the skin and, then, the stratum corneum sampling site 
is delimited by a template. The template is centred over the drug application site 
immediately before tape stripping begins. This template ensures that all tape strips are 
removed from the same site (and eliminates any potential problems created by the 
formulation spreading over the skin). The size of the piece of tape used for stripping 
is bigger than the opening in the template but smaller than the external dimensions of 
the template to ensure removing skin layers on the desired skin area only. The tape is 
applied to the template, pressed down, and then removed in one movement. The first 
tape strips remove a substantial amount of stratum corneum, which tends to 
progressively reduce as the stripping proceeds to the deeper layers.  
The number of strips to collect depends upon the individual’s SC thickness, 
formulation applied, the adhesiveness of the tape used, and whether or not it is 
necessary to completely remove the stratum corneum. The study protocol is often 
defined after a pilot study. 
Quantification of the drug in the tape strips is generally made by high – 
performance liquid chromatography (HPLC) after a suitable extraction procedure. The 
principle of quantitation by HPLC is based on chromatographic separation of different 
compounds in a sample, followed by detection. The detection method can be UV, 
fluorescence, or mass spectrometry depending on the characteristic of the drug and the 
required detection limit. Interpretation of the data recorded by the detector produces 
quantitative and qualitative information about the sample and its constituents. 
Chromatographic separation is achieved due to compounds having different 
relative affinity for a stationary phase (known as a column) versus affinity for the 
mobile phase (solvents). Separation is achieved by passing the mobile phase through 
the stationary phase under pressure. A HPLC system, as shown in Figure 8, is 
composed of some essential features: mobile phase, high pressure pump, sample 
injector, chromatographic column, detector and data acquisition system.  
Careful selection of the mobile phase/stationary phase pair is of utmost 
importance for a successful chromatographic separation of the components of a 
sample. Therefore, knowledge of the physicochemical characteristics of analytes 
involved in the process is helpful to obtain the desired separation.  
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Silica has been the preferred starting material for the preparation of stationary 
phases as it is mechanically stable to high pressure, easily modified and is 
commercially available in a wide variety of particle sizes, shapes and sizes of pores. 
 
Figure 8.  A High – Performance Liquid Chromatography (HPLC) system. 
Simultaneous measurements of transepidermal water loss (TEWL) during the 
tape-stripping process can be performed. These measurements can be useful for 
estimating the total thickness of the stratum corneum and for estimating when stratum 
corneum sampling in the treated site is sufficient but not excessive. 
 Normally, when the aim is to estimate the total thickness of the stratum 
corneum, the TEWL measurements are made at a position adjacent to the treated skin 
– to avoid potential artefacts affecting TEWL, for example evaporation of residual 
excipients from the formulation. Baseline TEWL (TEWL0) across unstripped stratum 
corneum of thickness L is given by Fick’s first law of diffusion: 
TEWL0 =
D .  K
L
 ∆C                                     (Equation 5) 
where D and K are the diffusion coefficient of water in the stratum corneum and the 
stratum corneum - viable tissue partition coefficient of water, respectively, and ΔC is 
the water concentration gradient across the stratum corneum. 
Subsequently, the stratum corneum is progressively removed by repeated 
adhesive tape-stripping and the TEWL is measured after each tape-strip removed. 
After tape-stripping has removed a depth x of stratum corneum, the TEWL will have 
increased to a new value given by: 
TEWLx =
D .  K
(L−x)
 ∆C                                                                                 (Equation 6) 
Tape-stripping is continued until the TEWL reaches at least fourfold the initial 
value. This is to ensure that at least 75% of the stratum corneum is removed without, 
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however, complete derangement of the barrier (Kalia, Pirot and Guy, 1996; Kalia et 
al., 2000; Wiedersberg and Nicoli, 2012). 
Based on Equation 6, Russell, Wiedersberg and Delgado-Charro (2008) 
developed a non-linear method which describes how transepidermal water loss 
increases as the stratum corneum barrier is removed (Equation 7). The advantage of 
Russell’s method for thickness estimation is that it takes into account that the stratum 
disjunctum, i.e., the looser outer stratum corneum layer, does not provide a significant 
contribution to the barrier to water loss. Therefore, a more precise value of L can be 
determined. 
TEWLx = B +
D .  K
(L−x)
 ∆C              (Equation 7) 
The drawbacks of the tape-stripping technique include (mainly when assessing 
mass of stratum corneum by gravimetric means): the procedure is laborious and 
measurements of mass of stratum corneum can be influenced by environmental 
conditions (e.g., humidity) and static electricity. Nonetheless, it shows advantages 
over other methods of quantifying mass of stratum corneum on tapes (e.g., extraction 
and quantification of proteins from tapes using the protein assay, spectrophotometric 
examination of the tape), such as it is a direct measure of mass of both stratum corneum 
and compounds of interest.   
 
Other in vivo approaches for measuring chemical compounds in the skin  
Microdialysis, including open-flow microperfusion, is an in vivo technique for 
sampling free compound in the extracellular fluid within tissues (de Lange, de Boer 
and Breimer, 2000). Although this is a highly demanding approach as a routine 
method; the technique has many advantages, such as, continuous measurements of a 
compound concentration with time and the probe (ideally) inserted into the site of 
interest. Recently, a series of experiments performed by Bodenlenz et al. (2017) 
demonstrated the utility of open-flow microperfusion as a dermato-pharmacokinetic 
approach to evaluate dermal bioavailability. The technique was capable of measuring 




Skin biopsy (invasive punch) is another approach used to assess the 
bioavailability of a compound in the skin. At first glance, the technique seems to be 
the most logical solution to measure the mass/concentration of a compound in the 
target tissue; however, the approach is unacceptable for routine use, especially 
considering the need to perform repeated biopsies to characterise the pharmacokinetic 
profile of the drug. 
Suction blister has also been applied as an approach to assess the 
bioavailability of a compound in the skin (Treffel et al., 1991; Svedman and Svedman, 
1998). The technique is performed by applying a partial negative pressure to the skin, 
which will disrupts the epidermal–dermal junction and forms a blister which fills 
progressively with interstitial fluid and serum (Volden et al., 1980). This liquid offers 
a pharmacokinetic ‘compartment’, therefore, in which a previously applied drug can 
be sampled and quantified; if multiple blisters are raised, then a concentration-time 
profile of the drug in the skin can be obtained. While on the surface attractive, this 
approach is also quite invasive and causes obvious scarring.  
 
1.4.3 Mathematical methods 
In parallel to the progression in experimental methods, mathematical 
modelling of dermal absorption has been demonstrated to be useful in predicting 
important parameters involved in skin absorption processes.  
Several mathematical models have been developed to explain, at least in part, 
percutaneous absorption kinetics (Moss et al., 2002; Yamashita and Hashida, 2003; 
Lian, Chen and Han, 2008; Mitragotri et al., 2011). The main beneﬁts of mathematical 
models over experimental measurements include reduction of resources (refining and 
reducing the need of experiments) and avoiding ethical issues. In addition, the models 
may assist in the better understanding of mechanisms of absorption (Tsakovska et al., 
2017).   
The principal objectives of a mathematical model is to (i) be able to represent 
the processes associated with absorption accurately, (ii) be able to describe/summarise 
experimental data with parametric equations, and (iii) predict kinetics under varying 




1.4.3.1 Steady-state membrane models 
The fundamental equation to describe the transport of a chemical compound 
through the skin under steady-state conditions can be given by Fick’s first law 
(Equation 8). It is worth pointing out that steady-state can only be reached after the 
lag time for diffusion of the permeant has passed. The lag time (TLag) can be 
mathematically described by Equation 9 and can be estimated from the x-intercept of 
the linear portion of the plot representing cumulative solute permeation as a function 
of time. TLag is related to the time necessary to establish a linear concentration profile 








                                                                                           (Equation 9) 
where Q is the amount of solute crossing the skin membrane of area, A, over a time 
period, T. Cs is the (constant) concentration gradient across the two interior surfaces 
of the skin, D is the diffusion coefficient in the skin membrane and L is the diffusion 
pathlength (or the thickness of the membrane). It is important saying that Equations 8 
and 9 assume that the skin barrier behaves as a homogeneous membrane, which means 
that its properties do not vary with time and/or position.     







             (Equation 10) 
Assuming the stratum corneum as the rate-limiting barrier for skin drug 
permeation, the maximum flux (Jmax) can be expressed in terms of thermodynamic 
activity (Higuchi, 1960). Therefore, Jmax will be reached when maximum solubility of 





                                   (Equation 11) 
where D is its diffusion coefficient in the stratum corneum, KSC/V is the partition 
coefficient of the permeant between the stratum corneum and the vehicle and Cv,sat is 
the saturation concentration of the permeant in the vehicle. The diffusion coefficient 
measures how easily the permeant traverses the stratum corneum, while KSC,v 
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describes the distribution of the permeant between the stratum corneum and the 





              (Equation 12) 
where CSC,sat is the saturation concentration of the permeant in the stratum corneum.  
The next section will further develop these principles to demonstrate the 
predictive value of mathematical models of skin permeability in defining the 
absorption of therapeutic and toxic compounds through the skin. 
 
1.4.3.1.1 Quantitative structure–permeation relationship (QSPR) models 
Quantitative-structure permeability relationships (QSPRs) are among the most 
intensively researched area, which correlate skin permeability to the structure of the 
permeant, described by physicochemical properties and other structural descriptors. 
These models rely on experimental data for skin permeability and build quantitative 
correlations using statistical approaches (e.g., multilinear regressions).  
The main focus of QSPRs has been the assessment of a permeability 
coefficient (kp) which is defined as the steady-state flux of compound across the skin 




                         (Equation 13) 
Often the concentration of the compound is essentially zero on one side of the 
skin (‘sink conditions’) and kp is then the ratio of Jss and Cv. By describing the skin as 




                                               (Equation 14) 
where K is the partition coefficient between skin-membrane. By assuming that the 
stratum corneum is the rate limiting barrier, which is often the case, and by using L as 
the thickness of the stratum corneum, then K and D in Equation 14 describe the 




 Knowledge of both kp and Cv,sat permits an estimation of the maximum flux 
(Jmax) of the molecule across the barrier (Equation 15): 
Jmax =  kp × Cv,sat             (Equation 15) 
Most QSPR models provide algorithms to calculate kp when the vehicle is 
assumed to be aqueous. A very frequently cited QSPR model is reported by Potts and 
Guy (1992). This model is based on Flynn’s dataset (93 compounds) (Flynn, 1990). 
The best fit of the equation was (Equation 16): 
log kp (cm h
−1) = −2.72 + 0.71 log P − 0.0061MW                              (Equation 16) 
which had an overall correlation coefficient (r2) of 0.67. The experimental values used 
to derive Equation 16 included chemicals with MWs ranging from 18 to over 750 and 
log P values from −3 to +6. The model clearly shows that small, lipophilic chemicals 
are those with the greatest skin permeabilities. Given the typical level of variability in 
skin permeability measurements, the Potts and Guy equation performs well and 
certainly provides reasonable predictions. However, the approach focuses on the 
stratum corneum as the exclusive rate-limiting barrier and therefore significantly 
overestimates kp for highly lipophilic compounds. This issue was successfully 
addressed by Cleek and Bunge (Cleek and Bunge, 1993; Bunge and Cleek, 1995), 
whereby a corrected kp value for lipophilic compounds (kp(corr)) may be calculated 







                                   (Equation 17) 
where kp is calculated from the Potts and Guy correlation (Equation 16). 
Many other QSPR models have been proposed and compared. For example, 
Lian, Chen and Han (2008) compared seven mathematical models using an 
experimental dataset of skin permeability for 124 chemical compounds compiled from 
various sources. They conclude that Potts and Guy correlation and a model developed 
by Mitragotri (2002) give the best predictions. It is important to say that both models 
have many features in common.  
Beyond the estimation of the permeability coefficient, QSPR relationships 
have also been used for estimation of the partition coefficients. Experimentally, 
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partition coefficient values can be obtained from equilibration experiments between a 
skin membrane and a solution of the compound of interest. Kretsos et al. (2008) 
investigated the partition coefficients between the dermis and water (Kde). The analysis 
was carried out on an experimentally obtained dataset of 26 chemicals ranging in MW 
from 18 – 476 Da and four species (human, guinea pig, rat and mouse). After 
experimental work, a mathematical model was developed to predict Kde (Equation 18). 
The Kde model involved ionization, binding to extravascular serum proteins and 
partitioning into a lipid compartment.   
Kde = 0.6 × (0.68 + 
0.32
Fu
+ 0.001 × Fnon  ×  P)                               (Equation 18) 
where fnon is the non-ionized the fraction of the compound in aqueous phase and fu is 
the fraction of compound not bound to albumin.  
 More recently, Yun and Edginton (2013) developed an algorithm able to 
predict partition coefficients between skin and plasma K(skin/p). The prediction models 
use physicochemical descriptors of the compound (log P, degree of ionization (Fi) and 
plasma protein binding (Fu,p)) and organism-specific data (rat volume of distribution 
at steady-state). Table 1 shows the best correlations found for predicting the log of 
K(skin,p) for strong to moderate bases (pKa ≥ 7.4, model 1) and for acids, weak bases 
and neutral compounds (pKa ≤ 7.4, model 2). 
 
Table 1. Mathematical models for predicting log of skin-to-plasma partition 
coefficient (K(skin/p)). Table adapted from Yun and Edginton (2013). 
 
Model Regression models n R2 
1 log K(skin/p) = –0.14 + 0.66(log Vss) + 0.03(log P) 28 0.80 
2 
log K(skin/p) = –0.33 + 0.54(log Vss) + 0.16(log P) –   
0.32(Fi) + 0.38(Fu,p) 
26 0.73 
 
 Despite being extremely useful, QSAR model concepts typically cannot 
provide information about the change of concentration in the barrier over time. 
Another drawback is the lack of predictive confidence of most models when using 
values of input parameters outside the range of values of the training set (Selzer, 




1.4.3.2 Non-steady-state membrane models 
While Fick's first law assumes steady-state, Fick's second law predicts changes in 
the concentration gradient, through diffusion, with time. According to Fick's second 
law, the concentration of a compound across a membrane, normally designated by 
C(t,x), where t is the period of time, can be estimated by the solution of the following 






                                               (Equation 19) 
where D is the diffusion coefficient which is assumed to be constant across the 
membrane. The negative sign means that the diffusion occurs in the direction of 
decreasing concentration; thus, the flux is always positive. C is the concentration of 
compound, in the skin, x is the depth (thickness) of skin.   
Additional terms can be included to address peculiarities of the skin barrier, for 
example binding phenomena (Frasch et al., 2011), enzymatic activity (Guy, Hadgraft 
and Bucks, 1987), corneocyte desquamation (Reddy, Guy and Bunge, 2000), or to 
model elimination or clearance of molecules from the stratum corneum (Nicoli et al., 
2009). 
The concentration profiles of a drug as a function of the relative position in the 
stratum corneum (x/L) have typically been fitted to a solution of Equation 20, 
assuming the following boundary conditions: i) the concentration of the permeant in 
the vehicle at  the surface of the stratum corneum is constant; ii) that the stratum 
corneum is initially free of the permeant; iii) that the stratum corneum is homogeneous 
in its barrier properties; and iv) that the viable epidermis provides a perfect sink for 
permeation. Under these circumstances, the concentration (Cx) of permeant, as a 
function of application time (tapp) and of position (x) in the SC of total thickness (L) is 
given by a solution of Fick's second law: 
Cx = KCv [1 −  
x
L







)] sin(mπx L⁄ )
m
∞
m=1 ]           (Equation 20) 
where Cv is the concentration of the permeant in the vehicle. By fitting the 
concentration profile to this equation, estimates of the compound’s stratum corneum–
vehicle partition coefficient (K) and its characteristic diffusion parameter (D/L2, which 
has units of [time]-1 like a first order rate constant) can be obtained. 
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 Herkenne et al. (2007) using the K and D/L2 values obtained from a 30 - minute 
exposure, satisfactorily predicted ibuprofen uptake for longer application times 
(Figure 8), suggesting that reliable and quantitative information can be obtained with 
this approach. A similarly good prediction was obtained for terbinafine (Alberti et al., 
2001) and betamethasone 17-valerate delivery (Wiedersberg, Leopold and Guy, 
2009). 
An important issue, when using this approach, is the choice of the exposure 
period used for the determination of K and D/L2. This period should be long enough 
to allow the achievement of a measurable profile inside the stratum corneum, but not 
so long that the steady state has been reached. In the latter case, the profile inside the 
membrane becomes linear (see Figure 9), information on the diffusive parameter D/L2 
is lost and Equations 20 simplifies to (Equation 21): 
Cx = KCv (1 −
𝑥
𝐿
)                                                                                      (Equation 21) 
 
  
Figure 9. Concentration-depth profiles following Equation 20, at increasing times, 
showing the kinetics of a diffusion process from short times (exponential decay) until 
steady-state (straight line). (Herkenne et al., 2007). Permission to reproduce this image 
has been granted by the publisher. 
 
To investigate the time variation of the mass of compound in the stratum corneum, 
two mechanistic models were derived by Cleek and Bunge (1993). One considers the 
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stratum corneum where it is assumed that the membrane is sufficiently thick and the 
exposure time short enough, such that it behaves as a semi-infinite membrane 
(Equation 22). The other considers the stratum corneum as a single finite membrane 






                              (Equation 22) 
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A













n=0 ]                                  (Equation 23) 
For short application times, when the compound has not reached the bottom of the 
stratum corneum, Equations 22 and 23 are applicable. Equation 23 is important for 
longer exposure times, when the compound has ‘discovered’ the lowest layer of the 
stratum corneum.  
 
1.4.3.2.1 Compartmental models 
Compartmental (or pharmacokinetic) models are often used to study the fate 
of chemical compounds entering and leaving the body. These models treat the skin as 
one or more well-stirred compartments, which eliminates the space dependency of the 
partial differential diffusion equation (Equation 20) and results in a series of ordinary 
differential equations (ODEs) that describe the change of amount of solute in different 
compartments over time. The transfer between the compartments is described by first-
order rate constant expressions.  
When skin is included in these models, it is usually represented either as a 
single compartment or by two compartments, separately distinguishing the lipophilic 
(stratum corneum) and hydrophilic layers (viable epidermis and dermis) of the skin. 
Figure 10 illustrates two simple examples of skin compartment models: a model which 
uses only a single compartment to account for the skin (one-compartment skin model) 
and a model which uses two compartments to represent the skin (two-compartment 
skin model).  In a one-compartment model, the skin compartment may represent the 
stratum corneum alone, the viable epidermis alone, the epidermis, or the epidermis 
plus dermis. In a two-compartment model, the first skin compartment usually 
represents the stratum corneum and the second, the viable epidermis (or the viable 
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epidermis plus dermis). In addition to the skin compartment(s), one compartment 
represents the vehicle and one compartment is used to represent the blood (or receptor 
solution in in vitro/ex vivo diffusion cell experiments). 
 
Figure 10. Schematic diagrams of (a) one-compartment and (b) two-compartment 
models. C denotes the average concentration in the compartment and V is the volume 
of the compartment.  
When the compartment model is used to analyse in vivo experiments, the 
dermis is completely vascularised, and blood flow removes the compound from the 
dermis quickly. Consequently, the dermis does not separate the viable epidermis from 
the blood compartment and the viable epidermis compartment should include only the 
viable epidermis. However, when the compartment model is used to analyse in vitro 
experiments, the blood compartment in Figure 9 represents the receptor chamber and 
compounds must diffuse across all skin layers present in the experiment (i.e., the 
stratum corneum only, the epidermis only, or the epidermis plus dermis) to reach the 
receptor chamber. In this case, both the viable epidermis and dermis (or portions 
thereof) should be included in the skin description.  
In the most common exposure scenario, chemical transfers from the vehicle 
into, eventually, the blood stream. However, the actual direction of transfer depends 
on the concentration gradient of the chemical in the skin, and transfer from blood to 
vehicle can, theoretically, occur if the concentration in the blood is large relative to 
the vehicle. To allow for transfer in both directions and to make transfer stop when the 
concentration gradient reaches zero, both forward rate constants (e.g., k1) and reverse 
rate constants (e.g., k-1) are included in compartment models. 
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A differential mass balance of chemical in the one-compartment skin layer 




=  𝑘1𝐶𝑣 −  𝑘−1𝐶𝑠𝑘𝑖𝑛 −  𝑘2𝐶𝑠𝑘𝑖𝑛 +  𝑘−2𝐶𝑏𝑙𝑜𝑜𝑑        (Equation 24) 
where Cskin is the averaged concentration in the skin layer. For a two-compartment 
model, differential mass balances of chemical in each layer produce the following 








=  𝑘2𝐶𝑠𝑐 −   𝑘−2𝐶𝑣𝑒 −  𝑘3𝐶𝑣𝑒 +  𝑘−3𝐶𝑏                    (Equation 26) 
where Csc and Cve are the averaged concentrations in the stratum corneum and viable 
epidermis (or the combined viable epidermis and dermis for in vitro experiments that 
include dermis), respectively. 
One drawback of compartmental models is that, in the majority of these 
models, values for rate constants were estimated by fitting experimental data without 
relating the result to the physiological and physical parameters of skin (McCarley and 
Bunge, 2001). The integration of these experimental data with subsequent events in 
the body [via physiologically-based pharmacokinetics (PBPK)] has been more often 
seen in the toxicological rather than pharmaceutical publications. However, the use of 
PBPK modelling for multicomponent systems, such as topical drug products, that are 
applied on the skin is a technique that has gained attention in recent years (Polak et 
al., 2012; Chen et al., 2015). 
In general, PBPK models can be used to describe a variety of exposure routes 
(e.g., inhalation, oral, intravenous, or dermal). PBPK models are constructed from 
mathematical descriptions of system-dependent parameters that include species-
specific anatomy and physiology information (i.e., tissue volume, blood flow, 
glomerular filtration rate, plasma protein and enzyme abundance) and of drug-
dependent parameters (e.g., molecular weight, solubility, pKa and log P) (van der 
Merwe et al., 2005). This approach involves a mechanistic description of processes 
involved in absorption, disposition and elimination of administered compounds into 
and from different compartments/organs. The advantages of PBPK models are, 
however, difﬁcult to realise because the necessary anatomical and physiological 
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parameters are often not available, and the processes are not well understood. This can 
result in oversimpliﬁcation of the physiological processes involved, which limits the 
advantage of PBPK models over traditional compartmental models. 
In summary, membrane models more accurately represent the physiological 
character of skin with respect to the dermal absorption process. However, 
mathematical solutions of membrane models can be cumbersome. On the other hand, 
compartmental models treating the skin as a well-stirred compartment(s) offer 
simplified mathematics for these situations. Nevertheless, relating compartment model 
rate constants to physiological parameters is still a challenge. 
 
1.5 Transdermal drug delivery 
Transdermal products have unique advantages relative to other dosage forms and 
routes of administration. They can provide several advantages (when compared with 
other administration routes), such as: sustained drug delivery for several days, 
avoidance of first pass metabolism of a drug by the liver and the option to remove at 
any time to stop drug delivery, if needed.  
Currently, there are 18 transdermal drugs (Table 2) present in over 25 FDA-
approved products (FDA Orange Book database of the end of 2017). These systems 
are, usually, complex drug-device combination products that may be broadly 
categorised as having either a reservoir or a matrix design. A reservoir-type patch 
holds the drug in a solution or gel, from which drug delivery can be governed by a 
rate-controlling membrane positioned between the drug reservoir and skin. Reservoir-
type patches offer an advantage over matrix-type patches in terms of formulation 
flexibility and tighter control over delivery rates, although they can have an initial 
burst of drug release. Reservoir-type patches usually involve greater design 
complexity. By contrast, matrix-type patches, which were introduced after reservoir-
type patches, combine the drug, adhesive and mechanical backbone of the patch into 
a simpler design that does not involve a rate-controlling membrane; skin permeability 
usually governs the rate of drug delivery. Although these patches are easier to 
fabricate, they have limited flexibility in their design compared with reservoir-type 
patches (Prausnitz, Mitragotri and Langer, 2004). 
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Although, transdermal drug delivery aims to deliver the active to the systemic 
circulation, in comparison with intravenous or oral administration, the kinetics of 
transdermal delivery into the systemic circulation can be distinctive due to the 
significant differences in absorption rates. In general, the absorption rate constant of a 
compound after oral administration is greater than its elimination rate constant from 
the body. On the other hand, for transdermal delivery, absorption rate constant can be 
much slower than elimination, leading to so-called ‘flip–flop kinetics’ where the usual 
rate-dependence on elimination observed from oral (immediate release products) and 
intravenous administration is ‘flipped’, and the absorption rate becomes the rate-
determining step (Figure 11) (Oliyai and Stella, 1993; Lefevre et al., 2007).  
 
Figure 11. Demonstration of ‘flip–flop’ kinetics, comparing the terminal phase either 
rate-limited by the drug disposition kinetic (oral administration, open circles) or by 
the drug absorption kinetics (topical administration, closed circles). (Jepps et al., 
2013). Permission to reproduce this image has been granted by the publisher. 
 
Although, transdermally delivered drugs are not meant to target structures 
within the skin, they use the skin as an entrance and provide valuable information 
about a drug’s transport from the skin surface to the systemic compartment. To be 
specific, for all transdermal patches currently approved, there are published 
pharmacokinetic data telling the drug input-rate and resulting systemic plasma 
concentration levels during patch wear and after removal. In contrast, topical 
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dermatological products, such as creams, ointments and gels, or even in topical 
patches, designed to produce a local effect (for example, to treat joint pain), the rate 
of drug entering the skin is not well characterised.  
Therefore, it is clear that as the true input-rate is known, the transdermal 
products can be useful for assessing the validity of experimental approaches for 




Table 2. FDA-approved transdermal patches.  
Drug Trade name Patch design 
Strength 
(mg) 
Active delivery area 
(cm2) 
Input-rate 
(μg cm-2 h-1) 
Labelled 
application period 
Buprenorphine Butrans® Matrix 5.0 – 20.0 6.2 – 25a 0.8 7 days 
Clonidine Catapress-TTS® Reservoir 2.5 – 7.5 3.5 – 10.5 1.2 7 days 
Estradiolb 
Estraderm® Reservoir 4.0 – 8.0 10 – 20 0.2 3 – 4 days 
Climara® Matrix 2.0 – 7.6 6.5 – 25 0.2 7 days 
Vivelle® Matrix 4.3 – 8.7 14.5 – 29 0.1 3 – 4 days 
Alora® Matrix 0.77 – 3.1 9 – 26 0.1 3 – 4 days 
Vivelle-dot® Matrix 0.39 – 1.56 2.5 – 10 0.4 3 – 4 days 
Menostar® Matrix 1.0 3.25 0.2 7 days 
Minivelle® Matrix 0.62 – 1.65 2.48 – 6.6 0.6 3 – 4 days 
Estradiol (E) & Norethisterone 
Acetatec (NAc) 
Combipatch® Matrix 
E/NAc: 0.6/2.7 &  
0.51/4.8 
9 – 16 E/NAc: 0.2/0.4 3 – 4 days 
Estradiol (E) & Levonorgestrel (L) Climara Pro® Matrix E/L: 4.4/1.39 22 E/L: 0.09/0.03 7 days 
Ethinyl estradiol (EE) & 
Norelgestromind  (N) 
Xulane® Matrix EE/N: 0.53/4.86 14 EE/N: 0.1/0.4 7 days 
Fentanyl Duragesic® Matrix 1.55 – 12.4 5.5 - 44 2.3 72 h 
Glyceryl Trinitratee 
Nitro-Dur® Matrix 20 – 160 5 – 40 20 12 – 14 h 
Minitran® Matrix 9 – 54 3.3 – 20 11.1 12 – 14 h 
Granisetron Sancuso® Matrix 34.3 52 2.5 Up to 7 days 
Methylphenidate Daytrana® Matrix 27.5 – 82.5 12.5 – 37.5 ~ 87 Up to 9 h 
Nicotine 
Nicoderm CQ® Reservoir 36 – 114 10 – 30 29.2 24 h 
Habitrol® Matrix 36 – 114 10 – 30 29.2 24 h 
Oxybutynin Oxytrol® Matrix 36 39 4.2 3 – 4 days 
Rivastigmine Exelon® Matrix 9 – 27 5 – 15 ~ 38 24 h 
Rotigotine Neupro® Matrix 2.25 – 18 5 – 40 8.3 24 h 
Scopolamine Transderm Scop® Reservoir 1.5 2.5 5.5 72 h 
Selegiline Emsam® Matrix 6 – 12 20 – 40 12.5 24 h 
Testosterone Androderm® Reservoir 9.7 – 24.3 6 – 15f 13.9 24 h 
aSize of the patch reported corresponds to the active area, size of the patch are from 20.25 – 51.84 cm2; bAlso spelled as Oestradiol; cAlso spelled as 
Norethindrone acetate; dAlso spelled as Norelgestromine; eAlso known as Nitroglycerine;  fSize of the patch reported corresponds to the active area, size of the 
patch are from 32 – 44 cm2. 
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2. Aims and organisation of the thesis 
This project aims to characterise, and obtain mechanistic insight, into topical 
dermal delivery. The main target of this work is to explore whether a drug could 
achieve an effective concentration at the target tissue by tracking the drug behaviour 
following skin application. The generalised model describing drug concentration in a 
tissue is dependent on the drug input into the skin and its clearance therefrom.  
Therefore, these two main processes (input into the skin and clearance from the skin) 
were investigated. The influence of other components commonly present in topical 
formulations, which potentially will act as penetration enhancers, on drug absorption 
was also evaluated.   
The work described in Chapter 2 focused on characterising the input functions of 
two transdermal drugs, buprenorphine and nicotine, from commercially available 
patches. The characterisation was performed experimentally using in vitro permeation 
tests. In addition, the input-rate of diclofenac from a medicated plaster, which is 
indicated for a local effect, was determined using the same approach as demonstrated 
for the transdermal drugs. 
In Chapter 3 a further investigation of the behaviour of diclofenac in the stratum 
corneum was taken. The uptake of diclofenac into the stratum corneum and its 
clearance therefrom following application of a medicated plaster was investigated in 
vivo in human.  
The results described in chapter 3 suggested that diclofenac uptake into the stratum 
corneum may be modified by the presence of excipient(s). Therefore, the work 
described in Chapter 4 focused on exploring the uptake of two excipients/co-solvents, 
propylene glycol and butylene glycol, into the stratum corneum in vivo in human, 
following application of the diclofenac medicated plaster.  
The work described in Chapter 5 investigated the hypothesis that information 
about clearance from the skin can be derived from available systemic pharmacokinetic 
data for drugs administered via transdermal delivery systems. A statistical 
mathematical model describing drug clearance from the skin in terms of drug 
molecular descriptors was developed. 
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Finally, Chapter 6 summarises the key findings from each chapter and presents 
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Chapter 2: Deducing drug input-rate from topical 
products using information from transdermal 
delivery 
 
Abbreviations and glossary of terms 
 
BUP      buprenorphine  
DF      diclofenac  
Drug input rate at which the drug reaches the sub-stratum 
corneum layers 
HPLC-UV high-performance liquid chromatography with 
ultraviolet detection 
IVPT     in vitro skin permeation test  
IVRT      in vitro release test 
JBUP      flux of buprenorphine into the receptor solution  
JDF     flux of diclofenac into the receptor solution 
JNIC     flux of nicotine into the receptor solution 
logP     log{octanol-water partition coefficient (P)} 
MW     molecular weight (Daltons)  
NIC      nicotine 
RS     receptor solution 
SC     stratum corneum 
Topical product products where the site of action in the skin or 
subcutaneous tissues 
Transdermal product products where the site of action of the drug is 
reached via the systemic circulation 










The skin has many features which make it an attractive site for both topical 
(dermatological and locally-acting) and systemic drug delivery (Zaffaroni, 1991; 
Kumar et al., 2014). Measurement of the bioavailability of a drug in the skin after 
topical application is an important objective when attempting to assess whether the 
target-site concentrations are satisfactory to treat the disease. However, determining 
the amount of drug that reaches the different skin layers is still a challenge (Schäfer-
Korting et al., 2007).  
In terms of dermato-pharmacokinetics, the skin is most frequently represented 
as a 2-compartment system: the stratum corneum (SC; usually the rate-limiting 
barrier), which is predominantly lipophilic, and the viable epidermis and dermis which 
are often considered as a single, hydrophilic, compartment (McCarley and Bunge, 
2001; Roberts et al., 2001). The viable epidermal and upper dermal compartments are 
the site of action of the vast majority of topically applied drugs. It follows that 
knowledge of the ‘drug input’ would help to derive the concentration of the drug in 
this region. 
For topical dermatological products, such as creams, ointments and gels, or 
even in topical patches, designed to produce a local effect (for example, to treat joint 
pain), the rate of drug entering the skin is not provided by the manufacturer. Local 
tissue or blood level data, from which useful information about drug ‘input function’ 
could be extracted, is scarce. Although in vitro approaches, such as skin permeation 
tests, are useful to estimate drug input-rate from such products, validation of these 
approaches is difficult due to the lack of in vivo data.   
In contrast, for transdermal3 patches, the rate at which the drug reaches the 
systemic circulation is provided on the product label. This delivery rate can be deduced 
by deconvoluting the resulting systemic plasma time profile. One method commonly 
used for this purpose is called Wagner-Nelson (Wagner & Nelson 1964) analysis.  
Wagner–Nelson deconvolution analysis (Equation 1) can be applied only to 
one-compartment drugs. This method is based on the mass balance theory, where no 
                                                          
3 The word ‘transdermal’ here is used to mean products where the site of action of the drug is reached 
via the systemic circulation; an example is a nicotine patch, where nicotine must reach the brain to 
achieve its therapeutic effect 
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kinetic model for the absorption process is assumed. The method does not require 
intravenous drug administration, because it assumes identical elimination rate 
coefficient (ke) between intra- and extra-venous administrations and, therefore ke can 
be estimated from the final stage of the oral curve. However, when flip-flop occurs, 
intravenous drug administration is therefore needed to estimate ke. 







∞                          (Equation 1) 
where Fabs is the fraction absorbed, At is the drug amount absorbed at time t, A∞ is the 
drug amount absorbed at infinite time, Ct is the drug concentration at time t, ke is the 
elimination rate coefficient, AUC0
t  is the area under the curve from time 0 to time t and 
AUC0
∞ is the area under the curve from time 0 to infinity. 
Knowing Fabs, the in vivo drug input rate can be calculated from the slope of 
the line obtained from the plot of log fraction unabsorbed versus time (Rao et al., 
2001).  
It is clear that as the true input-rate is known, these products can be useful for 
assessing the validity of experimental approaches for determining input-rates from 
dermatological and locally acting topical products.  
Therefore, the first component of this work was to characterise experimentally, 
in vitro, the input functions of two transdermal drugs, buprenorphine and nicotine, 
from commercially available patches, namely Transtec® and Nicotinell®, respectively. 
Currently, there are 18 transdermal drugs present in over 25 FDA-approved 
transdermal products (FDA Orange Book database of the end of 2017). These drugs 
span a relatively wide range of physicochemical properties: for example, molecular 
weights between 160 and 470 Daltons and log{octanol-water partition coefficient (P)} 
values from about 1.0 to 5.0. Buprenorphine and nicotine (Table 1) are at the limits of 
the physicochemical range of drugs in approved transdermal products, having 
molecular weights of 162 and 468 Daltons and log P values of about 1.2 and 5.0, 
respectively. 
The second component focused on determining the input function of 
diclofenac from a medicated plaster (from now on also referred to as a patch) which 
is indicated for a local effect (therefore there is no requirement for the manufacturer 
to provide the input-rate). 
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Table 1. Selected physicochemical properties of the three drugs studied in this chapter 
and specification of the drug delivery systems in which they are formulated. 
 








Molecular weight (Da) 468 162 411.32b 
log P  4.98 1.17 4.26c 
Drug content (mg) a 20 17.5 180 
Active delivery area (cm2) a 25 10.0 140 
Labelled in vivo delivery 
rate a 
35 µg/h 7 mg/24h 
Not 
available 
Labelled application period 
(h) a 
72 24 12 
aInformation provided in the manufacturer’s packing insert; 
bMolecular weight of diclofenac epolamine; 
clog P of diclofenac acid. 
 
2. Materials and Methods 
2.1. Chemicals and reagents 
The transdermal patches tested were: Transtec® (35 µg/h, 20 mg of buprenorphine 
over 25 cm2) from NAPP (Cambridge, UK) and Nicotinell® (7 mg/24h, 17.5 mg of 
nicotine over 10 cm2) from Novartis (Camberley, UK). Voltaren® (medicated plaster, 
180 mg of diclofenac epolamine over 140 cm2) was from GlaxoSmithKline (Munich, 
Germany). Buprenorphine base was from Reckitt and Colman (UK). (-)-Nicotine from 
Sigma Aldrich (Dorset, UK). Diclofenac epolamine was from Toronto Research 
Chemicals (Toronto, Canada). All solvents were from Sigma Aldrich (Dorset, UK). 
Fresh abdominal porcine skin was obtained from a local abattoir, dermatomed 
(Zimmer®, Hudson, OH, USA) to a nominal thickness of 750 µm, frozen within 24 h 
of slaughter, and thawed before use.   
2.2. Analytical methods  
Assays for buprenorphine (BUP), nicotine (NIC) and diclofenac (DF) were 
developed using HPLC (Dionex, UK), with UV detection, using Chromeleon 
software. A HiQSil C18HS analytical reverse phase column (150 x 4.6 mm i.d.; 5 µm 
particle size) (Kromatek, UK) was used for the three drugs. The chromatographic 





Table 2. HPLC-UV method conditions used for quantification of BUP, NIC and DF. 











acid 0.1% v/v 
Oven Temp. (°C) 25 25 40 
Flow-rate (mL min-1) 1.0 1.0 1.2 
Retention time (min) 11.8 3.2 7.3 
Injection volume (µL) 75 50 100 
UV detection (nm) 220 260 280 
Limit of quantification 
(µg mL-1) 
0.14 0.12 0.10 
ACN: Acetonitrile; MeOH: Methanol; TFA: Trifluoroacetic acid; PBS: Phosphate 
buffered saline. 
 
2.3. In vitro release tests (IVRT) 
Drug release from the three formulations (Transtec®, Nicotinell® and Voltaren®) 
was evaluated using Franz-type diffusion cells. Patches were cut into disks and 
clamped (with no membrane present) in the diffusion cells (nominal diffusion area = 
1.77 cm2, PermeGear, Inc., Hellertown, PA, USA). The receptor chamber was filled 
with 7.4 mL of a receptor solution (Table 3) and stirred magnetically at a constant 
speed of 500 rpm. The temperature of the receptor solution was controlled by a 
circulating water bath at 37 ± 1 °C. Aliquots of the receptor solution (1.0, 1.5 and 0.5 
mL for BUP, NIC and DF, respectively) were withdrawn at each time point and 
immediately replaced with the same volume of fresh solution. The drug concentration 
in these samples was determined by the HPLC-UV method described above (Table 2). 
A correction was made for the previously removed samples when determining the total 
amount released. The data were expressed as the cumulative amount of drug released 
as a function of the square root of time (in accord with Fick’s second law of diffusion 
(Siepmann and Peppas, 2011)).  
 
2.4.  In vitro permeation tests (IVPT) 
The in vitro permeation of BUP, NIC and DF from approved patches was 
measured in Franz diffusion cells across dermatomed (~ 750 µm) pig skin. Each patch 
was cut into disks (surface area 1.54 cm2) and adhered to the external side of the skin 
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(before mounting the skin in the Franz cell). Pressure was applied with a roller (custom 
made; 10 times in two directions) to ensure complete adhesion. The skin samples were 
then positioned between the donor and receptor chamber of diffusion cells.  
In the first type of experiment (Figure 1 (a)), the disposition of the drug in the 
stratum corneum, ‘viable’ skin and receptor solution was evaluated over of time. At 
the end of each experiment, the total amount of drug delivered from the patch into and 
through the skin during the period of observation was determined; i.e., recovered 
quantities in the SC, in the remainder of the skin, and in the receptor compartment of 
the diffusion cell. 
The second type of experiment (Figure 1 (b)) investigated the cumulative 
delivery of BUP, NIC and DF into the receptor solution following application of the 
respective patches for 72, 24 and 30 hours, respectively. Aliquots of the receptor 
solution (1.0 mL for BUP and NIC; 0.5 mL for DF) were withdrawn at intervals and 
immediately replaced with the same volume of fresh solution.  Drug concentrations in 
these samples were again determined by HPLC (Table 2). A correction was made for 
the previously removed samples in determining the total amount permeated. The 
diffusion flux was calculated using Fick’s first law from the slope of the linear portion 
of the plot of the cumulative amount of drug permeated per area of skin against time.  
The third type of experiment (Figure 1 (c)) investigated the rate at which drug was 
cleared from the SC and the epidermis and dermis. Transtec® was applied on the skin 
for 72 hours, Nicotinell® for 2 hours and Voltaren® for 6 hours. Subsequently, the 
patches were removed and the skin left (mounted on the diffusion cell) for a further 
24 (Transtec®), 1.5 and 2 hours (Nicotinell®) or 5, 17 and 24 hours (Voltaren®) before 
tape-stripping.  
 At the end of each experiment, the amount of drug in the SC was assessed by 
sequential removal of this outer skin layer by tape-stripping. Templates (Scotch® 
Tape, 3M, The Consortium, UK), with a circular internal area of 1.54 cm2, were 
adhered to the skin, then an adhesive tape strip (2.0 cm x 2.5 cm, Scotch® Tape, 3M) 
was applied to the skin, pressed firmly down and removed quickly. The procedure was 
repeated until 20 strips had been taken. The mass of skin removed on each tape was 
determined by weight difference (Sartorius model SE2-F, Sartorius AG, Germany), 
before and after application to the skin. Before weighing, the tapes were discharged of 
static electricity (R50 discharging bar and ES50 power supply, Eltex Elektrostatik 
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GmbH, Weil am Rhein, Germany). From this mass, and knowing the area of SC on 
the tape, it was possible to calculate the SC thickness removed (assuming an SC 
density of 1 g cm-3, Anderson and Cassidy (1973)) and hence the corresponding 
position (or depth) within the barrier. After weighing, 
tapes were extracted individually (Table 3) and analysed for BUP, NIC or DF by the 
HPLC-UV method described above (Table 2). 
The methods used to ensure efficient extraction of the drugs from the SC tape-
strips and from the remaining skin post-stripping are described in Table 3. Mean 
extraction efficiencies were greater than 89% from tape strips and remaining tissue 
(details are provided in the ‘Supplementary Information’ (Tables S1 – 4)).  
Table 3. Details of the experimental set-up used for the in vitro permeation tests. 




PEG 400:PBS 10 mM (pH 
7.4)  (+ 0.01% of sodium 
azide) 
100% 




ACN:TFA 0.03% v/v a 
40:60 
ACN:PBS 10 mM 
(pH = 7.4)b 
100% 
Methanola 
aExtraction volumes were 1.5 mL for tape strips and 4 mL for remaining skin; 





Figure 1. Schematic representation of the IVPT experiments performed to assess: (a) disposition of the drug in the stratum corneum, ‘viable’ skin 
and receptor solution over time; (b) drug’s permeation profile into the receptor solution and (c) redistribution of the drug after patch removal. 
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2.5. Determination of nicotine loss during permeation experiments and on the 
tapes during storage 
 
As NIC has been described as a volatile and light sensitive substance (Ruela et al., 
2013; Davaran et al., 2005), experiments were carried out to identify whether there 
was a significant loss of drug during permeation experiments and from the tapes during 
storage. 
First, amount of NIC in the receptor solution was investigated in the presence and 
absence of light. Solutions of nicotine in PBS with a known drug concentration (25.0 
µg/mL, mean expected concentration in the receptor solution during permeation 
studies) were stored for 24, 48 or 72 hours in the presence (clear glass vial) or absence 
(amber glass vial) of direct light.  
Second, the volatility of NIC from adhesive tapes was evaluated by spiking tape 
stripped samples of untreated SC with a known concentration of drug (6.0 µg/mL, 
mean expected concentration in the SC). Spiked tapes were stored in the presence of 
light (transparent tray) and in the absence of light (tray wrapped in aluminium foil). 
After 24, 48 and 72 hours, NIC was extracted from the tapes by shaking overnight 
with 1.5 mL of acetonitrile and phosphate buffer pH 7.4 (40:60) and analysed by 
HPLC-UV. Standard solutions of NIC (for the HPLC analysis) were protected from 
direct light exposure.  
2.6. Statistical analysis  
Statistically significant differences between calculated input-rates and the 
claimed values were estimated by one sample t-test. Statistical significance was set 
at p < 0.05. Statistical tests were performed using GraphPad Prism (GraphPad 
software, version 7.03, La Jolla California, USA).  
3. Results and discussion 
3.1. Determination of nicotine loss during permeation experiments and on the 
tapes during storage 
There was no significant loss of NIC in the receptor solution and from the tapes 
for at least 72 hours (‘Supplementary Information’, Table S5). All the recoveries were 
above 99%. These results confirm that no NIC volatilisation occurred during the in 




The left-hand panel of Figure 2 shows data from the IVPT study. The cumulative 
permeation of BUP through porcine skin was 11.1 ± 2.4 µg cm-2 (~1.4% of the initial 
drug content) at 72 hours. In the IVRT experiments, on the other hand, the cumulative 
release of BUP from the patch increased linearly with the square root of time (r2 = 
0.99) and, at the end of the 72-hour experiment (√𝑡 = 8.5 h1/2), a total of 457 ± 53 μg 
cm-2 (~57% of the initial drug content) of the drug were released (Figure 2 - right 
panel).  It is clear, therefore, that the skin significantly rate-controlled the permeation 
of BUP to the receptor phase (Guy and Hadgraft, 1992).  
 
Figure 2. Left panel: Cumulative skin permeation of buprenorphine from Transtec® 
expressed as a function of time (mean ± S.D.; n = 6; Figure 1 (b)). The dashed line is 
the best fit linear regression line to the data from 24 h. Right panel: Cumulative release 
of buprenorphine from Transtec® as a function of the square-root of time (mean ± 
S.D.; n = 3).  
Figure 3 shows a composite distribution profile of BUP in each compartment: 
SC, ‘viable’ skin (i.e., that remaining after tape-stripping) and receptor solution 
during the patch application and after its removal. A relatively rapid accumulation of 
BUP in both SC and the ‘viable’ skin was observed between 2 and 8 hours, after 
which the drug concentrations in these ‘compartments’ remained quite constant until 
72 hours. The redistribution of the drug after patch removal was also observed. Whilst 
the reservoir of drug in the SC remained relatively constant after removal of the patch, 
drug in the ‘viable’ skin moved into the receptor. 
Despite the similar amounts of BUP recovered from the SC and the ‘viable’ 
skin, it is important to bear in mind that the concentration of BUP in the ‘viable’ skin 
was much lower than in the SC. This happened for two obvious reasons: first, the 
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thickness of the SC is only ~15 µm whereas the thickness of the ‘viable’ skin was 
~735 µm. Therefore, the volume of the SC is much smaller than the volume occupied 
by the ‘viable’ skin. Second, the lower concentration of BUP in the ‘viable’ skin may 
reflect slow partitioning of this lipophilic drug from the SC into a comparatively 
aqueous environment. These two phenomena are clearly linked to the greater 
concentration in this tissue. It should be noted, though, that the accumulation of drug 
observed in vitro may not reflect the situation in vivo, given that the skin 
microcirculation, just below the epidermis, is expected to guarantee relatively rapid 
clearance of a drug into the systemic circulation (Leal et al., 2017; Godin and 
Touitou, 2007). 
 
Figure 3. Distribution of buprenorphine in the stratum corneum, ‘viable’ skin (after 
tape-stripping) and receptor solution as a function of time (mean ± S.D.; n = 6; Figure 
1 (a) and (c)).  The arrow indicates the time of patch removal. 
 
The flux of BUP (JBUP) across the entire skin (i.e., determined from slope of 
the permeation profile into the receptor solution shown in Figure 1) was 0.16 ± 0.03 
µg h-1 cm-2. From the disposition of BUP in the in vitro experiments performed, and 
‘correcting’ for drug in ‘viable’ skin, JBUP was 0.81 ± 0.33 µg h-1 cm-2 (72-hour 
experiment). It follows that, the flux deduced from the receptor phase sampling does 
not take into account accumulation in the tissue and the fact that the normal clearance 
mechanism (i.e., the microcirculation) of drug from the skin is not operative in vitro.  
 65 
 
Therefore, a better estimate of the actual delivery should also include that quantity of 
drug which has entered the skin but not left.  When this is added in, the total delivery 
rate approaches the labelled value for the product, i.e., 1.4 µg h-1 cm-2 for Transtec® 
(Figure 4). It is clear (and previously documented; Roy et al. (1994)) that for BUP (in 
contrast to less lipophilic compounds), it is also the hydrophilic environment of the 
‘viable’ skin, and not only the SC, that is a significant absorption-limiting step. 
 
Figure 4. Input-rate of BUP from the Transtec® transdermal patch from two different 
data analysis approaches applied to the same data set (mean ± S.D.; n = 6). The dashed 




When the NIC patch was evaluated using the same IVRT and IVPT protocols, 
as described above, quite distinct behaviour was observed compared to that shown by 
the BUP delivery system. 
The left-hand panel of Figure 5 shows data from the NIC IVPT study. The 
cumulative permeation of NIC through porcine skin was 617 ± 355 µg cm-2 (~ 35% of 
the initial drug content) at 24 hours. In the IVRT experiments, on the other hand, the 
cumulative release of NIC from the patch increased linearly with the square root of 
time (r2 = 0.98) and, at the end of the 24-hour experiment (√𝑡 = 4.9 h1/2), a total 546 ± 
74 μg cm-2 (~ 31% of the initial drug content) of NIC was released from the patch 
(Figure 5 – right panel).  In contrast to BUP, therefore, the transport of NIC across the 
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skin was determined by its release rate from the patch rather than its subsequent 
penetration across the skin (Guy and Hadgraft, 1992). 
Figure 5. Left panel: Cumulative skin permeation of NIC from Nicotinell® expressed 
as a function of time (mean ± S.D.; n = 6). The dashed line is the best fit linear 
regression line to the data from 24 h (Figure 1 (b)). Right panel: Cumulative release 
of NIC from Nicotinell® as a function of the square-root of time (mean ± S.D.; n = 3). 
 
Unlike BUP, NIC penetrates skin very easily and a relatively small amount of 
NIC was recovered from the SC and ‘viable’ skin (Figure 6). After patch removal, 
the drug was cleared from the SC and ‘viable’ skin into the receptor solution 
relatively rapidly (Figure 7).  
 
Figure 6. Distribution of NIC in the stratum corneum, ‘viable’ skin (after tape-
stripping) and receptor solution as a function of time (mean ± S.D.; n = 6; Figure 1 




Figure 7. Redistribution of NIC after patch removal (mean ± S.D.; n = 6; Figure 1 
(c)).  
The NIC flux (JNIC) across the entire skin (i.e., determined from slope of the 
permeation profile into the receptor solution shown in Figure 5) was 25.7 ± 14.8 µg 
h-1 cm-2. From the disposition of NIC in the in vitro experiments performed, and 
‘correcting’ for drug in ‘viable’ skin, JNIC was 27.0 ± 15.6 µg h-1 cm-2 (24-hour 
experiment). Both approaches were close to the label claim (29.2 µg h-1 cm-2; Figure 
8). 
Clearly, there is a contrast to the case for BUP, where this correction not only 
gave a different value of input-rate, but more importantly, enabled the estimated 
delivery rate to much more closely approach the labelled performance in vivo. 
Thus, measuring flux into the receptor phase provided an accurate 
representation of in vivo performance, and ‘correcting’ for the effect of drug in 
SC/viable skin had little impact (unlike the case for BUP, where this ‘correction’ 
enabled the estimated delivery rate to much more closely approach the labelled 
performance in vivo). The fact that NIC has a balanced lipophilicity (log P ~ 1.2) and 
lower molecular weight (162 Da) is undoubtedly the major reason behind the high 




Previous studies carried out with Nicopatch® (a product with similar 
characteristics to Nicotinell®) using human skin gave a comparable skin permeation 
rate (~ 31.0 µg h-1 cm-2) (Olivier et al., 2003). 
 
Figure 8. Input-rate of NIC from the Nicotinell® transdermal patch from two different 
data analysis approaches applied to the same data set (mean ± S.D.; n = 6). The dashed 
line indicates the claimed value. RS = receptor solution. 
 
3.4. Diclofenac 
The results from the BUP and NIC experiments show that a combination of SC 
sampling and IVPT, informed by IVRT, can provide indicative prediction of in vivo 
drug input-rates from transdermal patches. In the case of NIC, only IVPT is necessary 
whereas, for BUP, the levels measured in the skin in vitro are necessary to provide 
additional information that supports the in vivo outcome of wearing the patch. 
Nonetheless, in any of the two situations, accounting both the receptor and the viable 
tissue provides a good estimate for the input-rate. 
The final component of the work in this paper, therefore, was to apply the approach 
to a topical patch which aims to deliver DF to treat pain and inflammation in 
subcutaneous tissue.  Although pharmacologically-effective systemic levels are not 
the goal of the DF patch, the use of the approach described for BUP and NIC should 
provide information about this drug’s input-rate to the subcutaneous tissue as well. 
The cumulative permeation profile of DF through porcine skin is shown in Figure 
9 (left panel). After 24 hours, 46 ± 10 µg cm-2 (~ 3.6% of the initial drug content) had 
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permeated the skin. On the other hand, the IVRT results for the DF patch reveal a 
linear relationship between the cumulative amount of drug released and the square-
root of time (r2 = 0.99). At the end of 24-hour experiment (√𝑡 = 4.9 h1/2), 692 ± 22 μg 
cm-2 (~ 53% of the initial drug content) of DF were released from the patch to the 
receptor solution (Figure 9 – right panel). The clear difference between the amounts 
of DF released in IVRT and permeated in IVPT suggests that the skin significantly 
rate-controls the permeation of DF to the receptor phase (Guy and Hadgraft, 1992). 
Figure 9.  Left panel: Cumulative skin permeation of DF from Voltaren® expressed as 
a function of time (mean ± S.D.; n = 6; Figure 1 (b)). The dashed line is the best fit 
linear regression line to the data from 24 h. Right panel: Cumulative release of DF 
from Voltaren® as a function of the square-root of time (mean ± S.D.; n = 3). 
 
Figure 10 shows a composite distribution profile of DF in each compartment: 
SC, ‘viable’ skin (i.e., that remaining after tape-stripping) and receptor solution 
during the patch application and after its removal. A relatively rapid accumulation of 
DF in both SC was observed during the first 2 hours, after which the drug 
concentrations in this ‘compartment’ remained quite constant until 30 hours. The 
redistribution of the drug after patch removal was also observed. Whilst the reservoir 
of drug in the SC remained relatively constant after removal of the patch, drug in the 
‘viable’ skin moved into the receptor (Figure 11).  
The DF flux (JDF) across the entire skin (i.e., determined from slope of the 
permeation profile into the receptor solution shown in Figure 9) was 0.17 ± 0.09 µg 
h-1 cm-2. From the disposition of DF in the in vitro experiments performed, and 
‘correcting’ for drug in ‘viable’ skin, JDF was 1.30 ± 0.31 µg h-1 cm-2 (30-hour 
experiment). The comparison between both approaches is shown in Figure 12. 
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Figure 10. Distribution of DF in the stratum corneum, ‘viable’ skin (after tape-stripping) 
and receptor solution as a function of time (mean ± S.D.; n = 6; Figure 1 (a)). 
 





Figure 12. Input-rate of DF from the Voltaren® medicated plaster from two different 
data analysis approaches applied to the same data set (mean ± S.D.; n = 6). RS = 
receptor solution. 
In broad terms, therefore, DF behaves much more like BUP than NIC. This 
observation is consistent with DF’s physiochemical properties – SC is definitely rate-
limiting the input flux, significant levels in the SC were measured and DF showed a 
strong affinity for the barrier layer of skin, and flux into the underlying skin tissue 
was comparable to that of BUP. 
 
4. Conclusion 
The good agreement between the experimentally determined input-rates of the two 
drugs and their labelled performance in vivo lends support to the potential utility of 
the in vitro approach proposed to define topical drug input-rates more broadly; that is, 
to apply the method not only to transdermally delivered drugs, but also to those, the 













































% ± SD 
0.15 93.1 ± 13.4 
0.3 92.9 ± 12.1 
0.6 95.8 ± 3.7 
1.5 101.7 ± 26.1 
3.0 99.7 ± 12.9 
6.0 100.3 ± 3.7 
12.0 101.0 ± 2.8 







% ± SD 
2.0 88.9 ± 4.0 
4.0 96.4 ± 19.0 
8.0 96.9 ± 8.5 
12.0 101.1 ± 2.3 
20.0 99.5 ± 2.5 





Tape ‘Viable’ skin 
% ± SD % ± SD 
3.0 99.7 ± 0.1 101.2 ± 0.4 
6.0 95.7 ± 1.8 98.7 ± 2.0 
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Table S5. Nicotine in the receptor solution and on tapes with and without light 
exposure (n=3). 
 
The mass of BUP, NIC and DF plotted as a function of depth in the SC is 
presented in Figure S1, S2 and S3, respectively. All the profiles show a typical 
decrease in drug in the SC with increasing depth. The amount of SC removed may be 
affected by both intrinsic factors, such as anatomical site, as well as extrinsic factors, 
such as the adhesive tape used (Lademann et al., 2009). That said, the effects of these 
factors on the measured drug mass are minimized as long as at least half of the SC is 
collected.  Specifically, the outermost half of the SC will contain 75% of the total drug 
mass if the drug concentration profile has reached steady-state (i.e., it is linear with 
position in the SC), and an even larger fraction if steady-state has not been established 
and the concentration profile is not linear.   
The average SC thickness removed by tape-stripping over different application 
times for Transtec®, Nicotinell® and Voltaren® was 15.6 ± 4.5 µm, 11.9 ± 3.2 µm and 
15.0 ± 2.7 µm, respectively.   
The total porcine SC thickness has been reported by several authors, see for 
instance: Herkenne et al., 2007; Sekkat et al., 2002; Kalia and Guy, 2001; Bronaugh 





Tape ‘Viable’ skin 
% ± SD % ± SD 
0.1 88.6 ± 17.7 103.3 ± 9.1 
1.0 83.3 ± 3.7 87.0 ± 7.5 
















































15 µm. Therefore, the SC removed during our experiments suggest that 20 tapes (the 
number of adhesive tapes used for each cell) were enough to collect most of the SC. 
 
Figure S1. Amount of BUP in stratum corneum as a function of depth, following 2, 





Figure S2. Amount of NIC in stratum corneum as a function of depth, following 2, 5, 





Figure S3. Amount of DF in stratum corneum as a function of depth, following 2, 6, 
9, 12 and 30 hours of treatment with Voltaren®. 
 
 To verify the variability in the mass of the blank tapes, i.e., after the tapes have 
been cut and before the tape-stripping experiments have been started, the mass of all 
the tapes used in each experiment was averaged and compared one another. As the 
tapes have been cut manually, therefore, the areas are not precisely the same, it is not 
a surprise that there is a variability in the mass of each blank tape. The variability, 
however, is not very different, overall, the relative standard deviations were always 
below 15% (Tables S6 – S8).  
The fact that during all the experiments the mass of the blank tapes kept 
relatively constant could be used as an indication of the calibration of the balance used 
to weigh the tapes. As a routine, however, to ensure that the readings from the 
instrument are accurate and consistent, the balance used in these experiments was 
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regularly calibrated using a standard. Figure S4 shows an example of a certificate of 
calibration. 
 
Table S6. Mass of blank tapes used before tape-stripping buprenorphine 
experiments. SD: Standard Deviation. RSD: Relative Standard Deviation. 
 
 2h 5h 8h 24h 48h 72h 
Average mass (mg) 62.9 63.0 56.9 63.7 62.2 61.3 
SD 7.1 8.8 7.3 6.5 8.9 8.9 
RSD (%) 11.3 13.9 12.8 10.1 14.3 14.4 
N 120 120 120 120 120 120 
 
Table S7. Mass of blank tapes used before tape-stripping nicotine experiments. SD: 
Standard Deviation. RSD: Relative Standard Deviation. 
  
2h 5h 8h 24h 
Average mass (mg) 63.9 66.1 63.1 65.9 
SD 9.3 8.4 8.8 9.0 
RSD (%) 14.6 12.7 14.0 13.7 
N 120 120 120 120 
 
Table S8. Mass of blank tapes used before tape-stripping diclofenac experiments. SD: 
Standard Deviation. RSD: Relative Standard Deviation. 
  
2h 6h 9h 12h 30h 
Average mass (mg) 68.7 66.9 60.0 69.90 64.8 
SD 6.8 8.7 8.9 7.20 6.3 
RSD (%) 10.0 13.0 14.9 10.3 6.3 
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Chapter 3: Determination of the skin 
pharmacokinetics of diclofenac from stratum 




∆C water concentration gradient across the stratum 
corneum 
∆t elapsed time interval between clearance and 
uptake times 
A sampled skin area 
B baseline parameter related to estimation of total 
thickness by TEWL values 
Cv drug concentration in the vehicle 
Cx the drug concentration at position x in the stratum 
corneum 
D drug diffusivity 
D0 diffusivity when clearance from the stratum 
corneum begins 
DF diclofenac  
Dw  diffusion coefficient of water in the stratum 
corneum 
HPLC-UV high-performance liquid chromatography with 
ultraviolet detection 
JAVE  average flux of drug out of stratum corneum into 
underlying tissue 
k 1st-order rate constant describing clearance from 
the stratum corneum 
K drug’s stratum corneum – vehicle partition 
coefficient 
Ksc,vt stratum corneum-viable tissue partition coefficient 
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L diffusion path-length through (or thickness of) a 
membrane 
log P log{octanol-water partition coefficient (P)} 
MSC mass of drug measured in the tape-strips 
SC stratum corneum 
tapp application time 
TEWL transepidermal water loss 
TLag time lag for diffusion through a membrane  
TSS time to achieve steady-state 
x/L relative depth in the stratum corneum 




















A key question in the development of a topical drug product (dermatological or 
locally acting) is whether target-site drug concentrations sufficient to treat the disease 
have been reached. Due to the difficulty of accessing the deep layers of the skin, the 
estimation of the rate and the extent to which a drug reaches its site of action on, 
within or below the skin, has not proved to be a facile task.  
The skin bioavailability4 of a drug mainly depends on two key physicochemical 
parameters, which impact significantly on the skin pharmacokinetics: partitioning into 
and diffusivity through the skin (Wiechers, 1989; Moser et al., 2001). In the past 
decades, a number of approaches (in vitro, in silico and in vivo) have been developed 
for predicting these key parameters (Barbero and Frasch, 2009; Russell and Guy, 
2009).  
In vitro experiments using excised skin (for example, human or porcine skin) are 
a recognised option for the assessment of drug penetration into the skin. Nevertheless, 
the lack of a functioning microcirculation means that information about drug clearance 
kinetics from the skin5 may be lacking (Leal et al., 2017).  
Several mathematical models have been developed to explain, at least in part, 
percutaneous absorption kinetics (Moss et al., 2002; Yamashita and Hashida, 2003; 
Lian, Chen and Han, 2008; Mitragotri et al., 2011). However, most of the existing 
models often suffer from being too complex, thereby rendering the model of little 
practical use.  
There are many in vivo methods for measuring dermal absorption of drugs, such 
as invasive skin biopsy, microdialysis (and open-flow microperfusion) and sampling 
of the SC by tape-stripping. Biopsy of the tissues beneath the SC, microdialysis and 
open-flow microperfusion seem to be ideal strategies to quantify the concentration 
profile of a topically applied drug within the skin. However, these approaches are 
invasive and highly demanding as a routine method. As an alternative, sampling the 
SC by tape-stripping, in vivo in human, is a relatively non-invasive and straightforward 
                                                          
4 The term ‘skin bioavailability’ here refers to the rate and the extent to which a drug reaches its site of 
action on, within or below the skin. 
5 The term ‘clearance from the skin’ here is used to mean the volume of skin from which a drug is 




technique which has proven useful to successfully estimate values relating to 
diffusivity and partitioning coefficients of drugs (Stinchcomb et al., 1999; Alberti et 
al., 2001; Herkenne et al., 2006, 2007; Nicoli et al., 2009; Rothe et al., 2017). Some 
previous studies have used the tape-stripping approach to evaluate products by 
measuring the mass of drug in the SC after an absorption (into the SC) phase and a 
clearance (from the SC) phase. This allowed the estimation of key diffusional and 
partitioning parameters for the drug together with an estimation of the drug’s flux out 
of the SC into underlying tissues (N’Dri-Stempfer et al., 2009; Cordery et al., 2017; 
de Araujo et al., 2018).   
Therefore, this study built on the SC sampling technique approach (tape-stripping) 
and applied different Fickian diffusion models to estimate useful skin pharmacokinetic 
parameters related to drug partitioning into and diffusion across the SC. The work was 
performed in human subjects, using diclofenac (DF) from a marketed medicated 
plaster. This product is indicated for pain relief in conditions such as knee 
osteoarthritis (Brühlmann et al., 2006), ankle sprains (Costantino et al., 2011) and 
epicondylitis (Jenoure et al., 1997). 
Advantages of using a medicated plaster (compared to, for example, a gel or a 
cream) in this study were: i. the drug concentration in the formulation was expected to 
remain relatively constant during the experiment, making it easier to interpret the 
findings; and ii. in contrast to a dermatological product, the plaster is administered to 
intact healthy skin, therefore, data was generated within a clinically relevant scenario. 
  
2. Materials and Methods 
2.1. Materials 
Voltaren® medicated plaster (GlaxoSmithKline, Munich, Germany) was 
purchased from Amazon UK. Diclofenac epolamine was purchased from Toronto 
Research Chemicals (Toronto, Canada), all the solvents and HPLC reagents were 
from Sigma-Aldrich Co., Ltd. (Gillingham, UK). 
2.2. Stratum corneum tape-stripping experiments 
Healthy subjects with no history of dermatological disease participated in this 
study, which was approved by the Research Ethics Approval Committee for Health 
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at the University of Bath (EP 16/17 142). Six subjects (age range: 23 – 53 years) 
participated in the study having given their consent. The study involved application 
of small sections of a Voltaren® marketed medicated plaster (180 mg of diclofenac 
epolamine in 140 cm2). The patient information leaflet recommends an application 
time of up to 12 hours per plaster. 
 
2.2.1 Design of the experiments  
The design of the experiments is illustrated in Figure 1.  
In a first set of experiment, the amount of DF in the SC was assessed after an 
‘uptake’ period following application of the plaster (0.5, 1, 2 and 6 hours). Sections 
of the plaster were cut to 5 cm2 (1 x 5 cm), 3 pieces were applied on the volar surface 
of one forearm and 3 pieces on the other forearm of 4 subjects (age range: 23 – 32 
years). There were duplicate application sites for each time on each subject.    
In a second set of experiment, the plaster was cut into 5 cm2 (1 x 5 cm) 
sections, 8 of which were applied on the volar surface of one forearm of all six 
subjects. The experiments assessed the amount of drug in the SC (a) after an ‘uptake’ 
period following application of the plaster (2, 6, 9 and 12 hours); and (b) following 
defined ‘clearance’ periods (5, 17 and 24 hours) after removal of the plaster sections 
at the end of a 6 hours ‘uptake’.  There were duplicate application sites for each time 
on each subject.  
All the subjects who participated in the second set of experiments also 
participated in the first set. To ensure that the SC was fully recovered, the two parts 
of the study were separated by at least 120 days. No lotion, cream or other personal 
care product was used on the forearms for at least 24 hours before and during the 
study. For the duration of the experiment, subjects were asked not to bathe or 







Figure 1. Schematic representation of the design of the tape-stripping experiments.  
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2.2.2 Stratum corneum sampling 
All the sites designated uptake were tape-stripped immediately after plaster 
removal. On the sites designated clearance, the plaster was removed after a 6-hour 
uptake and the edges of the clearance sites were demarcated using Mefix® tape 
(Molnlycke, Lancashire, UK), without encroaching on the treated area. Then, 5, 17 
or 24 hours later, sites were tape-stripped. No cleaning of the application area was 
performed. 
The SC sampling site was delimited by a template (Scotch® Book Tape, 3M, 
St Louis, MN, USA), with internal dimensions of 1 x 5 cm, which was placed on the 
skin immediately before tape-stripping began. Measurements of transepidermal water 
loss (TEWL, AquaFlux® evaporimeter, Biox System Ltd. London, UK) taken after 
plaster removal, before stripping and, intermittently, during tape-stripping, to indicate 
when most of the SC had been removed and before complete derangement of the 
barrier. Tape-stripping was therefore carried out until either (i) the rate of water loss 
reached 60 g m-2 h-1 or (ii) 30 tape-strips had been removed (Kalia, Pirot and Guy, 
1996; Kalia et al., 2000). All tapes were weighed (Microbalance SE-2F, precision 0.1 
μg; Sartorius AG, Goettingen, Germany) before and after stripping to determine the 
mass of SC removed; tapes were first discharged of static electricity (R50 discharging 
bar and ES50 power supply Eltex Elektrostatik GmbH, Weil am Rhein, Germany). 
 
2.2.3 Drug extraction and analysis  
DF was extracted from tape-strips into 3 mL of methanol in a glass vial by shaking 
overnight at room temperature. Samples were filtered (0.45 µm nylon membrane, 
SMI-Labhut, Ltd., Maisemore, UK) and transferred to HPLC vials for analysis. Drug 
was extracted from the first two tapes individually but, thereafter, tape-strips from the 
deeper SC were analysed in groups of up to 4 tapes to ensure, as far as possible, that 
the aggregated samples contained a sufficient drug amount to exceed the limit of 
quantification of the assay.  
200 μL of 0.1% formic acid in water were added to 800 μL of the extracted DF 
solution and the drug was then quantified by HPLC (Summit, Dionex, Camberley, 
UK) with UV detection (280 nm). Chromatography was performed on a HiQSil C18HS 
column (150 x 4.6 mm, 5 µm, Kya Technologies Corporation, Japan). The mobile 
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phase was 75:25 methanol: 0.1% formic acid aqueous solution. The flow rate was 1.2 
mL/min.  The injection volume was 100 µL and the retention time of DF was ~7 
minutes; limits of quantification and detection were 0.06 and 0.02 µg mL-1, 
respectively. 
Selectivity of the analytical method was confirmed by extraction of tapes with 
SC that had not been exposed to DF; no interference was found at the relevant 
retention time. Recovery of DF from tapes was assessed by spiking tape-stripped 
samples of untreated SC with known amounts of drug in solution which was left to 
dry for several hours before extraction. Mean extraction efficiencies were greater than 
82% from tape-strips (details are provided in the ‘Supplementary Information’ – 
Table S1). 
  
2.3. Determination of stratum corneum total thickness 
The apparent total thickness of the SC (L) was estimated from measurements of 
TEWL during the tape-stripping process (Russell, Wiedersberg and Delgado-Charro, 
2008). L was estimated from a site adjacent to the treated skin on each forearm 
(Figure 1). The average (arithmetic mean) of the two estimates (one from each arm) 
was used for further calculations.  
Briefly, as the SC is progressively removed by tape-stripping, TEWL increases 
from the baseline in a non-linear fashion, with respect to the thickness of SC removed 
(x), empirically described by Equation 1.  
TEWLx = B +  
DwKSC,VT∆C
L−x
                                                   (Equation 1)
    
where x is calculated from the mass of SC on each tape divided by the area sampled 
and the density of the SC, assumed to be 1 g cm-3 (Anderson and Cassidy, 1973); B is 
the initial TEWL value before stripping, Dw is the diffusion coefficient of water in the 
SC, KSC,V is the SC-viable tissue partition coefficient and ∆C is the water 
concentration gradient across the SC. Values for B, DwKSC,VT∆C and L were 
determined by nonlinear regression with uniform weighting of the TEWLx (g m
-2 h-1) 
versus x (m) measurements with initial estimates of L (m) = last x value + 1 and 
(DwKSC,VT∆C) = 30 (g m-2 h-1). 
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2.4. Data Analysis          
The mass of drug in the SC was expected to exhibit a log-normal distribution 
(Williams, Cornwell and Barry, 1992; Kasting et al., 1994; Cornwell and Barry, 1995). 
Therefore, the arithmetic average, standard deviation and 90% confidence intervals of 
the logarithm of the geometric mean of the duplicate measurements in the 6 subjects 
were calculated for ‘uptake’ and ‘clearance’ for each experiment time (N’Dri-
Stempfer et al., 2009).  
2.4.1. Diclofenac uptake into the stratum corneum 
From the data collected during the uptake experiments, three approaches for 
analysing the data were considered.  
First, the total quantity of DF recovered in the tape-strips per unit of area of 
exposure (MSC/A) was simply expressed as a function of time. 
Secondly, the concentration profile of DF across the SC (Cx) as a function of 
position in the SC (x/L) was analysed for all subjects at each uptake time considered. 
The data points from the two replicate sites were combined. Then, profiles were fitted 
to the relevant solution of Fick's second law of diffusion (Scheuplein, 1967; Crank, 
1979) (Equation 2) assuming the following boundary conditions: (i) the drug 
concentration in the vehicle (Cv) remains constant during the treatment period (tapp); 
(ii) the SC provides a homogeneous barrier to drug diffusion; (iii) there is no drug in 
the SC at t=0; and (iv) the viable epidermis acts as a perfect sink for the permeant. 
 
Cx = KCv [1 −  
x
L







)] sin(mπx L⁄ )
m
∞
m=1 ]              (Equation 2) 
 
where Cx is the drug concentration (mass of drug divided per mass of SC removed) at 
position x in the SC at the application time (tapp).  
The fitting of Equation 2 yields values for KCv (K is the drug’s SC-vehicle 
partition coefficient) and for D/L2, a first-order rate constant comprising the ratio of 
the drug diffusivity (D) in the SC to the total thickness (L) squared of the barrier. From 
these two parameters (KCv and D/L
2) and the corresponding L (estimated for each 
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subject using Equation 1), the lag-time (TLag = L
2/6D, Roberts, Anissimov and 
Gonsalvez (1999);), time to steady-state (TSS = ~2.4TLag, Cleek and Bunge (1993)) 
and steady-state flux across the SC (Jss = KCvD/L,) may be calculated. 
Thirdly, it was also possible to analyse the mass of DF after SC uptake using 
an approximate solution to Fick's second law of diffusion (Equation 3 and Equation 4) 
from which D may be estimated in a different way.  
The cumulative mass of DF measured in the tape-strips per unit of area of 
exposure (MSC/A) versus square-root of time profiles were compared to the solution 
of two models describing diffusion into a: (i) semi-infinite membrane (Equation 3), 
























n=0 ]                                   (Equation 4) 
 
The semi-infinite membrane model assumes that the application time of the 
formulation to the SC is insufficient for the drug to reach the lower surface of the 
barrier which therefore, in effect, behaves as a semi-infinite membrane (Equation 3); 
the finite membrane model, in contrast, considers the SC as a single finite membrane 
(Equation 4).  
The analytical solution to the semi-infinite model permits a value of D to be 
deduced. Then, using this D, Equation 4 can be used to predict the evolution of the 
MSC/A over time following the finite membrane model. Note that MSC/A corresponds 
to the average concentration in the SC multiplied by the SC thickness. 
 The application of Equations 3 and 4 requires estimates of the concentration 
of the permeant at x=0. In this study, we have assumed that the drug concentration at 
the surface of the SC is constant and equal to KCv (obtained from fitting the data to 
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Equation 2; the average of the KCv determined following 2 and 6 hours of application 
was used).  
Figure 2 summarises the steps involved in the estimation of pharmacokinetic 
drug parameters using Fick’s second law of diffusion (Equation 2) and the semi-
infinite and finite models (Equation 3 and 4, respectively). 
 
Figure 2. Schematic representation of the procedure used to estimate SC total 
thickness (L), drug SC-vehicle partition and diffusion across the SC parameters (KCv 
and D, respectively), lag-time (TLag), time to steady-state (TSS) and steady-state flux 




2.4.2. Diclofenac clearance out of the stratum corneum 
The next step was to evaluate the clearance of DF from the SC as a function 
of time post-removal of the plaster.  
Assuming that DF is cleared from the SC with first-order kinetics, the 






e(−k∆t)   (Equation 5) 
where Msc is the total mass of drug in the SC at the end of the clearance period (i.e., 
5, 17 or 24 hours), Msc,0 is the total mass of drug in the SC when clearance began 
(i.e., when the plaster was removed, after 6 hours of application), A is the sampled 
skin area and Δt is the elapsed time interval between clearance and uptake times. 
For each subject, k was calculated from the negative slope of a linear 
regression of the natural log of drug mass across the whole period of clearance.  
Assuming the only mechanism of elimination is via transfer to the viable 
epidermis, then the average flux of drug transferred from the SC to the underlying 
tissue (JAVE) during the clearance period was calculated for each subject as:   




                            (Equation 6) 
 
Another type of analysis performed with clearance data aimed to investigate the 
SC concentration (Cx) as a function of position in the SC (x/L) at each clearance time 
considered. Assuming that the drug is non-volatile and is not metabolised in the SC, 
the DF concentration profile during clearance is described by Equation 7 (Nicoli et 
al., 2009).  
Cx = 2KCv ∑ {[
1
γn2













                  (Equation 7) 
where Cx is the drug concentration at position x in the SC, tapp is the duration of the 
application (i.e., 6 hours), t is the duration of the experiment (i.e., application time 
plus clearance time) and Cv is the drug concentration in the vehicle just before 
removal, and  𝛾𝑛 =  (2𝑛 + 1) 𝜋 2⁄ .  
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Concentration profiles at each time point were fitted to the relevant solution 
of Equation 7 to yield values for KCv and D/L
2 assuming the boundary conditions 
that: (i) the flux of drug into the SC at the surface is zero; (ii) the SC is a homogeneous 
barrier; and (iii) the viable epidermis acts as a perfect sink.  
 
2.5. Statistics 
Statistically significant differences were estimated by a t-test or by one-way 
ANOVA followed by Tukey's test, assessed in a pairwise, within-subject comparison 
when appropriate. In all cases, statistical significance was set at p < 0.05. The 90% 
confidence interval was calculated using the Student’s T-distribution for the sample 
size and the sample standard deviation.  
 
3. Results and discussion 
Table 1 shows the SC total thickness estimated from two untreated sites, using 
Equation 1 on each subject. Individual profiles for estimation of L are shown in 
‘Supplementary Information’, Figures S1 and S2.  
Overall, the average thickness of SC collected was 9.4 m (min and max: 4.2 m 
and 16.5 m) and the average calculated total thickness was 12.4 m, therefore 
around 75% of the SC was collected.  
Table 1.  Estimation of stratum corneum apparent total thickness (L) using Equation 
1 for 6 subjects. The identification of ‘Uptake’ and ‘Clearance’ forearms are shown 
Figure 1. 






Subject 1 7.0 13.5 10.3 
Subject 2 12.7 11.7 12.2 
Subject 3 14.4 11.5 13.0 
Subject 4 12.4 19.0 15.7 
Subject 5 12.3 11.8 12.1 




Figures 3 and 4 show the total drug mass recovered from the SC for each subject 
at uptake and clearance times, respectively.  
Figure 3. Mass of diclofenac recovered from replicate skin sites at each uptake time, for 
all subjects (n = 4 – 6). Horizontal lines are the geometric means of the replicate values 





Figure 4. Mass of diclofenac recovered from replicate skin sites at each clearance 
time, for all subjects (n = 6). Horizontal lines are the geometric means of the replicate 
values shown by the squares. 
 
3.1 Diclofenac uptake into the stratum corneum 
Figure 5 shows the mass per unit area of DF in the SC as a function of the period 
of plaster application. It is clear that, at least up to 6 hours of exposure, increasing the 
application time led to an increase of DF in the SC, but that between 6 and 12 hours 





Figure 5. Average mass of diclofenac in human SC in vivo (6 subjects) following 
application of Voltaren® medicated plaster for different application times. The data 
points were experimentally determined and plotted as the anti-logarithm of the log-
transformed average of the geometric mean of duplicates in each subject ± 90% 
confidence interval. 
 
The SC concentration-depth profiles following different application times for 
each subject are shown in Figure 6. These data are plotted as a function of position 
within the SC (x) normalized by the predicted total thickness of the SC (L). The solid 
lines in Figure 6 were calculated from Equation 2 using the best fit of KCv and D/L
2 
values at the corresponding application time. The mean values of KCv and D/L
2 per 




Figure 6. Individual concentration profiles of DF across human SC in vivo for each 
subject following application of Voltaren® medicated plaster for different application 
times. The data points were experimentally determined; the solid lines  were calculated 
from Equation 2 using the best fit of KCv and D/L
2 values deduced from the best fit of 








Table 2. Diclofenac partitioning and diffusivity parameters as a function of 
application time derived from the best fit of Equation 2 to the concentration profiles 
shown in Figure 6. Values are the arithmetic means across the subjects, for each time 
point (lower and upper 90% CI, n = 4 – 6). Pairs of superscript letters indicate 











(7.7 – 38.7) 
5.1h,i,j,k,l 
(2.5 – 7.7) 
1† 
27.3e,f,g 
(11.5 – 43.2) 
2.5h,m 
(0.5 – 4.6) 
2‡ 
48.5a 
(38.3 – 58.8) 
1.5i 
(0.9 – 2.1) 
6‡ 
54.0b,e 
(41.2 – 66.8) 
1.0j 
(0.4 – 1.6) 
9‡ 
58.1c,f 
(51.4 – 64.7) 
0.6k 
(0.3 – 0.9) 
12‡ 
61.1d,g 
(53.4 – 68.9) 
0.2l,m 
(0.1 – 0.4) 
†n = 4 subjects; ‡n = 6 subjects. 
KCv and D/L
2 values were compared over time for statistical significance using 
parametric and non-parametric tests (one-way analysis of variance followed by 
Tukey’s post hoc test and Kruskal–Wallis with Bonferroni‐Dunn multiple 
comparisons, respectively). The same outcome was observed when comparing the 
partitioning (KCv) and diffusion (D/L
2) parameters following both statistical tests 
(parametric and non-parametric). It was observed that KCv and D/L
2 were not constant 
over all application times. This is noteworthy because the solution of Equation 2 
assumes that the opposite is true. In fact, as seen in Table 2, divergence from this 
assumption occurs primarily in the first 2 hours of the study; subsequently, the fitted 
parameters are relatively constant.  
The choice of which statistics to use for comparison depends on the type of 
data being compared. Each of the test has its own area of application, thus the wrong 
choice of the statistic can lead to the misrepresentation and misinterpretaion of the 
results. Nonparametric tests refer to statistical methods often used to analyse ordinal 
or nominal data with small sample sizes. Unlike parametric models, nonparametric 
models do not require making any assumptions about the distribution of the 
population. Also, this method is used when the data is quantitative but has an unknown 
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distribution, is non-normal, or has a sample size so small that the population 
distribution cannot be determined.  
Although, data comparison using parametric tests is a very common form of 
data analysis in skin permeation/penetration studies, often these studies are performed 
in a small sample and, therefore, it is not possible to determine the distribution of the 
population.  In this work, as the population size is small (n = 4-6), both types of 
analysis (parametric and non-parametric) were conducted to compare whether KCv 
and D/L2 are varying over application time.  
As the results in Table 2 suggest constant partition (KCv) and diffusivity (D/L
2) 
of the drug from 2 to 6 hours of application, the results deduced in this time interval 
were used to calculate additional kinetic parameters, specifically lag-time (TLag), time 
to steady-state (TSS) and steady-state flux across the SC (JSS). Table 3 presents these 
values (mean ± S.D.), which were calculated within each subject, then averaged first 
across all subjects and then averaged (arithmetic means) across application times. 
In general, dermal products contain a number of excipients/co-solvents which 
may influence not only the drug’s solubility in the formulation but also its solubility 
and partitioning into the SC. Typically, co-solvents are well absorbed into the SC and 
are then capable of changing the drug’s solubility in this outer layer of the skin 
(Alberti et al., 2001; Herkenne et al., 2008), allowing the dermal permeation rate to 
increase.  
The plaster used in this study contains over 20 ingredients, including the common 
co-solvents and reported penetration enhancers, propylene glycol and butylene glycol 
(Wotton et al., 1985; Barry, 1987; Huth et al., 1996; Lane, 2013).  Due to their low 
molecular weights and lipophilicities (log P) of 76 and 96 Da, and -0.92 and -0.29, 
respectively, these permeate the SC relatively quickly compared to DF.  
These glycols are expected, therefore, to impact on both drug partitioning and 
diffusivity (Oliveira, Hadgraft and Lane, 2012; Cadavona et al., 2016). It follows that 
the higher DF diffusivity observed in the early stages of the permeation may be 
related to the co-solvents reaching their maximum fluxes sooner than DF and creating 
a situation where drug delivery is transiently more efficient in the beginning of the 
treatment. Indeed, Trottet et al. (2004) reported exactly this effect of propylene glycol 
on the percutaneous permeation of loperamide hydrochloride.  
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As alternative way to analyse the uptake of DF in the SC, the semi-infinite and 
finite membrane models (Equations 3 and 4) were next explored.  Subjects 2 and 5 
were excluded from this data analysis as they did not take part in the 0.5- and 1.0-
hour uptake experiments.  
Estimates of KCv were derived from Equation 2 (average value between 0.5-, 1-, 
2- and 6-hour application time from each subject). Estimates of D/L2 were derived 
for each subject from the slope of the linear regression of MSC/A versus square-root 
of time measured at 0.5, 1, 2 and 6 h combined with the estimated L (from the average 
of each subject, Table 1) and the corresponding value of KCv. From the estimated 
D/L2 and L for each subject it was also possible to calculate lag-time (TLag = L
2/6D), 
time to steady-state (TSS ~ 2.4TLag), diffusivity across the SC (D) and steady-state 
flux (JSS = KCvD/L) were calculated; the results are collected in Table 3. 
Figure 7 compares the mean measured mass per area of DF in the SC as a function 
of the square-root of time to the semi-infinite membrane model (dashed line) 
(regression performed up to t = 6 h, √𝑡 ≤ 2.45 h1/2 data) and to the finite membrane 
(solid line). The solid line in Figure 7 was calculated using the finite membrane model 
(Equation 4) using average values of the 4 subjects for L (12.8 µm) and D derived 
from KCv (38.3 µg mg
-1, derived from drug concentration versus depth data, using 
Equation 2, average value between 0.5-, 1-, 2- and 6-hour application time) and the 
slope of the linear regression of MSC/A versus the square-root of time for t < 6 h.  
Consistent with the experimental data, the data for 9 and 12 h diverge from Equation 
3 and suggest (as shown by the best fit of Equation 4) that the semi-infinite boundary 
conditions are no longer met. The individual plots of MSC/A versus √𝑡 are in 









Table 3. Pharmacokinetic parameters deduced for DF in human SC in vivo following 
application of Voltaren® medicated plaster. Values were deduced from either SC 
concentration versus depth profile (Equation 2) or the MSC/A versus √𝑡 profile 
(Equation 3). The mean values (± standard deviation) were calculated within each 
subject, then averaged (arithmetic mean) across all subjects and then averaged 
(arithmetic mean) across the application times.   
 
Parameters 
From SC concentration 
versus depth profile  
From MSC/A versus √𝒕 
profile  
KCv (µg mg-1) 51.3 ± 3.9a 38.3 ± 15.3b 
102 D/L2 (h-1) 1.2 ± 0.4a 1.5 ± 1.8 c 
TLag (h) d 22 ± 11 14 ± 10 
TSS (h) e 52 ± 25 34 ± 24 
JSS (μg cm-2 h-1) f 0.7 ± 0.2 1.0 ± 1.0 
aCalculated using Equation 2, average value between 2- and 6-hour application time;  
bCalculated using Equation 2, average value between 0.5-, 1-, 2- and 6-hour 
application time;  
cCalculated using Equation 3. 
 
Figure 7. Average mass of diclofenac in human SC in vivo (4 subjects) following 
application of Voltaren® medicated plaster for different application times. The data 
points were experimentally determined and plotted as the anti-logarithm of the log-
transformed average of the geometric mean of duplicates in each subject ± 90% 
confidence interval; the dashed line represents the solution of the semi-infinite 
membrane theory (regressions on t ≤ 6 h, √𝑡 = 2.45 h1/2 data, Equation 3) and the red 
solid line represents the solution of the finite membrane theory (Equation 4) predicted 
with diffusivity (D) derived from semi-infinite theory slope. 
 
The best-fit of Equation 3 results in an almost perfect straight line up to the 6-h 
point. The good agreement between observed and predicted MSC/A suggests that, at 
least during the first six hours, there is no change in either partition or diffusion 
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parameters, which, to a certain extent, contradicts the findings using the Fick’s law 
model (Equation 2). However, it is important to bear in mind that the calculation of 
slope of the linear regression of MSC/A versus the square-root of time using Equation 
3 takes into account the product of KCv and D
1/2 (Equation 8). It follows that the 
reason that the semi-infinite model fits the data between 0.5 and 6 hours may be 
because the observed smaller values of KCv and the higher values of D/L
2, derived 
using Equation 2, at the shortest times are compensating one another. As shown in 
Table 4, the products {(KCv) (D/L
2)1/2} are reasonably constant and there is no 
systematic increase or decrease with time, with exception of the values obtained from 
the 2- and 12-hour application time, which are statistically different (one-way 
analysis of variance followed by Tukey’s post hoc test, p = 0.04).   





                                    (Equation 8) 
 
Table 4. Product of KCv and (D/L
2)1/2 derived from the best fit of Equation 2 (Table 
2). Values are the arithmetic means across the subjects, for each time point (lower 
and upper 90% CI, n = 4 – 6). Pairs of superscript letters indicate statistical 
differences (p < 0.05).  
 
Application time (h) KCv  √𝐃 𝐋𝟐⁄  
0.5† 4.7 (2.8 – 6.7) 
1† 3.9 (2.3 – 5.4) 
2‡ 5.5a (4.5 – 6.5) 
6‡ 4.7 (3.3 – 6.1) 
9‡ 4.1 (3.0 – 5.2) 
12‡ 2.9a (1.7 – 4.1) 
†n = 4 subjects; ‡n = 6 subjects. 
 One advantage of using the approach (Cx versus x/L) to estimate a kinetic 
profile is that data from a specific (and relatively short) application time can be used 
to predict the entire absorption profile of the drug up to steady-state (Stinchcomb et 
al., 1999; Alberti et al., 2001; Herkenne et al., 2006, 2007; Rothe et al., 2017). 
However, the partitioning and diffusion need to be constant over time.  
On the other hand, analysing the mass of the drug in the SC versus square-root of 
time, an approximation solution to Fick’s second law of diffusion, also provides 
information about the drug’s kinetics through the SC. One clear advantage of this 
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simpler model is that it is not necessary to know the concentration of the drug in the 
SC (i.e., the determination of the mass of SC is not required). However, two 
limitations of this metric can be cited: (i) a minimum number of application times are 
required to accurately estimate the inclination of the curve and, therefore, a value for 
drug diffusion; (ii) the nature of the extracted information mixes what is happening 
to the partition and diffusion parameters (KCv and D) and there is a risk that both may 
be changing and the metric will not be able to detect any difference in terms of 
diffusivity and partitioning. 
 
3.2 Diclofenac clearance out of the stratum corneum 
From the mass of drug remaining in the SC over time post-removal of the delivery 
system, an elimination rate constant (k) and the average flux out of the SC were 
calculated (Figure 8 and Table 5).  While the mass of DF in the SC decreased over 
the time of clearance, the transfer of drug out of the SC was relatively slow. Only 
after 24 hours of clearance the drug level in SC was significantly lower than that 
present at the end of the 6 h uptake (one-way ANOVA, followed by Tukey post hoc 
test).  
The average depletion of drug from the SC at 5, 17 and 24 hours after plaster 
removal was 6, 34 and 43%, respectively. This is consistent with results for three 
distinctly different DF formulations for which about 32% of the drug in the SC after 
a 6-hour uptake had been cleared 17 hours post-removal from the skin (Cordery et 
al., 2017).  
The DF clearance from the SC profiles for each subject is in ‘Supplementary 




Figure 8. Amount of drug in the SC plotted against the time of clearance (n = 6). The 
data points were experimentally determined and plotted as the anti-logarithm of the 
log-transformed average of the geometric mean of duplicates in each subject ± 90% 
confidence interval. 
Table 5. Deduced DF average ﬂux from the SC into the underlying viable tissue 
during the clearance period (JAVE) and the ﬁrst-order rate constant (k) describing 
clearance from the SC. The mean values (± standard deviation) were calculated 
within each subject, then averaged (arithmetic mean) across all subjects. 
 
Parameters Mean ± Standard deviation 
102 k (h-1) a 2.7 ± 1.6 
JAVE (μg cm-2 h-1) b 0.32 ± 0.20 
aSlope of the ln(MSC/A) versus time curve;  
bCalculated using Equation 6 and assuming ∆t = 24 hours. 
 
Predicted DF concentration profiles across the SC during the clearance phase 
were generated using Equation 7 and are compared with the experimental data in 
Figure 9. There was poor agreement between theory and experiment with the model 
clearly predicting a faster decline in DF concentration in the SC post-removal of the 




Figure 9. Concentration profiles of DF across human SC in vivo (6 subjects) 
following application of Voltaren® medicated plaster for different clearance times. 
The data points were experimentally determined; the lines through the results were 
calculated using Equation 7. 
 
As Equation 7 poorly described the concentration of DF in the SC after removal 
of the plaster, a phenomenological approach was adopted relaxing the requirement 
that drug diffusivity is a constant; in line with fitting the experimental data, it was 
proposed that diffusivity (D(t)) decays exponentially over time, with a 1st-order 
constant rate α during clearance: 
𝐷(𝑡) =  𝐷0𝑒
−𝛼(𝑡−𝑡𝑎𝑝𝑝)                            (Equation 9) 
where D0 is the diffusivity when clearance from the SC begins.  Equation 7 is then 
re-expressed as: 
𝐶𝑥 = 2K𝐶𝑣 ∑ {[
1
𝛾𝑛









𝐿⁄ ) exp [−𝛾𝑛
2 𝐷0 𝐿
2⁄ (







The value of α was estimated by amalgamating the data points for the three 
clearance times and, then, a nonlinear least square fit using D0/L
2 and KCv from the 
uptake phase (0.01 h-1 and 54 μg mg-1, respectively) was carried out. In this way, a 
single mean value for α, equal to 0.13 h-1, was determined. The strategy considerably 
improved agreement between experimental data and model predictions (Figure 10). 
For the moment, however, this finding is empirical and lacks mechanistic under-
pinning. The extent to which the drug may become immobilised during its passage 
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across the SC, such as by protein binding, and its impact on D requires further 
investigation. 
 
Figure 10. Concentration profiles of DF across human SC in vivo (6 subjects) 
following application of Voltaren® medicated plaster for different clearance times. 
The data points were experimentally determined; the lines through the results were 
calculated using Equation 9. 
 
4. Conclusion 
In conclusion, the results presented have utility with respect to the application of 
SC tape-stripping in vivo in human to derive useful skin pharmacokinetic parameters 
related to drug partitioning into (KCv) and diffusion across the SC (D/L
2). 
In addition, evaluation of KCv and D/L
2 values as a function of formulation 
application time may indicate whether the drug distributes rapidly from the 
formulation into the SC at the skin surface and/or whether there are interactions 
between the vehicle constituents and the skin that may alter its permeability. 
The potential effects of different excipients on the predicted kinetic parameters and 
the manner in which excipient(s) behaviour may impact on the rate and extent at which 
the drug crosses the SC is further explored in Chapter 4 of this thesis. 
From the ‘clearance experiments’, concentration profiles suggest that diclofenac 
elimination may be retarded by immobilisation in the SC. Nevertheless, analysis of 
the change in mass of drug over time after plaster removal permits its average flux 
into the underlying viable tissue, as well as the rate constant (k) at which drug is 

















% ± SD 
0.1 83.7 ± 6.5 
1.0 82.3 ± 1.5 












Figure S3. Mass of diclofenac in human SC in vivo for each subject following 
application of Voltaren® medicated plaster for different application times. The data 
points were experimentally determined (the replicate values are shown by the same 
symbols) and the solid line represents a linear regression. 
 
 
Figure S4. Amount of drug in the SC for each subject plotted against the time of 
clearance. The data points were experimentally determined (the replicate values are 
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Chapter 4: Tracking excipients from a topical drug 




A     sampled skin area 
BG     1,3-butylene glycol 
Cv     permeant concentration in the vehicle 
Cx the permeant concentration at position x in the 
stratum corneum 
D permeant diffusivity 
HPLC-UV high-performance liquid chromatography with 
ultraviolet detection 
K permeant’s stratum corneum – vehicle partition 
coefficient 
L diffusion path-length through (or thickness of) a 
membrane 
log P     log(octanol-water partition coefficient (P)) 
MSC       mass of permeant measured in the tape-strips 
PG     propylene glycol 
SC     stratum corneum 
tapp     application time 
TEWL transepidermal water loss 
TLag      time lag for diffusion through a membrane  
TSS                time to achieve steady-state 












 Penetration of drugs into and through the skin is often limited by the barrier 
properties of the stratum corneum (SC). This barrier can sometimes be overcome by 
the addition of excipients to topical formulations (Aungst, Blake and Hussain, 1990; 
Karande and Mitragotri, 2009). These excipients may each perform one or more 
roles. Among those roles, particularly important are (Barry, 1987; Adrian C. 
Williams and Barry, 2004; Choi et al., 2008; Gee et al., 2014; Pham, Topgaard and 
Sparr, 2017):  
(i) modifying solubility of the drug in the vehicle; 
(ii) uptake into the SC and transiently changing barrier function to permit 
more facile diffusion of drug across the barrier, and;  
(iii) co-diffusion with the drug into the SC and altering drug solubility in the 
barrier. 
Therefore, when the skin is exposed to topical products, drug disposition is 
likely to be greatly influenced by the time-dependent skin concentrations of certain 
excipients present in the formulation. 
There is clear evidence in the literature that the behaviour of the excipient and 
the behaviour of the drug are closely linked. For example, the addition of oleic acid 
(5%) to a formulation (50:50, ethanol:isopropyl myristate) containing terbinafine 
enhanced drug uptake into the human SC in vivo by increasing the drug diffusivity 
across the SC, although there was no effect on drug partitioning between the vehicle 
and the SC (Alberti et al., 2001). In contrast, propylene glycol (PG) in a series of 
ibuprofen formulations (specifically, mixtures of PG and water, containing from 0 to 
100% v/v PG) significantly influenced the partitioning of the drug from the vehicle 
into the SC (in human in vivo), whereas its diffusivity across the barrier was unaltered 
(Herkenne et al., 2008). In addition, Trottet et al. (2004) investigated the in vitro 
percutaneous permeation of propylene glycol and loperamide hydrochloride in 
formulations containing PG under finite dose conditions; dose effects were also 
examined. The data showed a correlation between the amount of PG dosed on the skin 
and the amount of drug that had permeated. 
Clearly, knowledge of the disposition of key formulation components can help 
understanding of the skin pharmacokinetics of the drug. Yet, it is relatively unusual 
 115 
 
that the uptake and transport of formulation excipients are simultaneously monitored 
when assessing topical drug penetration.  
The results described in Chapter 3 suggested that diclofenac uptake into the 
SC may be modified by certain excipient(s). Therefore, the work described here aimed 
to quantify the uptake of two excipients, propylene glycol and butylene glycol, present 
in the diclofenac medicated plaster, into the SC. Both compounds have been reported 
to act as effective co-solvents and as potential penetration enhancers (Wotton et al., 
1985; Barry, 1987; Huth et al., 1996; Lane, 2013). 
The ultimate objective was to better understand SC uptake and clearance of 
diclofenac as a function of time after topical application of the medicated plaster to 
human skin in vivo. The SC tape-stripping technique was again employed for this 
purpose.  
 
2. Materials and Methods 
 
2.1. Materials 
Voltaren® medicated plaster (GlaxoSmithKline, Munich, Germany) was 
purchased from Amazon UK. Propylene glycol, 1,3-butylene glycol, all the solvents 
and HPLC (high-performance liquid chromatography) reagents were from Sigma 
(Gillingham, UK). 
2.2. Stratum corneum tape-stripping experiments 
Four subjects (one male, three females, age range: 23 – 32 years) with no 
history of dermatological disease participated in this study, which was approved by 
the Research Ethics Approval Committee for Health at the University of Bath (EP 
16/17 142). Informed consent was provided by all subjects. All the subjects enrolled 
in this study also took part in the previous diclofenac study (Chapter 3). 
The drug product studied was Voltaren® medicated plaster, which contains 180 
mg of diclofenac epolamine (1.3%) and 420 mg (3%) of propylene glycol (PG) over 
140 cm2; the amount of butylene glycol (BG) present, however, is not publicly 
available. The patient information leaflet recommends application of the plaster for up 
to 12 hours.   
From a single plaster, 5 cm2 (1 x 5 cm) pieces were cut and 4 of these were 
applied to the volar surface of each forearm of each subject. The plaster pieces were 
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left in contact with the skin for 0.5, 1, 2 or 6 hours. There were duplicate application 
sites on each subject for each application time (Figure 1).  
For the duration of the experiment, subjects refrained from bathing or 
participating in vigorous physical activity, but otherwise pursued their normal 
lifestyle. After 0.5, 1, 2 and 6 hours of contact, the plaster was removed; the 
application area was not cleaned.  
 
Figure 1. Schematic representation of the design of the tape-stripping experiments. 
The subject identifiers (S1, S3, S4 and S6) are the same as the ones used in Chapter 3. 
 
 
All the sites were tape-stripped immediately after plaster removal. The SC 
sampling site was delimited by a template (Scotch® Book Tape, 3M, St Louis, MN, 
USA), with internal dimensions of 1 x 5 cm, which was placed on the skin immediately 
before tape-stripping began. Measurements of transepidermal water loss (TEWL, 
AquaFlux® evaporimeter, Biox System Ltd. London, UK) taken after plaster removal, 
before stripping and, intermittently, during tape-stripping, indicated whether most of 
the SC had been sampled but ensured that complete derangement of the barrier was 
avoided. Tape-stripping was carried out until either (i) the rate of water loss reached 
60 g m-2 h-1 or (ii) 30 tape-strips had been removed (Kalia, Pirot and Guy, 1996; Kalia 
et al., 2000). All tapes were weighed (Microbalance SE-2F, precision 0.1 μg; Sartorius 
AG, Goettingen, Germany) before and after stripping to determine the mass of SC 
 117 
 
removed; tapes were first discharged of static electricity (R50 discharging bar and 
ES50 power supply Eltex Elektrostatik GmbH, Weil am Rhein, Germany).  
From the mass of SC removed, and knowing the area sampled and the density 
of the SC (assumed to be 1 g cm-3; Anderson and Cassidy, 1973), it was possible to 
calculate the thickness of the SC removed on each tape. 
PG and BG were extracted from the first two tapes individually but, thereafter, 
tape-strips from the deeper SC were analysed in groups of up to 4 tapes to ensure, as 
far as possible, that the aggregated samples contained an amount of permeant greater 
than the limit of quantification of the assay. 
 The two glycols were extracted from the tape-strips with 3 mL of acetonitrile 
per sample and the vials were placed on a horizontal shaker (HS 260 Basic, 
IKA Group) and shaken overnight at room temperature. To minimise loss of glycols 
from the tapes by evaporation, the tapes were weighed, rolled and put in contact with 
the extraction solvent immediately after SC collection. Similarly, the residual amounts 
of glycols in each section of plaster was measured post-application by extracting the 
glycols from the plaster immediately after its removal from the skin.  
 
2.3. Sample preparation  
PG and BG lack a chromophore, and chemical derivatization was therefore 
required to enable their detection by HPLC-UV detection. The previously described 
derivatisation method (Zhou et al., 2007), which had been used to simultaneously 
analyse propylene glycol and diethylene glycol in pharmaceutical products, was 
closely followed. The derivatization reagent was a 20% solution of p-toluenesulfonyl 
isocyanate (TSIC), in acetonitrile (v/v). Sixty μL of this TSIC solution was added to 
600 μL of the sample in an Eppendorf tube, vortex-mixed for 30 s, and allowed to 
stand at room temperature for 10 min. Subsequently, 60 μL of water was added and 
the solution was vortex-mixed again for a further 30 s. The resulting solution was 
filtered (0.45 µm nylon membrane, Labhut, Maisemore, UK) before analysis by 
HPLC. Calibration curves were prepared under same conditions as the tested samples.  
 
2.4. Analysis of propylene and butylene glycol  
The derivatised glycols were quantified simultaneously by HPLC (Summit, 
Dionex, UK) with UV detection (230 nm). Chromatography was performed on a HiQSil 
C18HS column (150 x 4.6 mm, 5 µm, Kya Technologies Corporation, Japan). A 
 118 
 
mobile phase gradient was applied with 0.1% of formic acid in water (A) and acetonitrile 
(B). The gradient conditions were as follows: (i) a linear gradient from 70% to 40% of (A) 
from 0 to 15 min, (ii) from 15.1 to 20 min, the mobile phase composition was 40% (A) and 
60 % (B), and (iii) from 20.1 to 25 min, the mobile phase was held at 70% (A) and 30% 
(B) to re-equilibrate the system.  The total run time was 25 min. The flow rate was 1.2 mL 
min−1. Retention times were ~ 12 and 13 min for the derivatisation products of PG and 
BG, respectively. The injection volume was 40 µL and the column temperature was 
maintained at 30°C. Selectivity of the method was confirmed by extraction of tapes 
with SC but without any contact with the two glycols investigated. No interference 
was found at the relevant retention times. Limits of detection for PG and BG were 0.04 
and 0.06 µg mL-1, respectively. Limits of quantification for PG and BG were 0.12 and 
0.24 µg mL-1, respectively. 
Confirmation of the structures of the derivatives was obtained by liquid 
chromatography with mass spectroscopy (LC-MS). Samples prepared as described 
above were analysed on a QTOF-UHPLC (MaXis HD quadrupole electrospray time-
of-flight (ESI-QTOF) mass spectrometer (Bruker Daltonik GmbH, Bremen, 
Germany), operated in ESI positive-ion MS mode). The QTOF was coupled to an 
Ultimate 3000 UHPLC (Thermo Fisher Scientific, California, USA). The capillary 
voltage was set at 4500 V, nebulizing gas at 4 bar, and drying gas at 12 L min−1 at 
220 °C. The TOF scan range was from 50 – 750 mass-to-charge ratio (m/z). The in-
source CID was set to 0.0 eV, with the collision energy for TOF MS acquisition at 7.0 
eV. The conditions of the liquid chromatography analysis were the same as used for 
the HPLC-UV, with the exception of the injection volume being 5 μL and a split flow 
post column before the mass spectrometry detector with a flow rate of 0.3 mL min−1. 
The MS instrument was calibrated using a range of sodium formate clusters introduced 
by 10 µL loop-injection prior to the chromatographic run. The mass calibrant solution 
consisted of 3 parts of 1 M NaOH to 97 parts of 50:50 water:isopropanol with 0.2% 
formic acid. The observed mass and isotope patterns of the formate clusters were used 
to calibrate the instrument to within 1 ppm mass accuracy. Data processing was 
performed using the data analysis software version 4.3 (Bruker Daltonik GmbH, 






2.5. Estimation of loss of glycols from the plaster by evaporation 
Loss of the glycols from the formulation was investigated in two different 
scenarios. In the first, the release liner (the backing layer that protects the adhesive 
surface until use) from 5 cm2 (1 x 5 cm) pieces of plaster was removed, and the sections 
were positioned on a glass slide in an oven at 32°C. In the second, the entire plaster 
(140 cm2, releaser liner not removed) was placed in an oven at 32°C.  
The plaster pieces were analysed immediately upon removal from the packaging, 
and at 0.5, 1, 2, 4, 6, 8 and 10 hours exposure to the two different conditions. Glycols 
were extracted from each section with 40 mL of acetonitrile in Eppendorf tubes, which 
were placed on a horizontal shaker (overnight at room temperature; HS 260 Basic, 
IKA Group), and then derivatized with TSIC and analysed by HPLC-UV as described 
above.  
 
2.6. Data analysis 
The analysis of diclofenac uptake data into the SC closely mirrored that described 
in Chapter 3. 
The mass of permeant in the SC was expected to exhibit a log-normal distribution 
(AC Williams, Cornwell and Barry, 1992; Kasting et al., 1994; Cornwell and Barry, 
1995). Therefore, the arithmetic average, standard deviation and 90% confidence 
intervals of the logarithm of the geometric mean of the duplicate measurements in the 
4 subjects were calculated for each experiment time (N’Dri-Stempfer et al., 2009). 
Firstly, the concentration profile of PG and BG across the SC (Cx) as a function of 
position in the SC (x/L) was analysed for all subjects at each uptake time considered. 
The data points from the two replicate sites were combined. Then, profiles were fitted 
to the relevant solution of Fick's second law of diffusion (Scheuplein, 1967; Crank, 
1979) (Equation 2) assuming the following boundary conditions: (i) that the permeant 
concentration in the vehicle (Cv) remains constant during the treatment period (tapp); 
(ii) that the SC provides a homogeneous barrier to permeant diffusion; (iii) that there 
is no permeant in the SC at t=0; and (iv) the viable epidermis acts as a perfect sink for 
the permeant. 
 
𝐶𝑥 = K𝐶𝑣 [1 −  
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where Cx is PG or BG concentration (mass of permeant divided per mass of SC 
removed) at position x in the SC at the application time (tapp).  
The fitting yields values for KCv (K is the permeant’s SC-vehicle partition 
coefficient) and for D/L2, a first-order rate constant comprising the ratio of the 
permeant diffusivity (D) in the SC to the total thickness of the barrier (L) squared. 
From these two parameters (KCv and D/L
2) and the corresponding L (estimated for 
each subject using Equation 1 in Chapter 3), the lag-time (TLag = L
2/6D, Roberts, 
Anissimov and Gonsalvez (1999)), time to steady-state (TSS = ~2.4TLag, Cleek and 
Bunge (1993)) and steady-state flux across the SC (Jss = KCvD/L,) may be calculated. 
Note that, as all the subjects enrolled in this study also took part in the ‘diclofenac 
study’ (Chapter 3), the value for L used for the analysis was the average values showed 
previously in Chapter 3 (Table S1 in ‘Supplementary Information’).  
Secondly, it is also possible to analyse the mass of DF after SC uptake using 
an approximate solution to Fick's second law of diffusion (Equation 2 and Equation 3) 
from which D may be estimated in a different way.  
The cumulative mass of DF measured in the tape-strips per unit of area of 
exposure (MSC/A) versus square-root of time profiles were compared to the solution 
of two models describing diffusion into a: (i) semi-infinite membrane (Equation 2), 
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The semi-infinite membrane model assumes that the application time of the 
formulation to the SC is insufficient for the permeant to reach the lower surface of the 
barrier which therefore, in effect, behaves as a semi-infinite membrane (Equation 2); 
the finite membrane model, in contrast, considers the SC as a single finite membrane 
(Equation 3).  
The analytical solution to the semi-infinite model permits a value of D to be 
deduced. Then, using this D, Equation 4 can be used to predict the evolution of the 
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MSC/A over time following the finite membrane model. Note that MSC/A corresponds 
to the average concentration in the SC multiplied by the SC thickness. 
The application of Equations 2 and 3 requires estimates of the concentration 
of the permeant at x=0. In this study, we have assumed that the permeant 
concentration at the surface of the SC is constant and equal to KCv (obtained from 
fitting the data to Equation 1; the average of the KCv determined following 0.5, 1 and 
2-hour of application was used).  
 
2.7. Statistics 
Statistically significant differences were estimated by a t-test or by one-way 
ANOVA followed by Tukey's test, assessed in a pairwise, within-subject comparison 
when appropriate. In all cases, statistical significance was set at p < 0.05. The 90% 
confidence interval was calculated using the Student’s T-distribution for the sample 
size and the sample standard deviation.  
 
3. Results and discussion 
 
3.1. Analysis of propylene and butylene glycol  
LC-MS confirmed that the peaks quantified by HPLC-UV were the two glycol 
derivatization products and that two TSIC molecules (one per hydroxyl group) had 
been added to both PG and to BG. Details of these results and the mass spectra are in 
the ‘Supplementary information’, Figure S1 and Table S2.   
 
3.2. Stratum corneum tape-stripping experiments 
The total masses of PG and BG recovered from the SC of each subject are shown 




Figure 2. Mass of propylene glycol (PG) recovered from each skin site at each uptake 
time, with replicate determinations performed as a function of time in 4 subjects. 
Horizontal lines are the geometric means of the replicate values indicated by the open 
circles.  
 
Figure 3. Mass of butylene glycol (BG) recovered from each skin site at each uptake 
time, with replicate determinations performed as a function of time in 4 subjects. 




The SC concentration-depth profiles following different application times for 
each subject are shown in Figure 4. These data are plotted as a function of position 
within the SC (x) normalized by the predicted total thickness of the SC (L). The solid 
lines in Figure 4 were calculated from Equation 1 using the best fit of KCv and D/L
2 
values at the corresponding application time. The mean values of KCv and D/L
2 per 
time for all subjects are in Table 1. 
It was not possible to determine D/L2 from the fit to the SC concentration-depth 
profile at 6 hours for either PG or BG; by this time, the exponential function in 
Equation 2 is negligible and the concentration profiles close to linear. 
Within the obvious constraints of this study, which only involved a total of four 
subjects, a one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test 
indicated that, for both glycols, there was no significant difference in the partitioning 
parameters (KCv) deduced at the application times investigated. In contrast, the 
estimated diffusion parameter (D/L2) for PG at 0.5 h was significantly greater than that 






Figure 4. Individual concentration profiles of PG (left panels) and BG (right panels) 
across human SC in vivo following application of Voltaren® medicated plaster for 
different application times. The data points were experimentally determined; the solid 
lines  were calculated from Equation 1 using the best fit of KCv and D/L
2 values 
deduced from the best fit of the corresponding application time. 
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Table 1. Propylene glycol and butylene glycol partitioning and diffusivity parameters 
as a function of application time derived from the best fit of Equation 1. Values are 
the arithmetic means across 4 subjects, for each time point (lower and upper 90% CI).  
aAnalysis of variance (one-way ANOVA, followed by Tukey’s post hoc test) indicated 
that D/L2 at 0.5 h was significantly greater than that at 2 h (p = 0.03). No other 
statistically significant difference was found. 
 
To illustrate the determination of additional kinetic parameters from these 
results, average values of KCv and D/L
2 were combined with the mean SC thicknesses 
(L) assessed by measurements of TEWL during tape-stripping.  The average KCv and 
D/L2 results in Table 2 were calculated from the data in Table 1, while the measured 
L values are collected in the ‘Supplementary Information’, Table S1.  Using these data 
for the two glycols, lag-time (TLag = L
2/6D), time to steady-state (TSS ~ 2.4TLag), 
diffusivity across the SC (D) and steady-state flux (JSS = KCvD/L) were calculated; 
the results are collected in Table 2. 
 
Table 2. Pharmacokinetic parameters deduced for PG and BG in human SC in vivo 
following application of Voltaren® medicated plaster. Values were deduced from the 
SC concentration versus depth profile (Equation 1). The mean values (± standard 
deviation) were calculated within each subject, then averaged (arithmetic mean) 
across all subjects and then averaged (arithmetic mean) across the application times.  
  
Parameters PG BG 
KCv (µg mg-1) a 22.7 ± 1.3 70.5 ± 5.2 
102 D/L2 (h-1) a 7.6 ± 2.6 10.9 ± 2.5 
108 D (cm2 h-1) b 12.9 ± 4.5 16.9 ± 4.7 
TLag (h) 3.1 ± 1.1 1.9 ± 0.6 
TSS (h) 7.4 ± 2.7 4.5 ± 1.4 
JSS (μg cm-2 h-1) 1.8 ± 0.9  9.0 ± 1.8  
aCalculated using Equation 2, average value of KCv derived from 0.5-, 1-, 2-hour 
application time; bCalculated using individual estimated value for D/L2 times L 







 Propylene glycol 
0.5 21.3 (16.4 – 26.1) 10.2 a (6.3 – 14.0) 
1 23.8 (13.5 – 34.1) 7.7 (0.4 – 15.0) 
2 23.0 (17.3 – 28.7) 4.9 a (2.9 – 6.9) 
 Butylene glycol 
0.5 64.8 (56.3 – 73.3) 13.9 (9.4 – 18.4) 
1 71.7 (54.4 – 89.1) 9.7 (6.2 – 13.2) 
2 75.0 (63.0 – 86.9) 9.3 (0.9 – 17.6) 
 126 
 
The uptake of PG and BG into the SC was also explored using the semi-infinite 
and finite membrane models (Equations 2 and 3).   
Estimates of KCv were derived from Equation 1. Estimates of D/L
2 were derived 
for each subject from the slope of the linear regression of MSC/A versus square-root 
of time (regressions on t ≤ 1 h, √𝑡 ≤ 1.4 h1/2 and without forcing the origin) combined 
with the mean individual estimated value for L and the corresponding value of KCv. 
From the estimated D/L2, L and KCv for each subject it was also possible to calculate 
TLag, TSS and Jss (Table 3). 
 
Table 3. Diffusion parameters of PG and BG in human SC in vivo (4 subjects) 
following application of Voltaren® medicated plaster. Values were deduced from the 
MSC/A versus √𝑡 profiles (Equation 2). The mean values (± standard deviation) were 
calculated within each subject, then averaged (arithmetic mean) across all subjects 
and then averaged (arithmetic mean) across the application times.  
  
Parameters PG BG 
Intercept at t =0 h (μg cm-2)  4.7 ± 0.9 11.7 ± 7.9 
KCv (μg mg-1) a 22.7 ± 1.3 70.5 ± 5.2 
108 D (cm2 h-1) b 1.7 ± 0.9 4.7 ± 3.4 
102 D/L2 (h-1) c 0.9 ± 0.4 3.1 ± 2.2 
TLag (h)  22.4 ± 15.3 10.5 ± 11.4 
TSS (h)  60.5 ± 41.4 28.4 ± 30.9 
JSS (μg cm-2 h-1)  0.3 ± 0.1 2.7 ± 2.0 
aAverage value of KCv derived from 0.5-, 1-, 2-hour application time (Equation 1);   
bDerived from KCv and the slope of the linear regression of MSC/A versus the square-
root of time for t < 2 h; 
cCalculated using individual value for D divided by L (individual average value, 
Table 1) squared. 
 
Figure 5 compares the mean measured mass per area of PG and BG in the SC as 
a function of the square-root of time to the semi-infinite membrane model (dashed 
line) and to the finite membrane (solid line). The solid line in Figure 5 was calculated 
using the average values of the 4 subjects for L (12.8 µm) and D derived from KCv 
(Table 2) and the slope of the linear regression.  
Consistent with the experimental data, at 6 h (√𝑡 = 2.45 h1/2) the curve for BG 
diverged from Equation 2, and suggests (as shown by the best fit of Equation 3) that 
the semi-infinite boundary conditions are no longer met. Within the 6-hour period 
investigated in this work, neither the experimental data nor the finite membrane model 




Figure 5.  Average mass of PG and BG in human SC in vivo (4 subjects) following 
application of Voltaren® medicated plaster for different application times. The data 
points were experimentally determined and plotted as the anti-logarithm of the log-
transformed average of the geometric mean of duplicates in each subject ± 90% 
confidence interval; the dashed line represents the solution of the semi-infinite 
membrane theory (regressions on t ≤ 2 h, √𝑡 = 1.4 h1/2 data, Equation 2) and solid 
line represents the solution of the finite membrane theory predicted with diffusivity 
(D) derived from semi-infinite theory slope (Equation 3).The dot-dashed lines 
represent the solution of the finite membrane theory predicted with diffusivity (D) 
and KCv derived using Equation 1. 
 
A further observation, from the MSC/A versus square-root of time plot, was that 
the linear regressions led to a non-zero value at t = 0. It suggests a rapid transfer of a 
measurable quantity of BG (11.7 μg cm-2) and PG (4.7 µg cm-2) to the SC when the 
plaster is first applied to the skin. From a mechanistic standpoint, these intercepts 
could represent the mass of PG and BG, which is distributed across the surface of the 
SC, immediately after plaster application, with possible accumulation in the SC-
microcrevices and/or loosely attached corneocytes, therefore, not true absorption. 
Also, these masses could characterise a faster penetration of PG and BG via a hair 
shaft. This last hypothesis is in line with stimulated Raman scattering microscopy 
experiments that tracked the uptake of PG into mouse skin (Saar et al., 2011). The 
work described by these authors compared the uptake of PG via hair shafts and via the 
SC intercellular lipids. They found that PG penetration via the hair shaft was rapid and 
 128 
 
attained steady-state before 26 min post-application of the formulation (Saar et al., 
2011).       
In summary, the analysis of the Cx versus x/L curves gives D and KCv values that 
correspond to much larger slopes (calculated using the definition of the slope in 
Equation 2) than observed by the MSC/A versus square-root of time data. This larger 
slope is consistent with the faster rate of BG and PG transfer before t = 0.5 h, however, 
this larger slope is inconsistent with uptake over the period of 0.5 to 2 h (which appears 
to be linear with a smaller slope).  
In addition, in order to have a better visualisation of the difference between values 
derived using Fick’s second law or its simplified model, the prediction of the MSC/A 
versus square-root of time curves from the finite membrane model assuming D and 
KCv from the Cx versus x/L analysis (Table 2) and assuming D and KCv are related to 
each other according to the slope defined in Equation 2 is shown in Figure 5 (dot-
dashed curves).  
 
3.3. Analysis of the glycols residual in the plaster 
Glycols from the plaster were extracted immediately after removal from the 
packaging as well as after removal from the skin. This analysis allowed us to measure 
the efficiency of the extraction solvent (at least for PG, since the amount of PG loaded 
in the plaster is known) and, also, to investigate the mass of PG and BG that had been 
released from the plaster during skin application. Table 4 summarises these findings. 
 
Table 4. Mass of PG and BG extracted from the plaster either immediately after 
removal from the packaging or after removal from the skin at different application 
times. The mean values (± standard deviation) were calculated within each subject, 








0a 1192 ± 92 3111 ± 218 
0.5 756 ± 263 2423 ± 290 
1 680 ± 201 2222 ± 251 
2 534 ± 150 1790 ± 148 
6 288 ± 93 768 ± 261 
aExtracted immediately after removal from the packaging, n = 9. 
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 The amount of PG measured immediately after removal from the packaging is 
~1200 µg cm-2, which is ~40% of the amount declared in the patient information 
leaflet. This percentage corresponds to the yield of the extraction process.  
The amount of PG and BG released from the plaster was calculated as the 
difference between the measured amount of PG and BG immediately after removal 
from the packaging and the residual content measured after its removal from the skin 
at each time point (Table 4). On the basis of this analysis, the total amount of glycols 
released from the plaster after 6 h of skin contact was ~ 900 and 2342 µg cm-2 of PG 
and BG, respectively, which is equivalent to ~75% of the amount of each compound 
extracted immediately after removal from the packaging (Figure 6). 
 
Figure 6. Average mass of PG and BG out of the plaster after wear of Voltaren® 
medicated plaster for different application times (4 subjects). The values were 
obtained by measuring the residual in the plaster after application and comparing with 
the t=0. Values are the arithmetic mean for each time point (± standard deviation, n = 
4). 
Comparing the mass of PG and BG recovered from the tape-strips (Figure 5) and 
losses of PG and BG from the plaster after 6 hour of plaster wear (Figure 6), it was 
possible to observe that the masses of glycols out of plaster were ~ 77- and 58-fold 
higher, respectively, than the amount recovered from the tape-strips.  
In addition, the observation that the measured MSC/A is linear with square-root of 
time up to 2 h (√𝑡 = 1.41 h1/2) for BG and up to 6 h (√𝑡 = 2.45 h1/2) for PG suggests 
that little if any of the glycols have reached the bottom of the SC (Figure 6). Therefore, 
nearly all of the glycol transferred to the SC was still in the SC at the sampling times. 
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It follows that the measured losses of glycol from the plasters cannot be explained by 
the small transfers to the skin.   
A separate, related, point is that, even though the mass of BG and PG in the plaster 
drops significantly, the mass-ratio of BG-to-PG remains nearly constant (at ~ 2) over 
6 h.  Also, the MSC/A versus square-root of time analysis suggests that D and KCv also 
remain essentially constant over the interval of 0.5 to 2 h for BG and for 0.5 to 6 h for 
PG; these two observations imply that the thermodynamic activity of BG and PG must 
have remained relatively constant over this interval, despite the significant 
concentration decrease in the plaster. A logical explanation for this observation is that 
while the mass of PG and BG is depleting significantly, the glycols would be contained 
in a ‘reservoir’ that stays at essentially constant thermodynamic activity until they are 
nearly depleted.  For example, if the BG and PG were liquids ‘trapped’ in the adhesive 
material then the vehicle concentrations for PG and BG would remain constant even 
though the masses of PG and BG changed dramatically.  
 
3.4. Estimation of loss of glycols from the plaster by evaporation 
Due to the discrepancy between the mass of PG and BG which has left the plaster 
and has been absorbed into the SC, a test to estimate the loss of glycols from the plaster 
by evaporation was conducted. 
Voltaren® medicated plaster is comprised of an adhesive material which is applied 
to a non-woven polyester felt backing and covered with a polypropylene film release 
liner which is removed prior to topical application to the skin (patient information 
leaflet). Therefore, it was hypothesised that evaporation of PG and/or BG would be 
possible through the non-occlusive felt backing and/or through the cut edges of plaster.  
The results are presented in Figure 7, which shows that both scenarios, i.e., when 
the plaster was cut into smaller sections (scenario 1) or not (scenario 2), gave 
remarkably similar profiles. It suggests that the principal route of loss of glycols from 
the plaster is evaporation via the backing, as it appears that PG and BG evaporate from 
the plaster just as easily regardless as to whether the plaster has been cut or not. Note 
that the time zero corresponds to the amount of glycols extracted from the plaster 
immediately after removal from the packaging. 
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Figure 7. Percentage of PG (left panel) and BG (right panel) lost from the plaster over 
time, under two different scenarios. In scenario 1, the release liner was removed, the 
pieces of plaster were positioned on a glass slide and then placed in an oven at 32 °C. 
In scenario 2, the entire plaster (without release liner removal) was placed in an oven 
at 32 °C. The values were obtained by measuring the residual and comparing with the 
amount of PG and BG measured immediately after removal from the packaging (Table 
6). Values are the arithmetic mean for each time point (± standard deviation, n = 3). 
 
This loss is in line with previous findings. Tsai et al. (1992) reported that the PG 
recovery after the application of 35 µL (~ 20 µL cm-2) of a PG:ethanol:water mixture 
(20:60:20) to hairless mouse skin in vitro, was 40% of the applied PG dose after a 12 
h exposure time. A study developed by Trottet et al. (2004) shows that not all the PG 
applied is recovered at the end of an in vitro experiment, using human skin. When 40 
mg cm-2 of a gel loaded with 12% of PG was applied on the skin, 25% of the PG initial 
content evaporated. When a lower dose (10 mg cm-2) of formulation (gel with 12% 
PG and cream with 15% and 40% PG) was applied a larger proportion of PG 
evaporated (39 – 61%). Santos et al. (2010) observed that the skin permeation (using 
heat separated human epidermis) of an ethanolic solution of 25% PG resulted in a total 
recovery (amounts permeated and recovery from the washes and extractions) of PG of 
around 30% of the total dose applied (3.6 µL cm-2), suggesting that PG was probably 





3.5. Effect of PG and BG on diclofenac absorption into the stratum corneum 
The results described in Chapter 3 of this thesis suggested that diclofenac (DF) 
uptake into the SC may be modified by the presence of excipient(s). Therefore, this 
chapter focused on exploring the uptake of two excipients/co-solvents, propylene 
glycol and butylene glycol, into the SC in vivo in human. The experiments with these 
glycols were conducted using the same diclofenac medicated plaster used in the 
previous chapter (Voltaren®) and this product was applied on the forearms of the same 
subjects enrolled in the previous study (Chapter 3, ‘diclofenac study’). 
The work described here shows that PG and BG themselves penetrate into the SC. 
Analysis of variance (one-way ANOVA, followed by Tukey’s post hoc test) indicated 
that estimated steady-state flux of BG across the SC (Table 2) was significantly greater 
than that of DF (p = 0.0003). No statistically significant difference was found between 
the estimated steady-state flux of PG and DF across the SC. Therefore, BG penetrates 
the SC faster than the drug or than PG. It follows that the higher DF diffusivity and 
partitioning observed in the early stages of the experiment may be related to the 
concomitant presence of these glycols in the SC. The glycols may create a situation 
where drug delivery is transiently more efficient in the beginning of the treatment. 
The mechanism by which PG and BG enhance drug permeation/penetration into 
the SC is not clearly established. Studies which investigated how PG enhances drug 
permeation, however, provide some evidence that it has a carrier-solvent effect 
(Hoelgaard and Møllgaard, 1985); and/or may increase the solubility of the drug in the 
SC (Kasting, Francis and Roberts, 1993).  
Although the literature does not address the mechanism of action of BG, it seems 
likely that its co-solvent properties and skin uptake are also key to its application as a 
permeation enhancer (Lane, 2013).  
To establish whether these glycols are, synergically or individually, acting as 
permeation enhancers would require further experiments, for example, investigation 








SC sampling, using tape-stripping technique associated with HPLC-UV analysis, 
has been successfully used to track the fast uptake of PG and BG into the human SC 
and to characterise the diffusion of these excipients across the tissue. 
The analysis by the MSC/A versus square-root of time indicates that mass has been 
transferred to the SC within the first 0.5 h at a rate that is not consistent with the 
transfer rate over the interval of 0.5-2 h (which is consistent with constant D and 
constant KCv). This suggests that this rapid transfer soon after plaster application is 
by a different mechanism than absorption into the skin via the intercellular pathway.   
Assuming that KCv estimated from the Fick’s second law analysis (Cx versus x/L) 
applies to the semi-infinite and finite models (MSC/A versus square-root of time), then 
D estimated from former analysis (Cx versus x/L) is larger to account for the mass that 
is rapidly transferred to the SC in the first 0.5 h after the plaster has been applied.   
There was a much larger loss of the glycols from the plaster than could be 
explained by glycol transfer to the skin. Consequently, it was further demonstrated 
that PG and BG can evaporate from the formulation, which could change drug 
solubility in the formulation, thereby affecting the rate and extent of drug absorption 
into and through the SC.  
In summary, the research described here has a significant importance as it allows 
useful quantitative information about the excipients to be extracted. An improved 
model, linking excipient kinetic parameters deduced here with the 
behaviour/disposition of the active compound (diclofenac) may ultimately improve 














Table S1.  Estimation of stratum corneum apparent total thickness (L) using Equation 
1 (in Chapter 3) for 6 subjects. The identification of ‘Uptake’ and ‘Clearance’ 
forearms are shown Figure 1 (in Chapter 3). 
 






Subject 1 7.0 13.5 10.3 
Subject 2 12.7 11.7 12.2 
Subject 3 14.4 11.5 13.0 
Subject 4 12.4 19.0 15.7 
Subject 5 12.3 11.8 12.1 




































Figure S1. Mass spectra of the derivatives of propylene glycol (a) and butylene glycol 
(b) obtained by LC-MS in positive mode. Two quasimolecular ion peaks per compound 
corresponded to the protonated and ammoniated species. 
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Table S2. Quasimolecular ions obtained from the derivatives of propylene glycol and 
butylene glycol. 
 
The mass spectra yielded the quasimolecular ions corresponding to the 
protonated and ammonium-coordinated species. The summary of results for the 
derivatives of propylene glycol and butylene glycol extracted from tape-strips 
including the measured and theoretical masses for the protonated and ammonium-
coordinated species is shown in Table S1. The mass accuracy of all measured masses 




Figure S2. Mass of propylene glycol in human SC in vivo for each subject following 
application of Voltaren® medicated plaster for different application times. The data 
points were experimentally determined (the replicate values are shown by the same 




Theoretical mass Observed mass 
Mass error 
(ppm) Propylene glycol 
Protonated 471.0890 471.0896 1.3 
Ammonium adduct 488.1156 488.1162 1.2 
Butylene glycol  
Protonated 485.1047 485.1028 -3.9 




Figure S3. Mass of butylene glycol in human SC in vivo for each subject following 
application of Voltaren® medicated plaster for different application times. The data 
points were experimentally determined (the replicate values are shown by the same 
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ACl mass of drug in the skin (stratum corneum plus 
epidermis/dermis) after a delay time between 
the removal of the patch and the end of the 
experiment (clearance time) 
AUP mass of drug in the skin (stratum corneum plus 
epidermis/dermis) immediately after patch 
removal (uptake time) 
Clskin     drug clearance from the skin 
Clskin,exp drug clearance from the skin calculated using 
experimental data 
Clskin,pred predicted drug clearance from the skin  
Cp       systemic plasma concentration 
Css steady-state concentration 
Ei     extraction ratio 
Fi               degree of ionization 
Fu,p                plasma protein binding 
K(skin/p) drug’s coefficient of partition between the skin 
and the plasma 
ke systemic elimination rate constant 
ke,skin elimination rate constant from the skin 
Ktissue,plasma tissue-to-plasma partition coefficient 
log P log of n-octanol/water partition coefficient 
t1/2     terminal half-life 
VIF variance inflation factor 
Vplasma volume of the plasma 
Vskin volume of the viable skin   
Vss     systemic volume of distribution at steady-state 
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Vss,skin     skin volume of distribution 
Vtissue volume of the tissue 





























1. Introduction  
 
Skin disease is one of the leading causes of global disease burden, affecting 
millions of people worldwide (Hay et al., 2014).  The effective delivery of a locally-
acting, dermatological drug demands knowledge of its ‘skin pharmacokinetics’ to 
determine the rate and extent with which it reaches its site of action in the 
epidermis/dermis. Of necessity, this requires understanding of not only the input-rate 
of the drug into the skin but also its clearance from the ‘skin compartment’6 into the 
systemic circulation.  
For topical drug products that target sites of action in the viable epidermal and/or 
upper dermal compartment of the skin, the local concentration profiles have proven 
difficult to quantify because both drug input into the viable cutaneous tissue and its 
clearance therefrom are not well characterised (Nicoli et al., 2009). Without such 
knowledge, of course, it is difficult – if not impossible – to predict a priori whether 
and over what time-frame a topical formulation will permit an effective concentration 
of drug to be achieved within the skin compartment.  
Substantial progress has been made toward interpreting drug movement and 
disposition in the skin in terms of mathematical-pharmacokinetic models (McCarley 
and Bunge, 2001; Mitragotri et al., 2011). But, it is no surprise, given the multistep 
nature of the dermal absorption process, the many formulation types, and the complex 
nature of the physiological barrier, that most of these models suffer from one or more 
flaws including (but not limited to), for example, the need to ‘guesstimate’ many 
parameters to permit simulations to be performed, or the incorrect relation of ‘rate 
constants’ to drug physicochemical parameters, or the inability to obtain a prediction 
of drug concentration in the viable epidermis, thereby rendering the model (for most 
dermal products) of little practical use. 
Considering these challenges, it is necessary to develop methods that are simple, 
yet realistic and mechanistically meaningful, to estimate the key dermato-
pharmacokinetic parameters. Among the various approaches currently employed are 
the physiologically-based pharmacokinetic (PBPK) models, which consist of 
                                                          
6 The term ‘clearance from the skin’ here is used to mean the volume of skin from which a drug is 
completely removed per unit time. 
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physiologically realistic compartmental structures into which input parameters from 
different sources (e.g., in silico predictions, in vitro or in vivo experiments) can be 
combined to predict plasma and/or tissue concentration-time profiles (Bouzom et al., 
2012; Hartmanshenn, Scherholz and Androulakis, 2016).  
PBPK models take into account properties, related to physiology of the tissue in 
question, that are not dependent on the drug and can, therefore, be applied to any 
compound, and also to characteristics intrinsic to the drug. One difference between 
PBPK and classical pharmacokinetic models (e.g., one‐ or two‐compartmental 
pharmacokinetic models) is that they traditionally employ what is commonly known 
as a ‘bottom‐up’ approach, as opposed to the ‘top‐down’ approach of classical models 
(Jamei, 2016). Rather than estimating model parameters based on in vivo data 
(commonly from plasma/blood concentration versus time profiles), parameters are 
determined a priori from in vitro experiments, in silico predictions or, if required, in 
vivo data. 
However, most PBPK models require some level of calibration or optimisation of 
their parameters. In general, a drug’s concentration in a tissue is determined by the 
systemic volume of distribution at steady-state (Vss) and clearance (Cl); assuming a 
simple one-compartment model with 1st-order elimination from the tissue 
compartment, the ratio of these independent physiological parameters provides the 
systemic elimination rate constant ke (Equation 1): 
ke =  Cl VSS⁄                                                            (Equation 1) 
Vss is an apparent volume that describes the extent of drug distribution and binding to 
the tissues and plasma (Equation 2): 
Vss =  Vplasma +  ∑ Ktissue,plasma
n
1 × Vtissue,i × (1 − Ei)                     (Equation 2) 
Vplasma is the volume of the plasma and Vtissue,i is the volume of the ith tissue; 
Ktissue,plasma is the tissue-to-plasma partition coefficient; Ei is the extraction ratio and, 
for non-eliminating tissues, as it is generally the case of the skin (Ye, Nagar and 
Korzekwa, 2016), Ei equals zero. 
Here, we test the hypothesis that valuable information about drug disposition, 
and specifically its clearance, in the skin can be derived from available systemic 
pharmacokinetic data for drugs administered via transdermal delivery systems.   
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Figure 1 is a simplistic schematic of the drug absorption process across the skin 
following application of a topical formulation. When a transdermal patch is applied, 
the drug delivery rate to the skin has been determined (the ‘input-rate’) and the 
resulting systemic plasma concentration (Cp) versus time profile has been measured 
both during patch wear and after its removal. The decline in Cp post-patch removal is 
characterised by a terminal rate constant (ke) that is much smaller than that associated 
with the drug’s elimination half-life from the body when administered intravenously, 
for example, demonstrating clearly that ‘flip-flop’ kinetics are operative. In other 
words, in transdermal drug delivery, the skin absorption process is normally much 
slower than the elimination. Therefore, the disposition of a drug following transdermal 
application is usually rate-controlled by the skin absorption. Thus, in this work, we 
have assumed that the elimination rate constant from the skin (ke,skin) should equal the 
systemic terminal rate constant ke. In addition, we hypothesise that ke is related to the 
drug’s clearance from the skin (via the corresponding ‘local’ volume of distribution) 
and that this kinetic parameter will be a sensitive function of key physicochemical 
parameters of the drug.  
To examine this idea, the transdermal delivery literature was searched and 
values of ke were identified for the 18 drugs present in over 25 FDA-approved products 
(FDA Orange Book database of the end of 2017) for this route of administration. 
Importantly, the physicochemical properties of these transdermal drugs are quite 
broad: for example, molecular weights (MW) between 160 and 470 Daltons and 
log(octanol-water partition coefficient (P)) values from ~1.0 to 5.0 (Wiedersberg and 














2. Methods  
 
The calculation of drug dermal clearance was conducted in 3 steps: (i) extraction 
of the terminal half-lives (t1/2) and the corresponding ke values from Cp versus time 
profiles; (ii) estimation of the skin volume of distribution (Vss,skin) and, finally, (iii) 
estimation of the drug clearance from the skin (Clskin). 
 
2.1. Extraction of the terminal half-lives (t1/2) and the corresponding terminal 
rate constant (ke) 
A literature search on pharmacokinetic studies of the 18 transdermal drugs enabled 
extraction of the terminal half-lives (t1/2) of the drugs. Information pertaining to 
lidocaine was also utilised7.  
When not directly provided, the values for t1/2 were calculated from the 
corresponding terminal rate constant (ke) by extracting the Cp versus time profiles 
using WebPlotDigitizer software (version 3.10; Ankit Rohatgi; Austin, TX, USA) and 
assuming that the terminal phase was governed by 1st-order processes (t1/2 = ln(2)/ke). 
If more than one reference was available, an arithmetic mean of the values was used. 
For each drug, a search in PubMed was conducted using different combinations of 
the key words: ‘cutaneous’, ‘skin’, ‘transdermal patch’, ‘pharmacokinetic’ or 
‘clearance’. In addition, pharmacokinetic information was collected from drug 
approval packages on the Drug@FDA public repositories (FDA-Clinical 
Pharmacology and Biopharmaceutics Review(s)).  
                                                          
7 Although lidocaine is not intended to produce systemic effect, there is plasma concentration versus 
time data available following delivery from a topical patch system.  
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The inclusion criteria for the data were: healthy adults (maximum age = 71 years 
old); Cp versus time profile with at least 3 time-points measured after patch removal 
and at least 5 replicates per time-point; sufficient information about the population 
(e.g., sampling number, mean age or health status). Two exceptions were permitted: 
(a) although almost all studies involving testosterone were conducted in patients with 
hypogonadism, these data were accepted into the analysis; and (b) likewise, for 
methylphenidate, as the data available were only from children (age: 6 – 12 years old), 
these results were included. Table 2 shows the mean value of ke derived for each drug 
and used for further analysis.  
 
 
2.2. Estimation of the skin volume of distribution (Vss,skin) 
 The steady-state concentration (Css) likely to be achieved in the ‘skin 
compartment’ is estimated using the clearance from the skin (Clskin) and drug delivery 
rate to the skin (input-rate8,9, R). In turn, Clskin can be estimated using the a relationship 
between ke and the dermal volume of distribution of a drug (Vss,skin).  






                      (Equation 3) 
Equation 2 indicates that each/tissue organ contributes to the estimation of the 
systemic volume of distribution (Vss). Given the lack of a generalised definition of 
Vss,skin, the idea proposed here is that Vss,skin can be estimated, as an approximation, as 
follows:  
Vss,skin =  Vskin  ×  K(skin/p)                                               (Equation 4)   
Where Vskin is the volume of the viable skin and K(skin/p) is the drug’s partition 
coefficient between the skin and the plasma. It is relevant to point out that protein 
binding can occur within the viable skin and Kskin/p is likely to be greater than one, 
therefore. Also, the transdermal drugs are either neutral compounds or weak bases, the 
degree of ionisation of the latter being an important parameter, perhaps, to consider.   
                                                          
8 At steady-state, the rate at which the drug is delivered to the systemic circulation will be the same as 
input rate to the skin.  




 Yun and Edginton (2013) developed a correlation-based model to predict 
K(skin/p), which uses physicochemical descriptors (log P, degree of ionization (Fi) and 
plasma protein binding (Fu,p)) and organism-specific data (rat volume of distribution 
at steady-state). Table 1 shows the best correlations found by Yun and Edginton (2013) 
for predicting the log(K(skin/p)) for bases (pKa ≥ 7.4, model 1) and for acids and neutral 
compounds (pKa ≤ 7.4, model 2).  
Table 1. Mathematical models for predicting log of skin-to-plasma partition 
coefficient (K(skin/p)). Table adapted from Yun and Edginton (2013). 
 
Model Regression models n 
Adjusted 
R2 
1 logK(skin/p) = –0.14 + 0.66(logVss) + 0.03(log P) 28 0.80 
2 
logK(skin/p) = –0.33 + 0.54(logVss) + 0.16(log P) –
0.32(Fi) + 0.38(Fu,p) 
26 0.73 
 
In summary, to estimate Vss,skin using Equation 4, two parameters are required: 
Vskin and K(skin/p). Here, Vskin was assumed to be 2.6 L (based on a standard body weight 
of 70 kg, Brown et al. (1997)) and K(skin/p)was estimated using either Model 1 or 2 
(Table 1). One modification to estimate K(skin/p) was made. Instead of using Vss derived 
from rats, K(skin/p), values were estimated with Vss from humans.  
Values of volume of distribution at steady-state after intravenous administration 
in humans (Vss, L/kg) and plasma protein binding (Fu,p) were from the literature. If 
more than one reference was available, an arithmetic mean was used. The calculated 
K(skin/p) values, the human Vss and the relevant drug physicochemical properties are in 
Table 2. The sources of Vss are in ‘Supplementary Information’ Table S1. Finally, the 
degree of ionization (Fi) at physiological pH 7.4 (FipH=7.4) was calculated using 
Equation 5:  
 
Fi,pH=7.4 = 1 −  (
1
1+ 10pKa−7.4
)            (Equation 5) 
 
2.3.   Estimation of the drug clearance from the skin (Clskin) 
Finally, assuming that skin pharmacokinetics can be described using a one-
compartmental model, Clskin (L h
-1 kg-1) was estimated using Equation 6.   
 




 Figure 2 shows a schematic representation of the steps involved in the 
calculation of Clskin. 
 
 
Figure 2. Schematic representation of the steps involved in the calculation of Clskin. 
 
 
2.4. Collection of molecular descriptors  
 
The physicochemical descriptors: log(n-octanol/water partition coefficient) (log 
P), molecular weight (MW) and melting point (MP) were from EPA’s CompTox 
Chemistry Dashboard (https://comptox.epa.gov/dashboard). Experimental values 
were used when available. When several experimental values were available, the 
median value was used. In addition, log n-octanol/water partition coefficient at pH = 
7.4 (log D7.4), the number of rotatable bonds (RotB), the number of hydrogen-bond 
acceptors (HBA) and donors (HBD), and their sum (HBT), molecular volume (MV), 
topological polar surface area (TPSA) and pKa were calculated (ACDLabs, Toronto, 
Canada, version 5.0). Table 3 collects the physical chemical properties of the 19 drugs. 
 
2.5. Multiple Linear Regression (MLR) model development 
 
MLR, using the ordinary least squares (OLS) method, was used to obtain an 
empirical relationship which best described the relationship between dermal clearance 
(log transformed, log Clskin) and the key physical chemical properties of the drugs.  
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Stepwise MLR was performed using The Unscrambler® X software (Version 10.5, 
Camo A/S, Oslo, Norway). In each regression analysis, a variable was either added or 
removed. The process was stopped when the fit yielded the higher adjusted and 
predicted coefficient of determination (R2) and all the predictors were statistically 
significant (p-value ≤ 0.05). In addition, to detect if the predictor variables were 
linearly related (i.e., the multi-collinearity issue), the variance inflation factor (VIF) 
for each equation was screened. The VIF indicates the increase in the variance due to 
collinearity. A VIF value of 5 was used as the cut-off criterion (Montgomery, Peck 
and Vining, 2012). 
Multiple linear regression attempts to model the relationship between two or more 
explanatory variables and a response variable by fitting a linear equation to observed 
data. Every value of an independent variable x is associated with a value of the 
dependent variable y. The population regression line for k explanatory variables x1, 
x2, ... , xk is defined to be  µy = β1 + β2x2 + β3x3 + ... +  βkxk. This line describes how 
the mean response µy changes with the explanatory variables. The observed values for 
y vary about their means µy and are assumed to have the same standard deviation σ. 
The fitted values b1, b2, ..., bk estimate the parameters β1, β2, …, βk of the population 
regression line (Johnson and Wichern, 2002). 
Since the observed values for y vary about their means µy, the multiple regression 
model includes a term for this variation. In other words, the model is expressed as 
DATA = FIT + RESIDUAL, where the "FIT" term represents the expression β1 + β2x2 
+ β3x3 + ... + βkxk. The "RESIDUAL" term represents the deviations of the observed 
values y from their means µy, which are normally distributed with mean 0 and variance 
σ. The notation for the model deviations is ɛ. 
Formally, the model for multiple linear regression, given n observations, is: 
yi = β1 + β2x2i + β3x3i + ... +  βkxki + ɛi for i = 1,2, ... n. 
The first explanatory variable x1 is defined by x1i = 1 for every i = 1, … , n, and for 
simplicity it can be written as b1 instead of b1x1i. For purposes of analysis it is 
convenient to express the model in matrix form:  
















)  . 
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Note that in the n × k matrix X = (xji) the first index j (j = 1, … , k) refers to the 
variable number (in columns) and the second index i (i = 1, … , n) refers to the 
observation number (in rows). The above matrix notation can also be written as:  
𝐲 = 𝐗𝛃 +  ɛ  
where β is a k ×1 vector of unknown parameters and ɛ is an n ×1 vector of 
unobserved values. 
In the least-squares model, the best-fitting line for the observed data is calculated 
by minimising the sum of the squares of the vertical deviations from each data point 
to the line (if a point lies on the fitted line exactly, then its vertical deviation is 0). 
Because the deviations are first squared, then summed, there are no cancellations 
between positive and negative values. The fitted values b1, b2, ..., bk which estimate 
the parameters β1, β2, …, βk  are obtained by solving the following equation:  
𝐛 =  (𝐗′𝐗)−1𝐗′𝐲  
Subsequently, internal validations were performed to estimate the predictive value 
of the final model, defined by the determination coefficient of leave-25%-out (Q²25%) 
and of leave-one-out cross-validation (Q2LOO) procedures (Baumann, 2003).  
In leave-25%-out cross validation, the data set consisting of 19 compounds and 
selected descriptors were randomly divided into training (n = 14) and test sets (n = 5). 
Using the parameters in the linear regression model, test set was moved aside and new 
coefficients of determination (R2) and prediction (Q²25%) were obtained by regression 
on the remaining 14 observations.  
Calculation of Q2LOO (leave-one-out cross-validation) involved omission of one 
observation and estimation of a regression model using the remaining data points. The 
equation obtained is then used to predict the response variable for the omitted data 
point. The correlation between the predicted and observed values in the newly 
generated data set is used to judge the fit. Q2 can be used to validate the model without 
selecting another sample or splitting the data. 
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Table 2. Values of input-rate, ke, Vss, Fi,pH=7.4, Fu,p as well as the predicted values for K(skin/p) and Vss,skin.  
 
Drug Trade name 
Input-ratee 





Fi,pH=7.4 h Fu,p f K(skin/p) i 
VSS,skin j 
(L/kg) 
Buprenorphine Butrans® 0.8 0.02 6.7 0.87 0.04 3.7 9.6 
Clonidine Catapress-TTS® 1.2 0.04 2.9 0.81 0.80 1.6 4.3 
Estradiola 
Estraderm® 0.2 







Estradiol (E) &  
Norethisterone Acetateb (NAc) 
Combipatch® E/NAc: 0.2/0.4 E/NAc: 0.04/0.05 E/NAc: 1.0/ 4.0 0 E/NAc: 0.02/0.03 E/NAc: 2.0/4.0 E/NAc: 5.3/10.3 
Estradiol (E) & Levonorgestrel (L) Climara Pro® E/L: 0.09/0.03 E/L: 0.21/0.02 E/L: 1.0/1.8 0 E/L: 0.02/0.06 E/L: 2.0/2.3 E/L: 5.3/5.9 
Ethinyl estradiol (EE) &  
Norelgestrominc  (N) 
Xulane® EE/N: 0.1/0.4 EE/N: 0.04/0.02 EE/N: 5.0/3.0 0 EE/N: 0.05/0.03 EE/N: 4.4/4.2 EE/N: 11.6/11.0 
Fentanyl Duragesic® 2.3 0.03 6.0 0.97 0.16 3.2 8.3 
Glyceryl Trinitrated 
Nitro-Dur® 20 
1.15 3.3 0 0.40 2.3 6.0 
Minitran® 11.1 
Granisetron Sancuso® 2.5 0.02 3.0 1.00 0.35 1.7 4.5 
Lidocaine Lidoderrn® NA 0.116 1.5 0.78 0.38 1.1 3.0 
Methylphenidate Daytrana® ~ 87 0.20 2.6 0.99 0.85 1.6 4.2 
Nicotine 
Nicoderm CQ® 
29.2 0.20 2.5 0.75 0.95 1.4 3.7 
Habitrol® 
Oxybutynin Oxytron® 4.2 0.06 2.8 0.86 0.09 1.9 4.9 
Rivastigmine Exelon® ~ 38 0.24 2.2 0.94 0.60 1.5 3.8 
Rotigotine Neupro® 8.3 0.12 53.8 0.96 0.10 14.5 37.7 
Scopolamine Transderm Scop® 5.5 0.07 1.0 0.80 0.90 0.8 2.0 
Selegiline Emsam® 12.5 0.03 26.5 0.57 0.06 7.9 20.4 
Testosterone Androderm® 13.9 0.31 1.0 0 0.01 1.6 4.2 
a Also spelled as Oestradiol; b Also spelled as Norethindrone acetate; c Also spelled as Norelgestromine; d Also known as Nitroglycerine; e Value described on 
the product label; f Extracted from the literature; g Data from IV clinical studies; h Calculated using Equation 5; i Calculated using models described in 
Table 1; j Calculated using Equation 4; NA: not available.         
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MW (Da) MV (cm3 mol-1) log P log D7.4 MP (° C) TPSA (Å2) HBA HBD HBT RotB 
Buprenorphine 467.6 368.2 4.98 3.85 219 62.2 2 5 7 5 
Clonidine 230.1 153.1 1.59 1.33 130 36.4 2 3 5 1 
Estradiol 272.4 232.6 4.01 3.36 179 40.5 2 2 4 0 
Ethinyl estradiol 296.4 244.4 3.67 3.54 163 40.5 2 2 4 1 
Fentanyl 336.5 309.3 4.05 3.44 86 23.5 0 3 3 6 
Glyceryl Trinitrate 227.1 135.8 1.62 2.00 13.4 174.2 0 12 12 8 
Granisetron 312.4 234.8 2.12 1.04 156 50.2 1 5 6 2 
Levonorgestrel 312.4 274.3 3.33 3.15 228 37.3 1 2 3 2 
Lidocaine 234.3 228.3 2.44 1.66 68.7 32.3 1 3 4 5 
Methylphenidate 233.3 218 2.33 0.70 225 38.3 1 3 4 4 
Nicotine 162.2 157.1 1.17 0.13 -79 16.1 0 2 2 1 
Norelgestromin 327.5 265 4.34 4.07 226 52.8 2 3 5 2 
Norethisterone Acetate 340.5 296.1 3.72 3.55 171 43.4 0 3 3 3 
Oxybutynin 357.5 325.7 3.96 3.83 130 49.8 1 4 5 10 
Rivastigmine 250.3 241.1 2.24 2.30 66.9 32.8 0 4 4 5 
Rotigotine 315.5 272 4.79 3.28 136 51.7 3 1 4 6 
Scopolamine 303.1 230.9 0.98 0.51 59 71.5 1 5 6 5 
Selegiline 187.3 196.1 2.90 2.75 142 3.2 0 1 1 5 





3. Results and discussion 
To examine the hypothesis that ke is related to drug’s clearance from the skin and 
that clearance will be a sensitive function of key physicochemical parameters of the 
drug, the first step of this study was to collect the elimination half-life of the 18 drugs 
present in marketed transdermal products. In fact, in the end, a total of 19 drugs were 
analysed as sufficient information was available for a locally-acting lidocaine product 
as well.  
Over 70 studies were assessed and provided, in the end, a final set of 160 half-live 
values. However, in some cases (e.g., for scopolamine and norethisterone acetate), 
only a single half-life was found while, for other drugs (such as nicotine and ethinyl 
estradiol) 20 individual half-life values were discovered. The distribution of the half-
lives collected for each drug are presented as a box and whisker plot in Figure 3. From 
the mean values, ke (= ln 2/t1/2) for each drug was then calculated (see ‘Supplementary 
Information’, Table S2). 
The second step was to estimate drug’s volume of distribution in the skin (Vss,skin). 
To do so, it was necessary first to calculate the drug’s skin-to-plasma partition 
coefficient (K(skin/p)) using the models in Table 1. Values of K(skin/p)  ranged from 1.4  
for nicotine to 14.5  for rotigotine. The relatively high lipophilicity (log P = 4.7) and 
systemic volume of distribution (Vss = 53.8 L/kg) of rotigotine already suggest that 
this drug is likely to accumulate in the tissues and its relatively high K(skin/p) is not 
unexpected. On the other hand, the fact that nicotine has a balanced lipophilicity (log 
P ~ 1.2) and relatively low systemic volume of distribution (Vss = 2.5 L/kg) is 
undoubtedly the major reason behind its much smaller K(skin/p). With the calculated 
K(skin/p) for each drug and the volume of the skin, it was then possible to calculate 
Vss,skin via Equation 4; the results are in Table 2. 
Subsequently, drug clearance from the skin (Clskin in L/kg) was assessed using 
Equation 6. The calculated values of log Clskin are in Table 4 and range from 0.84 for 




Figure 3. Box and whisker plot of the systemic half-life values reported for each drug 
following patch removal. The boxes represent the median (line), mean (dot), 25th and 
75th percentiles. The bars extend to the minimum and maximum value gathered. The 
number (n) of half-lives collected for each drug are described on the right hand side of 




The third step was to derive an empirical model, using multiple linear 
regression (MLR), to predict dermal drug clearance. MLR is a statistical technique 
that can use a number of molecular descriptors to identify predictive, albeit empirical, 
relationships in data sets. The advantage of MLR is its simplicity and the easily 
interpretable mathematical results. The sign of the coefficient derived for each 
molecular descriptor indicates whether it contributes positively or negatively to the 
predicted parameter and its magnitude is a measure of the relative importance. 
However, MLR works best when (i) the structure-activity relationship is linear, (ii) the 
set of molecular descriptors are independent (i.e., descriptors do not show 
collinearity), and (iii) the number of compounds in the training set exceeds the number 
of molecular descriptors by at least a factor of five (Yap et al., 2007).  
At the outset, MLR was performed using ten molecular descriptors (MW, log 
P, MP, logD7.4, RotB, HBA, HBD, HBT, MV and TPSA) as potential predictors of 
drug clearance from skin; the values used are in Table 3. In the end, a model based 
only on MW, log P and TPSA explained best the calculated dermal clearance of 19 
drugs (Equation 7):  
logCLskin(L h
−1 Kg−1) = 0.28 − 0.008(MW) + 0.38(log P) + 0.010(TPSA) 
                       (Equation 7) 
The intercept of this model was, however, statistically non-significant (p = 
0.38), was therefore removed to yield the final solution (Equation 8, Table 4 and 
Figures 4 and 5):  
logCLskin(L h
−1 Kg−1) = −0.007(MW) + 0.37(log P) + 0.010(TPSA)  
                       (Equation 8) 
with an adjusted R2 = 0.72; Q2LOO = 0.70 and p < 0.05 for all three variables; adjusted 
R2 is the square of the determination coefficient adjusted for degrees of freedom; 
Q2LOO is the cross-validated (leave-one-out) square of the determination coefficient 
and p-value is related to the significance of the parameters. The statistics of the three 
descriptors are summarized in Table 5. 
The general principle of cross-validation is to split a data set into a training and 
a test set. The training set is used to fit the model and the test set is used to evaluate 
the fitted model’s predictive adequacy. Leave-one-out (LOO) cross validation 
repeatedly partitions the data set into a training set which consists of all data points 
except one and then evaluates the predictive density for the held-out data point where 
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predictions are generated based on the leave-one-out posterior distribution. The LOO 
estimator is nearly unbiased. 
On the other hand, the leave-25%-out cross validation, which is normally 
employed when data set is large, due to the necessity of choose a subset of data to test 
the model, the validation estimate can be highly variable, which depends on which 
observations are in the training and test.  To illustrate this, the cross validation was 
repeated 10 times and the results are shown in Table 6. 
As can be seen in Table 6, for 10 regressions using the same data set (but 
different subsets), different results can be achieved. For example, if comparing the 
regression 2 with 5, the difference is overwhelming discrepant. Therefore, for small 
data set, which the case of this study, the LOO is reasonable method of validation.  
Moreover, the predictors did not display multi-collinearity, with all VIF values 
being less than 5. It has been found that, when collinear descriptors are used, the 
derived coefficients tend to be larger than the real values and sometimes have opposite 
signs (Yap et al., 2007). Therefore, the assumption of a linear relationship between a 
set of molecular descriptors and a specific activity may not always be appropriate, 




















Table 4. List of the logClskin calculated from the experimental data analysed and the 




(L h-1 Kg-1) 
Calculated Predicted 
1 Buprenorphine -0.63 -0.64 
2 Clonidine -0.80 -0.58 
3 Estradiol 0.05 0.08 
4 Ethinyl estradiol -0.34 -0.21 
5 Fentanyl -0.56 -0.50 
6 Glyceryl Trinitrate 0.84 0.85 
7 Granisetron -1.01 -0.79 
8 Levonorgestrel -0.90 -0.47 
9 Lidocaine -0.47 -0.33 
10 Methylphenidate -0.08 -0.30 
11 Nicotine -0.14 -0.48 
12 Norelgestromin -0.57 -0.04 
13 Norethisterone Acetate -0.32 -0.45 
14 Oxybutynin -0.56 -0.41 
15 Rivastigmine -0.04 -0.51 
16 Rotigotine 0.67 0.19 
17 Scopolamine -0.83 -0.93 
18 Selegiline -0.16 -0.14 
19 Testosterone 0.12 -0.32 
 
Figure 4. Graphical depiction of the relationship between log Clskin calculated from 
experimental data and log Clskin predicted by the MLR-derived Equation 8. The dashed 
lines represent 95% prediction limits for a prospective compound and the solid red 
lines represent 95% confidence limits of the line of best fit. The number against each 




Figure 5. Graphical representation of the residual of the log Clskin model. 
 
 
Table 5. Summary of the statistics of the three descriptors of the MLR model 






± standard error 
p-value 
MW 2.2 -0.007 ± 0.001 0.0000 
log P 2.2 0.370 ± 0.087 0.0006 
TPSA 1.1 0.010 ± 0.002 0.0003 
 
Table 6. List of the coefficient of determination (R2) and determination coefficient of 
leave-25%-out (Q²25%) for 10 regressions using the same data set.  
  
Regression ID Drugs omitted (see Table 4) R2 Q225% 
1 4, 5, 6, 7 and 11 0.60 0.47 
2 2, 5, 10, 15 and 19 0.78 0.72 
3 3, 5, 9, 15 and 16 0.77 0.46 
4 6, 8, 9, 10 and 13 0.65 0.54 
5 6, 8, 16, 17 and 18 0.68 0.35 
6 1, 3, 9, 15 and 16 0.77 0.57 
7 2, 6, 8, 14 and 16 0.69 0.62 
8 2, 5, 8, 14 and 19 0.70 0.63 
8 1, 2, 4, 12 and 15 0.77 0.50 
10 2, 5, 7, 8 and 12 0.70 0.65 
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In general, drug permeability across biomembranes, such as the skin and the 
capillary wall, is widely known to increase with permeant lipophilicity and decrease 
with molecular size (Potts and Guy, 1992; Lien and Gaot, 1995; Kokate et al., 2009; 
Bujak et al., 2015). It is, therefore, not surprising that both log P and MW are important 
in governing drug elimination across the skin-blood barrier as well. In addition to these 
descriptors, TPSA was also found to be important in predicting drug clearance from 
the skin. Previous studies have demonstrated that TPSA is a predictor inversely 
correlated with the passage of molecules through the brain-blood barrier (Clark, 1999; 
Kelder et al., 1999) and the intestinal membrane (Palm et al., 1997; Winiwarter et al., 
1998; Stenberg et al., 1999). Thus, the positive correlation found in this study was, in 
principle, unexpected.   
The TPSA is the surface area associated with polarity, hydrogen-bonding potential 
and water solubility of organic molecules (Ertl, 2008; Ali et al., 2012). A study by 
Potts and Guy (1995) shows that an increase in the hydrogen bonding activity (both 
acceptor and donor) results in a decrease in the partitioning into the organic phase due 
to the free energy cost associated with the disruption of the hydrogen bonds in the 
aqueous phase. On the other hand, a compensating effect of TPSA may occur if a 
molecule associates with polar head groups via specific polar interactions (El 
Maghraby; Kwon, Liljestrand and Katz, 2006). However, further mechanistic 
evaluations are needed to elucidate the influence of this molecular feature on the 
elimination of drugs from the skin. 
Although validation R2 obtained from the regression can serve as an indicator of 
the predictive ability of a model, the following was done as an example of how an 
empirical model combined with results typically available for topical applied drug, 
such as in vitro permeation tests, could be used to predict drug clearance from the skin. 
The experimental results described in Chapter 2 of this thesis were used for this 
purpose. In brief, the in vitro permeation experiments were performed using static 
Franz cells (using freshly excised porcine skin) aiming to investigate the rate at which 
drug is cleared from the skin (i.e., from the stratum corneum and epidermis and 
dermis) towards the receptor solution. Firstly, the mass of three drugs (buprenorphine, 
nicotine and diclofenac, BUP, NIC and DF, respectively) in the stratum corneum plus 
epidermis and dermis was measured after an ‘uptake’ (application) time. Secondly, 
the patches were applied for a period of time (uptake time) and, subsequently, they 
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were removed and the skin left (mounted on the diffusion cell) for a further period of 
time (‘clearance time’) (Table 7). 
Table 7. Summary of the in vitro permeation experiments described in the Chapter 2 
of this thesis. 




Buprenorphine Transtec® 35 µg/h 72 24 
Nicotine Nicotinell® 7 mg/24 hours 2 1.5 and 3.0 
Diclofenac Voltaren® 180 mg 6 5, 17 and 24 
 
From the analysis of the mass of the drugs in the skin immediately after patch 
removal (uptake, AUp) and after a delay time between the removal of the patch and the 
end of the experiment (clearance, ACl), it was possible to calculate the elimination rate 
constant from the skin (ke,skin). Assuming that the drugs are cleared from the skin 
following a 1st-order kinetics, ke,skin was estimated from the slope of the natural-log 
transformed mass-time data of each drug using least square regression analysis (Figure 
6). The systemic steady-state volume of distribution (Vss) was collected from the 
literature, the skin-to-plasma partition coefficient (K(skin/p)) was estimated using model 
1 (Table 1), the dermal steady-state volume of distribution (Vss,skin) was calculated 
using Equation 4 and the  experimental dermal clearance (Clskin,exp) was calculated 
using Equation 6. Table 7 summarises the calculated clearance from the skin of BUP, 
NIC and DF based on experimentally measured ke,skin (Clskin,exp) or predicted (Clskin,pred) 
using Equation 8 and the parameters used for the calculations.  
Although the experimental clearance values were calculated from in vitro 
experiments and, therefore, an effect of the dermal microcirculation (which may 
greatly affect the clearance of a compound from the ‘viable’ skin) is not presented, a 
comparison of the Clskin,exp and Clskin,pred may provide insights into the value of the 
predictive model. In fact, a good agreement between Clskin,exp and Clskin,pred was 
observed. As can be seen in Table 8, Clskin,exp for BUP and DF agrees remarkably well 
with Clskin,pred; for nicotine, the experimental value was ~5-fold higher than that 
predicted using Equation 7.  Given the assumptions and variability involved in the 
approach, as well as the differences between an in vitro penetration test with porcine 
skin and a clinical study in humans, this still indicates a good convergence of 
experiment and prediction. Nevertheless, the results of the experimental work, 
 161 
 
although based on a relatively small number of drugs, further supported the statistical 
accuracy of the model. 
 
Figure 6. Natural logarithm of the amount of drug in the epidermis/dermis plotted 
against the time of clearance. Mean values are presented as the average ± standard 
deviation (n = 6). The slope of the linear regression of ln(drug mass in 






















Table 8. Calculated clearance from the skin of the compounds studied based on 
experimentally measured ke,skin (Clskin,exp) or predicted (Clskin,pred) using Equation 11.  
 aAverage drug amounts recovered from the stratum corneum plus epidermis/dermis 
after uptake;  
bAverage drug amounts recovered from the stratum corneum plus epidermis/dermis 
after clearance(s);  
cke,skin is the first-order rate constant describing clearance from the ‘skin 
compartment’ and calculated by the slope of the linear regression of ln(drug mass in 
stratum corneum plus epidermis/dermis) with time;  
dData from IV clinical studies;  
eSkin-to-plasma partition coefficient;  
fCalculated using Equation 4;  
gClearance from skin, calculated using Equation 6 and using ke,skin obtained using 
experimental data; 
hClearance from skin, predicted using Equation 8 (values are the inverse of the 
logClskin);
  
iPhysicochemical properties of diclofenac: MW = 411.32 Da (diclofenac epolamine), 
log P = 4.16 (diclofenac acid), TPSA = 49.33 Å2;  
jMeasured after oral administration of diclofenac epolamine;  
kGiachetti et al. (1996). 
 
4. Conclusion 
The current study describes the development of an empirical model to describe 
drug clearance from the skin in terms of MW, log P and TPSA. In general, these 
parameters are readily available (either measured or predicted) and mechanistically 
interpretable in terms of size, molecular hydrophobicity and polarity that may 
influence the passive diffusion of chemicals across skin and, ultimately, its absorption 
into the systemic circulation. 
The model has a reasonably good predictive ability with predicted and calculated 
dermal clearances of compounds in a test set showing good agreement. It has been 
further demonstrated that the empirical model closely predicts the results obtained in 
in vitro skin experiments. Nevertheless, given that the model is currently based on a 
dataset comprising a limited number of drugs, further work is required to verify and 
extend the approach.  
 Buprenorphine Nicotine Diclofenac i 
AUp  (µg cm-2)  a 76.8 ± 39.4 21.3 ± 3.7 32.6 ± 3.0 
ACl (µg cm-2)  b 49.3 ± 20.2 6.6 ± 3.0 29.4 ± 3.5 
ke,skin (h-1) c 0.016 0.42 0.005 
Vss (L kg-1)   6.7 d 2.5 d 0.9 j,k 
K(skin/p) e 3.7 1.4 0.9 
Vss,skin (L kg-1) f 9.6 3.7 2.5 
Clskin,exp (L h-1 kg-1)g 0.15 1.55 0.12 





Table S1. Values of the volume of distribution (Vss) obtained from intravenous 
clinical studies. The information was collected from drug approval packages on the 
FDA website (FDA-Clinical Pharmacology and Biopharmaceutics Review(s)). When 
the information was not available on the FDA website, the source where Vss was 
obtained is specified.  
a Information collected from the Summary of Product Characteristics (SPC) approved 
















Drug Vss (L/kg) Reference 
Buprenorphine 6.7 Butrans® 
Clonidine 2.9 Catapress-TTS®  
Estradiol  1.0 Progynova® TS 100a 
Ethinyl estradiol 5.0 Eribelle® 
Fentanyl 6.0 Duragesic® 
Glyceryl Trinitrate 3.3 Nitrostat® 
Granisetron 3.0 Allen et al. (1995) 
Levonorgestrel 1.8 Violite® 
Lidocaine 1.5 Lidoderm® 
Methylphenidate 2.6 Ritalin® 
Nicotine 2.5 Nicorette Invisi® 10 mg 
Norelgestromin 3.0 Ortho Evra® 
Norethisterone Acetate 4.0 FemHRT® 
Oxybutynin 2.8 Oxytrol® 
Rivastigmine 2.2 Exilon® 
Rotigotine 53.8 Cawello et al. (2014) 
Scopolamine 1.0 Nachum, Shupak and Gordon (2006) 
Selegiline 26.5 Mahmood (1997) 
Testosterone 1.0 Lombardo et al. (2004) 
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Table S2. Values of systemic half-life and Ke calculated after removal of the patch, and Vss,skin used for the development of the model.  
a Arithmetic mean ± standard deviation; b The information was collected from drug approval packages on the FDA website (FDA-Clinical 
Pharmacology and Biopharmaceutics Review(s)).
Drug 
Half-life (h) 
(Mean ± SD)a  
ke (h-1) Reference 
Buprenorphine 28.4 ± 5.2 0.024 (Evans and Easthope, 2003; Kress, 2009; Kapil et al., 2013; Wang et al., 2016);   bButrans® 
Clonidine 18.7 ± 2.2 0.037 (MacGregor et al., 1985) 
Estradiol 3.3 ± 1.0 0.209 (Boyd et al., 1996; Ginsburg et al., 1998; Shulman, 2004) 
Ethinyl estradiol 17.4 ± 1.8 0.040 
(Abrams et al., 2001a; Abrams et al., 2001c; Abrams et al., 2002a; Abrams et al., 2002b; van den Heuvel et al., 2005; Devineni et 
al., 2007; Stanczyk et al., 2013);   bOrtho Evra® 
Fentanyl 21.1 ± 3.9 0.033 
(Holley and Van Steennis, 1988; Gourlay et al., 1989; Varvel et al., 1989; Portenoy et al., 1993; Thompson et al., 1998; Marier et 
al., 2007; Kress et al., 2010) 
Glyceryl Trinitrate 0.6 ± 0.6 1.155 (Sun et al., 1995);  bNitro-DUR® 
Granisetron 32.6 ± 2.9 0.021 (Howell et al., 2009) 
Levonorgestrel 32.9 ± 0.5 0.021 (Stanczyk et al., 2011; Archer et al., 2012; Stanczyk et al., 2013);   bClimaraPro® 
Lidocaine 6.0 ± 0.8 0.116 (Campbell et al., 2002; Gammaitoni, Alvarez and Galer, 2002; Kondamudi et al., 2016); bLidoderm® 
Methylphenidate 3.5 ± 0.4 0.198 (Anderson and Scott, 2006; Pierce et al., 2008; Patrick et al., 2009) 
Nicotine 3.5 ± 1.0 0.196 
(Bannon et al., 1989; Chan et al., 1990; Mulligan et al., 1990; Benowitz et al., 1991; Kochak et al., 1992; Lin, Ho and Chien, 1993; 
Gore and Chien, 1998; DeVeaugh-Geiss et al., 2010; Rasmussen, Horkan and Kotler, 2018) 
Norelgestromin 27.9 ± 3.0 0.025 
(Abrams et al., 2001a; Abrams et al., 2001b; Abrams et al., 2001c; Abrams et al., 2002a; Abrams et al., 2002b; Devineni et al., 
2007);   bOrtho Evra® 
Norethisterone Acetate 15.0 0.046  bEvorel Conti® 
Oxybutynin 12.3 ± 3.2 0.056 (Staskin, 2003; Zobrist et al., 2003; Starkman and Dmochowski, 2006; Mizushima et al., 2007); bOxytrol® 
Rivastigmine 2.9 ± 0.6 0.239 (Lefèvre et al., 2007; Lefèvre et al., 2008a; Lefèvre et al., 2008b; Lefèvre et al., 2009) 
Rotigotine 5.6 ± 0.6 0.124 (Braun et al., 2009; Cawello, Braun and Boekens, 2009; Cawello et al., 2012; Cawello et al., 2014; Cawello et al., 2016) 
Scopolamine 9.5  0.073 
bTransderm Scop® 
Selegiline 20.4 ± 0.4 0.034 (Rohatagi et al., 1997; Azzaro et al., 2007) 
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Chapter 6: General conclusion and Perspectives 
 
In this thesis, the use of different approaches to assess skin permeation has been 
investigated. The objectives were to characterise the processes involved in dermal 
absorption and disposition of drugs included in topical products and, using this 
information: 
(a) to evaluate the usefulness of transdermal drug products to predict the drug input-
rate into the skin tissues from topical products using in vitro permeation tests (coupled 
with stratum corneum tape-stripping); (b) to investigate whether the stratum corneum 
sampling technique approach (tape-stripping), together with the application of 
different Fickian diffusion models, is able to estimate skin pharmacokinetic 
parameters related to drug partitioning into and diffusion across the stratum corneum; 
(c) to investigate whether excipients present in topical formulation are capable of 
modifying the kinetic parameters of the drug; (d) to develop a mathematical model 
using available data from transdermal patches to deduce model parameters that 
describe drug clearance from the skin (Clskin), and to establish a relationship between 
Clskin and key physicochemical properties of the drugs, thereby enabling prediction of 
the former for topical drugs. The goal is to develop a model, which will predict drug 
absorption and disposition from dermal products thereby facilitating their optimisation 
and, ultimately, the development of high-performance medicines.   
In this work, different approaches were applied to explore drug behaviour 
following application of a product on the skin. 
First, in vitro permeation tests and stratum corneum tape-stripping were used to 
track two transdermal drugs, buprenorphine (Transtec® - transdermal patch) and 
nicotine (Nicotinell® - transdermal patch), and one locally-acting drug, diclofenac 
(Voltaren® medicated plaster), through the skin layers (porcine skin was used as a 
membrane model). The objective of this study was to characterise the rate at which 
the drug enters the skin after a topical (skin) application. The approach took advantage 
of the known input rates of the drugs delivered from transdermal patches. This 
information was used to optimise the robustness of the experimental approaches and 
to characterise the drug input function correctly. The results from the buprenorphine 
and nicotine experiments showed that a combination of stratum corneum sampling and 
in vitro permeation tests can provide indicative prediction of in vivo drug input rates 
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from transdermal patches. Subsequently, the approach was applied to a topical 
formulation which aims to deliver diclofenac to treat pain and inflammation in 
subcutaneous tissue. The good agreement between the experimentally determined 
input rates of the two drugs and their labelled performance in vivo lends support to the 
potential utility of the in vitro approach proposed to define topical drug input rates. 
An important future step is to apply the same approach more broadly; that is, to extend 
the methodology applied to patches for typical topical drug formulations, such as 
creams and gels.   
Second, diclofenac uptake into and clearance from the stratum corneum in vivo, 
in human volunteers, were evaluated. The study was built on the stratum corneum 
sampling technique approach (tape-stripping) and on the application of different 
Fickian diffusion models to estimate skin pharmacokinetic parameters. The results 
obtained from the uptake experiments demonstrated that stratum corneum tape- 
stripping (coupled with the application of diffusion mathematical models) is able to 
predict drug partitioning into and diffusion across the stratum corneum, at least when 
the formulation is on the skin. In addition, evaluation of partition and diffusion-related 
values as a function of formulation application time indicated the drug distributes 
rapidly from the formulation into the stratum corneum. Also, it was possible to observe 
that the partition and diffusion may not be constant over the application time, which 
implies that interactions between the vehicle constituents and the skin may occur, 
altering the drug permeability in the stratum corneum. Furthermore, the results 
obtained from the solution of the Fick second law did not agree well with the clearance 
experimental data, suggesting that drug clearance from the stratum corneum may be 
complicated by immobilisation of the active agent in the stratum corneum.  Although 
further investigation is needed, this may be the result of strong binding or a substantial 
decrease in drug solubility due to the more rapid diffusion of a co-delivered cosolvent. 
Furthermore, analysis of the change in mass of drug over time after plaster removal 
permits its average flux into the underlying viable tissue, as well as the rate constant 
(k) at which drug is ‘cleared’ from the stratum corneum to be determined. 
Third, the potential effects of different excipients on the predicted drug kinetic 
parameters and the manner in which excipient(s) behaviour may impact on the rate 
and extent at which the drug crosses the stratum corneum was further explored in vivo 
in human volunteers. The results obtained from the uptake of propylene and butylene 
glycol suggests that these volatile solvents were rapidly taken into the stratum 
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corneum and it is likely that they would transiently change the structure of the stratum 
corneum and assist in transferring the drug quickly from the formulation into the 
barrier. In parallel, evaporation of the solvents was identified.  From a thermodynamic 
point of view, the loss (by evaporation and stratum corneum uptake) of propylene and 
butylene glycol will eventually reach the point at which the amount of drug remaining 
at the skin surface can no longer be fully solubilised and drug transfer into the stratum 
corneum will slow down. These findings are in line with the results obtained for 
diclofenac, when a quicker transfer of the drug was observed during the first hours of 
the experiments.  Further studies are required to establish whether these two glycols 
are, synergically or individually, acting as permeation enhancers, for example, 
investigation of diclofenac behaviour in the presence or absence of one or other glycol. 
The last component of the thesis was to develop a multiple linear regression model 
using available data (plasma concentration versus time profiles, labelled drug input 
rates) from 19 marketed transdermal patches to deduce the parameters of the model 
that describe drug disposition between the bottom of the stratum corneum (i.e., after 
the input function) and the systemic compartment. It was possible, in this way, to 
demonstrate a clear relationship (R2 = 0.72) between the drug clearance from the skin 
and key physical chemical properties of the drug (MW, log P and TPSA). In addition, 
it was further demonstrated that the developed model has a good correlation with 
values derived from in vitro skin experiments (described in the Chapter 2 of this 
thesis). However, since the model was built on a dataset with a limited number of 
drugs, further work is required to verify and extend this correlation method.  
Overall, the research described in this thesis has a significant importance as it 
allows useful quantitative information about not only the drug but also excipients to 
be extracted. These findings would be useful to develop a model linking excipient 
kinetic parameters deduced here with the behaviour/disposition of the active 
compound. It may ultimately improve the understanding of drug bioavailability from 
a topical formulation under ‘real-life’ conditions and, consequently, it will help the 







Appendix: Ethical forms for in vivo experiments 
 
 
   
    
 
Participant information sheet 
 
Study: “Measurement of diclofenac absorption into skin from a 
medicated plaster” 
 
➢ You are being invited to take part in a research study. 
➢ Before you decide on your participation, it is important for you to understand why the 
research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. 
➢ Please contact us if there is anything that is not clear or if you would like more 
information. Our contact details are at the end of this document. 
➢ Take as much time as you want to decide whether or not you wish to take part in this 
study. 
 
Thank you for reading this information sheet! 
What is the purpose of this study? 
 
Application of drugs directly to the skin is very convenient to treat local diseases. 
Unfortunately, for most drugs, the only way to investigate the efficacy and compare 
formulations (creams, ointments, gels) is via long and expensive clinical trials that 
require many participants. The development of topical formulations would be very 
much aided if other, simpler methods, where available to predict the efficacy of topical 
medicines. In this way, only the best, optimized formulations would be finally tested 
in clinical trials.  
The aim of this research is to refine and validate the method of ‘tape-stripping’ 
using a medicated plaster containing diclofenac. In particular, we want to know 
whether tape-stripping can tell us how much diclofenac reaches the target site and how 
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quickly, after the plaster is applied onto the skin. To do this we will compare the 
known rate of delivery of the diclofenac plaster with the rate determined by tape-
stripping. To validate the model, we will also use data previously obtained by our 
group with other topical diclofenac gels.  
Tape-stripping is cheap, fast and relatively non-invasive; these are important 
advantages compared with long clinical trials. The outermost layer of the skin (called 
the stratum corneum) consists of dead cells specialised in opposing both the loss of 
water from the body and the entry of foreign compounds including drugs. It has been 
proposed that sampling the amount of drug in this layer may provide information about 
how quickly and how much of a drug can penetrate the skin.  
The tape-stripping technique has been used successfully to compare antifungal 
formulations, reaching the same conclusions as previous clinical trials. However, 
while antifungals act on the most external layer of the skin, other topical drugs such 
as diclofenac are meant to treat problems deeper in the skin, or in the muscle and other 
tissues below. For the moment, we do no not know whether tape-stripping can be used 
to compare all topical medicines and our research is designed to see if this is the case 
or not. In this study, we will perform tape-stripping of the skin after application of a 
medicated diclofenac plaster (Voltaren® 180 mg medicated plaster). 
Volunteer requirements 
For your own safety, and for the results of the experiment to be valid, the following 
criteria must be met by all the participants: 
All of the following “inclusion criteria” must be true for you: 
1. You are 18-72 years old, healthy, male or non-pregnant and non-breastfeeding female 
of any ethnic background. 
2. You are able to communicate well with the investigators. 
3. You are willing to provide basic information (i.e., age, height, weight, health, 
pregnancy status, gender and ethnicity and handedness) so that the investigator can 
verify your compliance with the inclusion and exclusion criteria.  
4. You are able and willing to adhere to the study restrictions and can be present at the 
research site at the times required. 
5. You provide written informed consent before initiation of any of the study procedures. 
6. You agree not to participate in another clinical trial or cosmetic study during your 
participation. 
 
On the contrary, you cannot participate in this study if any of the following “exclusion 
criteria” applies to you: 
1. For your own safety, you cannot take part in this research if you suffer from: (a) skin 
infection or chronic skin disease (e.g., eczema, psoriasis, atopic dermatitis); (b) 
hereditary skin disorders or any skin inflammatory conditions as reported by you or 
evident to the investigator; and (c) excessive pigmentation, tattoos, hair, moles, skin 
defects, sunburn, or blemishes.  
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2. You will be excluded if you are pregnant and/or breastfeeding. 
3. You will be excluded if you are a current smoker or obese as defined by BMI  30 
kg/m2 (the investigator can help you determine your BMI). This is because we 
anticipate these characteristics will modify our measurements and invalidate our 
results. 
4. You are a MPharm or B/MPharmacology undergraduate student at the University of 
Bath.  
5. If you are taking part, or have recently participated, in any other clinical trial or 
cosmetic study. 
6. If you are using any topical drug at or close to the test site area as this could interfere 
with the results. 
7. If you want to practice strenuous exercise during the study period: jogging, aerobics, 
swimming, cycling, etc. Or if you want to suntan and expose your arms to sun or UV 
light during your participation and/or during the week after. 
8. If you cannot be present at all times at which data will be collected. 
9. If you have, or suspect you may have, suffered any adverse reaction to diclofenac or 
to the other ingredients in the patch tested, to medical dressings or to adhesive tapes. 
A list of these ingredients is provided at the end of this form. 
10. If you have used any prescription medication during the previous 30 days or 
over-the-counter medication 5 days before entering the study (with the exception of 
contraceptives in female participants). 
11. If you are unable to communicate or co-operate with the investigators. 
Your participation in the research: 
It is up to you to decide whether or not to take part in this study. If you decide 
to take part, please contact one of the researchers. Then: 
1. You will be given a copy of this information sheet to keep for your records. 
2. You will be asked to sign a consent form and you will be given a copy of the consent 
form. 
3. If you change your mind, you are free to withdraw at any time and without giving 
a reason. 
 
Why do we want you to participate? 
We need volunteers with healthy skin to determine the best method to assess 
diclofenac delivery. Individuals suffering from skin disease cannot be used for this 
study because their condition introduces several factors that make it difficult for us to 
draw useful conclusions. For example, diclofenac may interfere with other 
medications being taken and these other treatments may interfere with the results 
obtained for diclofenac. Therefore, for your safety and for the results of the study to 
be valid, only healthy people not taking any medication (with the exception of 
contraceptives in female subjects) can participate. 
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Please note that the aim of the study is not to establish the efficacy or safety of 
the medicated plaster investigated but to develop a standardized method to determine 
the drug input rate from the patch to the skin.  
 
What will happen if I decide to participate? 
Your participation involves several sessions over two days. This will include 
one meeting with the investigator(s) before the experiment and nine experimental 
sessions that take place over two consecutive days.  
It is very important that you carefully read this information form and understand 
what your participation requires. Please ask for further clarification if needed before 
you make a decision. If you decide to participate, you will contact the research team 
and will meet with them to provide “written informed consent”. If you decide 
otherwise, there is no need to contact us or to provide any explanation for your 
decision. 
The experiments will take place in the research laboratories (5-West 3.22) of the 
principal investigators (Prof. R.H. Guy, and Dr. B. Delgado-Charro) in the Department 
of Pharmacy & Pharmacology at the University of Bath. 
 
The step by step procedure involves: 
Pre-Study Preparation 
At least 48 hours before the study, the investigator will meet with you to explain 
and agree the procedure and schedule, and ask you to complete a questionnaire and 
consent form. You will provide some personal information such as age, height, weight, 
your health status, particularly skin condition, and other questions aimed to verify that 
you meet the inclusion criteria but none of the exclusion criteria detailed above.  
We will also ask you not to use any lotions or moisturiser on your forearms for 
at least 24 hours prior to and throughout the study itself.   
If you have hair growth in the test region (the inside surfaces of your forearms), 
the investigator will shave it carefully using a new disposable razor at least 24 hours 
before the study begins. Typically, if shaving is necessary, it can be completed at this 
pre-study meeting.   
At this time, we will provide you with a written copy of the study schedule and 
protocol, including the timing for all your visits.  
We show below an example of the study schedule and protocol for an imaginary 
participant so you can appreciate the time that will be required for your participation. 
This is just an example, the specific hours and dates for your participation will be 
agreed during the Pre-Study preparation. 
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Eight medicated plasters will be applied to the 
right forearm, four plasters at 8:30 and the four 
other plasters at 9:00. 
Six medicated plasters will be applied to the left 
forearm, three at 8:30 and the three other 
plasters at 9:00. 
The untreated area of skin on the right forearm 





Two medicated plasters will be removed from 
the right forearm, one at 10:30, and another one 
at 11:00. The two sites will be tape-stripped. 






Two more medicated plasters will be removed 
from the right forearm, one at 14:30, and 
another one at 15:00. The two sites will be tape-
stripped.  
 
All six plasters will be removed from the left 
forearm, three at 14:30, and three other plasters 
at 15:00.  A protective covering will be placed 





Two more medicated plasters will be removed 
from the right forearm, one at 17:30, and 






Two sites on the left forearm will be tape-






The remaining two medicated plasters on the 
right forearm will be removed, one at 20:30, 








Two more sites on the left forearm will be tape-
stripped, one at 7:30, and another one at 8:00.  
The untreated area of skin on the left forearm 





The remaining two sites on the left forearm will 
be tape-stripped, one at 14:30, and another one 
at 15:00.  
         Your study will commence at 8:00 (8 a.m.) on Tue, Nov. 1 (for example) in 5W 
3.22, University of Bath.  
8:00-8:15 – The investigator will clean the skin of both inner forearm surfaces with a 
mild soap solution, rinse it with tepid water, and dry it with a soft towel. The purpose 
of this cleansing procedure is to ensure that the starting skin condition is similar for 
all subjects.   
8:30-9:00 – The medicated plaster will be applied to a maximum of 14 treatment sites. 
Fourteen pieces of commercially available diclofenac medicated plaster (Voltaren® 
180 mg medicated plaster) each cut to an area of 5 cm2 (5 cm x 1 cm) will be applied 
to the forearms, eight plasters will be applied to the right forearm and six plasters to 
the left forearm – see drawing below.  Each application area is marked for tape-















1.5 cm  
1 cm  











Untreated site  
1 cm  







5 cm  
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After application of the medicated plasters, we will 
tape-strip the untreated skin site on the right forearm. A non-
invasive probe (see opposite photo) will be used to measure 
water loss (trans-epidermal water loss or TEWL) from the 
the untreated skin site. A piece of tape will be placed on the 
untreated skin site, removed and then the TEWL 
measurement taken. The sequence will be repeated until 30 
tapes have been taken. From the amount of stratum corneum 
removed and the change in water loss rate, we can determine 
the total thickness of your stratum corneum. We can also use 
the same tape-strips to check our analytical method for 
diclofenac (these contain no drug and therefore act as 
valuable “blank” samples).  
  
Before beginning the tape-stripping, we will measure the TEWL from the skin 
of each treated site, and we will repeat the measurement approximately every 4-5 
tapes. This will tell us when a sufficient amount of skin cells have been removed, and 
will indicate to us when the tape stripping procedure should be stopped. The TEWL 
will be measured using a probe that is simply placed on the skin and records the value 
automatically. In any case, the tape-stripping will stop as soon as one of the following 
events occurs: (a) 30 tape-strips taken; or (b) the TEWL measurement is larger than 
either 60 g/m2/h1 or 6 times the TEWL value measured before stripping begins.  
 
10:30-11:30 – After an application period of 2 hours, two plasters from the right 
forearm (U1) will be removed (i.e., one at 10:30 and another one at 11:00) and the 
treated skin sites will be tape-stripped immediately.   
14:30-15:30 – After a further 4 hours (6 hours after application of the plaster), two 
more plasters from the right forearm (U 2) and the six plasters from the left forearm 
(Cl 1, Cl 2 and Cl 3) will be removed (i.e., half at 14:30 and another half at 15:00) and 
the treated skin sites on the right forearm will be tape-stripped immediately. The 
treated areas on the left forearm will be protected using a non-occlusive gauze.  
17:30-18:30 –  After a further 3 hours (9 hours after application of the plaster), two 
more plasters from the right forearm (U 3) will be removed (i.e., one at 17:30 and 
another one at 18:00) and the treated skin sites will be tape-stripped immediately.  
19:30-20:30 –  After a further 2 hours (11 hours after application of the plaster), two 
treated skin sites on the left forearm (Cl 1) will be tape-stripped (i.e., one at 19:30 and 
another one at 20:00). 
20:30-21:30 –  After a further 1 hour (12 hours after application of the plaster), two 
more plasters from the right forearm (U 4) will be removed (i.e., one at 20:30 and 




The next visit will take place on the following day, normally 23 hours after plaster 
application.  
After the last tape-stripping procedure on day 1, you are free to leave the laboratory 
but you should not swim, shower, engage in strenuous sports or apply creams to the 
area. Further, you should avoid exposing the skin sites (tape-stripped or not) to direct 
sun or UV light. If you wish, we will provide you with dressings for your forearms. 
You should also avoid scratching the skin at the tape-stripped sites.   
7:30-9:00 –  After a further 11 hours (23 hours after application of the plaster), two 
more treated skin sites on the left forearm (Cl 2) will be tape-stripped (i.e., one at 7:30 
and another one at 8:00). And we will tape-strip the untreated skin site on the left 
forearm, following the same procedure as described above. A piece of tape will be 
placed on the untreated skin site, removed and then the TEWL measurement taken. 
The sequence will be repeated until 30 tapes have been taken. From the amount of 
stratum corneum removed and the change in water loss rate, we can determine the 
total thickness of your stratum corneum.  
14:30-15:30 –  After a further 7 hours (30 hours after application of the plaster), two 
more treated skin sites on the left forearm (Cl 3) will be tape-stripped (i.e., one at 14:30 
and another one at 15:00). 
After the last tape-stripping procedure on day 2, you are free to leave the laboratory 
but you should avoid exposing the skin sites (tape-stripped or not) to direct sun or UV 
light for at least the next two weeks. If you wish, we will provide you with dressings 
for your forearms. You should also avoid scratching the skin at the tape-stripped sites.   
It is possible that the timings of plaster application and testing may be different than 
stated above. We will determine the optimum times in preliminary experiments and 
inform you if this modification is necessary. 
 
Tape-stripping 
Tape-stripping involves sticking pieces of special Sellotape to the skin of your 
forearms (see left panel of figure below). The strips are gently affixed by rubbing back 
and forth with tweezers (middle panel of figure below). When the strips are peeled 
away (right panel of figure below), they remove some dead skin cells with them. We 
weigh the tapes before and after applying them to your arm so that we can determine 
the tiny amount of skin removed. 
Later on, we measure the amount of diclofenac in these strips. Typically, the 
analysis is performed within 24 hours; in any case, the tape strips are stored for a 







Are there any side effects? 
Tape-stripping removes only the most superficial dead skin cells and causes a 
similar sensation to that experienced when removing a plaster. However, these dead 
cells are part of normal skin structure and contribute to its barrier function; therefore, 
some reddening or mild irritation of the skin frequently occurs after tape-stripping. 
These effects are usually short-lived and never last longer than two weeks.  
Skin redness, mild allergic reactions and hyperpigmentation can also be caused 
by the dressings, adhesives, and tapes. These minor side effects usually resolve in a 
few days but if uncomfortable they typically respond well to a brief course of treatment 
with emollient creams or with an over-the-counter corticosteroid, such as 
hydrocortisone.  
Typically, the tape-stripped skin will have been replaced completely in about 2 
weeks. It is very important that you do not scratch the skin application sites particularly 
after tape-stripping even if they feel itchy. The skin at tape-stripped sites is more 
fragile than normal skin and can be easily damaged by scratching or friction.  It also 
important to protect the application sites from light (sun/UV) exposure for at least a 
week following your participation in the study. 
The medicated plaster contains diclofenac and other inactive components. 
Diclofenac is used to treat pain and inflammation in rheumatic disease (including 
juvenile idiopathic arthritis) and other musculoskeletal disorders; acute gout; and 
postoperative pain. 
In total, only one-half of an actual diclofenac medicated plaster will be applied 
to your skin in the experiment (for comparison, you should know that up to two 
plasters can be applied per day according to the patient leaflet). It is known that only 
5% of the total drug in the entire plaster actually reaches the blood.  
The diclofenac medicated plaster has been approved for use and is commercially 
available. However, all medications have potential side effects. You may experience 
the following side effects: local skin reactions such as skin redness, burning sensation, 
itching, inflamed skin redness, skin rash, sometimes with pustules or wheals, 
hypersensitivity reactions or local allergic reactions (contact dermatitis). In patients 
externally using drugs from the same drug group as diclofenac, there have been 
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isolated reports of generalised skin rash, hypersensitivity reactions such as swelling of 
the skin and mucous membranes (such as lips, mouth and throat) and anaphylactic-
type (severe allergic) reactions. Including problems with blood circulation and light 
sensitivity reactions. 
Absorption of diclofenac into the body by the skin is very low compared to the 
drug concentration in the blood following diclofenac taken by mouth. Therefore, the 
likelihood of side effects occurring in the body as a whole (such as stomach or kidney 
problems or difficulty breathing) is very low. Because of the short duration of the 
study treatment, we expect that the worst side effects will be limited to stinging, 
irritation, itching and skin redness. 
It is, however, possible (although extremely unlikely) that you may experience 
another adverse event not listed here. 
If you experience any side effects other than mild skin redness or irritation at the 
treatment sites, you may consider contacting your GP for advice.  
At the end of this form, you will find a list of ingredients present in the 
diclofenac medicated plaster as provided in the patient information leaflet.   
 
Can you withdraw from the study at any time? 
Yes.  You are free to join the study and you may withdraw at any time or choose 
not to answer certain questions. Please note that we may exclude you from the study 
if we lack sufficient information to verify the exclusion and inclusion criteria listed 
before.  
Will the information obtained in the study be confidential? 
Yes. All your personal information (such as your age) will be treated in 
confidence. No names will be mentioned in any reports of the study and care will be 
taken so that individuals cannot be identified from details in these reports.  When the 
results are made public (published articles, public presentations), they will NOT 
include any names, initials or any type of information which could result in your 
identification. The samples (tape-strips) and data resulting from your participation will 
be identified by a code number.  When we enter data about you we will access your 
code number (e.g., subject A).  Access to the link between the code number and your 
name will be restricted to the research team.  
The researcher may ask for permission to take some photographs during the 
experiment. If you agree, the pictures will only include your treated forearms. You can 
refuse to have pictures taken and this will not exclude you from the study. 
Results of the study 
The results of this study will be published in scientific journals and/or presented 
during conferences and/or internal reports. You will be allowed to have a copy of any 
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published articles upon request. 
Who will profit from this study? 
There are no direct benefits for your involvement in this study. The samples 
taken from your skin will be treated as a gift and will be destroyed once we measure 
the amount of diclofenac present. However, the successful realisation of our research 
will permit the development of methodology to facilitate the optimisation of effective 
and less expensive drug products. The results of the study may be used by regulatory 
agencies to develop new guidelines to compare topical medicines. Other researchers 
may also use the results in further studies. Eventually, if successful, this method would 
permit topical medicines to be developed faster. This would benefit consumers, as it 
will reduce the cost of medicines.  
Acknowledgement 
A modest financial payment will be provided to recognise the inconvenience to 
you and for your time commitment to the study. You will be paid a total of £65 for 
completing the study. If you miss a scheduled component of the procedure described 
above by more than 30 minutes, you will be compensated only for those test sites that 
were tape-stripped as scheduled at the rate of £5.00/site. If you should develop an 
adverse skin reaction that is confirmed by A. Maciel Tabosa, Dr. B. Delgado-Charro 
or Prof. Guy, your remuneration will be based on the number of test sites that were 
tape-stripped at the rate of £6.00/site.   
What should you do if you have any concerns about taking part? 
If you have any problems, concerns, complaints or other questions about this 
study, you should preferably contact the investigators. 
Organisation and funding of the research: 
This study is performed at the Department of Pharmacy & Pharmacology, 
University of Bath, and is funded by the government of Brazil (Science Without 
Borders programme), Leo Foundation and the Austrian science fund (FWF), which 
supports the researchers involved. The protocol has been reviewed and approved by 
the Research Ethics Committee for Health of the University of Bath.  
Contact for further information: 
We will be more than happy to answer any questions you have about this 
research and your participation. Please contact: 
Please contact any one or more of the principal investigators: 
Prof. R.H. Guy  r.h.guy@bath.ac.uk  Tel. 01225 384901  
Dr. B. Delgado-Charro b.delgado-charro@bath.ac.uk   




You will be given a copy of this information sheet and a signed consent form to keep. 
 
Thank you for your interest in this study. 
 
Formulation Voltaren® 180 mg medicated plaster 
Components 














Edetate disodium (EDTA) 


























Consent form for the study: 
“Measurement of diclofenac absorption into skin from 
a medicated plaster” 
 
Before you participate in this study you must provide “informed consent”. 
This form must be completed in duplicate. You will get a signed copy for your 
records and we will keep the other. 
Please complete the whole of this sheet by yourself by circling one of the 
answers and sign and date at the end. The investigator will then date and sign the 
form. 
 
1. Have you read the volunteer information sheet?   YES/NO 
2. Have you had a chance to discuss the study?    YES/NO 
3. Have you had satisfactory answers to all of your questions?  YES/NO 
4. Have you been given enough information about the study?  YES/NO 
5. Who has explained the study to you?          
Dr/Mr/Miss/Mrs…………………………………………………………… 
6. Are you are able and willing to adhere to the study restrictions as described in 
the participant information form?      YES/NO 
7. Are you are able and willing to be at the research site at the times required as 
agreed with the investigator and described in your study schedule?  YES/NO 
8. Do you understand that you are free to withdraw from the study?  
• At any time?        YES/NO 
• Without having to give a reason?     YES/NO 
9. Do you give permission for the medicated plaster (Voltaren® 180 mg) 
containing diclofenac to be applied to your skin?    YES/NO 
10. Do you give permission for a sample of the top layer of dead cells from your 
skin to be taken by tape-stripping from sites to which formulation has been applied 
and from another to which no formulation has been applied?  YES/NO 
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11. Do you give permission for us to shave the test area in your forearms if necessary 
using a new disposable razor?       YES/NO 
12. Do you give permission for us to measure TEWL (water loss from the skin) 
levels using non-invasive probes?      YES/NO 
13. Do you understand that you may experience some local (skin) side-effects 
during your participation?       YES/NO 
14. Do you understand that it is possible that you may experience a serious 
adverse event not listed in the information form.     YES/NO 
15. Do you understand that your skin sample will be treated as a gift from you? 
That is, you cannot have it back.      YES/NO 
16. Do you give permission for your skin sample to be stored for up to 2 weeks 
in the Department of Pharmacy & Pharmacology at the University of Bath? YES/NO 
17. With the data from your participation, we may be able to optimise medicines 
designed to treat skin disease. This may require collaboration with other universities 
and regulatory bodies that will therefore have access to your anonymous data. 
• Do you give your permission for these organisations to have access to your 
anonymised data?                       YES/NO 
18. Do you agree for results derived from your data to be published and/or presented 
internally and externally, including outside the European Union?             YES/NO 
19. Do you agree that the researchers may take photographs of your forearms during 
the experiment?         YES/NO 
20. Do you understand how and when you will receive the monetary 
acknowledgement?          YES/NO 
21. Have you had enough time to come to your decision?   YES/NO 
22. Do you agree to take part in the study?     YES/NO 
 
PARTICIPANT          
 
Signed ……………………………………………..… Date ……………… 
 
Name (BLOCK LETTERS)………………………………………………. 
 
Participant code:  
(to be assigned by investigator) 
 
INVESTIGATOR 
I have explained the study to the above patient and he/she has indicated 
his/her willingness to take part. 
 
 
Signed ………………………………………………Date ………………… 
 










Questionnaire for the study: 
“Measurement of diclofenac absorption into skin from a 
medicated plaster” 
 
For your safety, and for the results of our research to be valid, we must check that 
you fit some criteria before you enter this study. 
Please, answer the following questions to the best of your knowledge.  
 
Age:           years.  Weight:            Height: 
Female/Male:        BMI:  (to be calculated by the investigator)        
 
1. If female:  
are you pregnant?        YES/NO     
are you breastfeeding?       YES/NO 
2. Do you feel that you can communicate well with the investigators?  YES/NO 
3. Are you healthy?        YES/NO 
4. Do you smoke?         YES/NO 
5. Do you suffer from? 
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(a) infections or chronic skin diseases (eczema, psoriasis, atopic dermatitis) 
          YES/NO 
(b) hereditary skin disorders, allergies or any skin inflammatory conditions? 
YES/NO 
(c) have you experienced sunburn recently or got a tattoo in your forearms? 
YES/NO 
6. Have you had in the past (or suspect you may have suffered) any adverse or 
allergic reaction to diclofenac or to the other ingredients in the medicated plaster, to 
medical dressings or to adhesive tapes? A list of these ingredients is provided at the 
end of the information form.       YES/NO 
 
7.  Are you using any topical drugs in your forearms?   YES/NO 
8.  Have you used any prescription medication (with the exception of contraceptives) 
in the last month?       YES/NO 
9.  Have you used any over-the-counter medication in the last 5 days?  YES/NO 
10.  Are you participating, or have recently participated in another clinical or 
cosmetic study?        YES/NO 
If yes: When? Did it involve use of medicines and/or cosmetics? 
 
11. Are you a current undergraduate MPharm or B/MPharmacology student at the 
University of Bath?                 YES/NO 
 
 
 
 
